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ABSTRACT 
Alpha (α)-tomatine is a major saponin found in tomatoes (Lycopersicon esculentum). 
The present study investigates the molecular mechanisms by which α-tomatine exerts its 
anti-cancer effect on human prostatic adenocarcinoma cells. Treatment of human 
androgen-dependent LNCaP and androgen-independent PC-3 prostate cancer cells with 
α-tomatine resulted in a concentration-dependent inhibition of cell growth with a half-
maximal efficient concentration (EC50) value of 2.65 ± 0.1 µM and 1.67 ± 0.3 μM, 
respectively. PC-3 cells appear to be more sensitive to α-tomatine-induced growth 
inhibition compared to LNCaP cells. Importantly, α-tomatine treatment is also less 
cytotoxic to non-tumorigenic human liver WRL-68 and human prostatic epithelial 
RWPE-1 cells. Due to the higher sensitivity of PC-3 cells to α-tomatine and significant 
morbidity of metastatic androgen-independent prostate cancer, it is of interest to study 
in greater detail the mechanisms of action of α-tomatine in PC-3 cells. Results from the 
present study showed that the inhibitory effect of α-tomatine on PC-3 cell growth was 
mainly due to the induction of apoptosis via the inhibition of nuclear factor-kappa B 
(NF-κB) pathway. Alpha-tomatine suppresses both basal constitutive and tumor 
necrosis factor-alpha (TNF-α)-induced NF-κB activation. The suppression of NF-κB 
activation by α-tomatine occurs through the inhibition of Akt, leading to the inhibition 
of IκBα kinase (IKK) activity and subsequently suppression of NF-κB nuclear 
translocation in PC-3 cells. The inhibition of NF-κB signaling pathway by α-tomatine 
was accompanied by significant reduction in the expression of NF-κB-dependent anti-
apoptotic proteins. The anti-tumor study of α-tomatine against PC-3 cells was extended 
to subcutaneous xenograft and orthotopic mouse models. Intraperitoneal administration 
of α-tomatine significantly attenuates the growth of PC-3 cell tumors grown at both 
sites without significant body weight loss. In agreement to the in vitro data, analysis of 
tumor materials showed an increase in tumor cell apoptosis and a decrease in the basal 
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nuclear localization of NF-κB p50 and p65. The present study further investigated the 
efficacy of α-tomatine in combination with low-dose of paclitaxel in PC-3 cells. 
Treatment with sub-toxic dose of α-tomatine in combination with low-dose paclitaxel 
resulted in a decrease in cell viability with concomitant increase in apoptosis in PC-3 
cells but not in non-tumorigenic human prostatic epithelial RWPE-1 cells. Results from 
these in vitro experiments indicated that the induction of apoptosis by the combined 
treatment was accompanied by the inhibition of phosphatidylinositol-3-kinase 
(PI3K)/protein kinase B (Akt) pro-survival signaling, which is an upstream mediator of 
NF-κB and known to confer chemoresistance in prostate cancer. The combined 
treatment also completely suppressed subcutaneous tumor growth in mouse xenograft 
without apparent body weight loss.  Analysis of tumor materials showed an increase in 
tumor cell apoptosis with a reduction in the protein expression of activated PI3K/Akt. In 
summary, results from the present study provide comprehensive evidence that α-
tomatine is an effective naturally-derived anti-tumor agent against androgen-
independent prostate cancer and when used in combination, it can enhance the efficacy 
of taxane-based agent. The clinical applications of α-tomatine in prostate cancer 
treatment should be further explored.  
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ABSTRAK 
Alpha (α)-tomatine merupakan saponin utama yang didapati di dalam buah tomato 
(Lycopersicon esculentum). Kajian ini bertujuan untuk mengkaji potensi terapeutik α-
tomatine terhadap sel-sel  adenokarsinoma  prostat manusia. Rawatan α-tomatine terhadap 
sel kanser prostat LNCaP yang bergantung kepada androgen dan sel kanser prostat bebas 
androgen PC-3 telah mengakibatkan perencatan pertumbuhan yang berkadar langsung 
dengan dos α-tomatine dengan nilai EC50 (half-maximal efficient concentration) iaitu 2.65 
± 0.1 μM dan 1,67 ± 0.3 μM, masing-masing. Oleh itu, didapati bahawa sel kanser prostat 
bebas androgen PC-3 adalah lebih sensitif terhadap perencatan pertumbuhan akibat kesan 
rawatan α-tomatine berbanding dengan sel kanser prostat LNCaP yang bergantung kepada 
androgen. Lebih menariknya, rawatan α-tomatine tidak memberi kesan negatif terhadap sel 
hati (WRL-68) dan sel epithelium prostat (RWPE-1) manusia yang normal. Oleh kerana 
kanser prostat bebas androgen adalah lebih metastatik dan sel PC-3 yang lebih sensitif 
terhadap rawatan α-tomatine, kajian yang lebih terperinci tentang mekanisme tindakan α-
tomatine terhadap sel PC-3 dijalankan dengan selanjutnya. Kajian kami telah 
membuktikan bahawa α-tomatine merencatkan pertumbuhan sel PC-3 melalui induksi 
apoptosis. Selaras dengan keupayaan α-tomatine yang mendorong sel mati melalui 
apoptosis terhadap sel PC-3, α-tomatine juga boleh mengurangkan pengaktifan laluan 
nuklear faktor-kappa B (NF-κB) samada secara konstitutif ataupun yang diinduksikan oleh 
tumor necrosis factor-alpha (TNF-α). Analisis in vitro secara terperinci menunjukkan 
bahawa pengurangan pengaktifan laluan NF-κB oleh α-tomatine adalah melalui perencatan 
Akt, yang seterusnya membawa kepada perencatan aktiviti kinase IκBα (IKK) dan 
akhirnya perencatan translokasi nuklear NF-κB di dalam sel PC-3. Keberkesanan α-
tomatine di dalam perencatan pengaktifan laluan NF-κB  diiringi oleh pengurangan 
ekspresi protein yang berkaitan dengan proses anti-apoptosis. Aktiviti antitumor α-
tomatine terhadap sel PC-3 juga diselidik secara in vivo dalam model mencit xenograf 
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subkutan dan orthotopik. Rawatan α-tomatine secara intraperitoneum dapat merencat 
pertumbuhan tumor subkutan dan orthotopik PC-3 di dalam mencit tanpa menjejaskan 
berat badan mencit tersebut. Selaras dengan data in vitro, analisis tumor yang dirawat 
dengan α-tomatine juga menunjukkan bahawa terdapat peningkatan di dalam apoptosis 
serta pengurangan translokasi komponen NF-κB p50 dan p65 translokasi nuklear. 
Seterusnya, kajian terperinci telah dilakukan untuk menyiasat keberkesanan rawatan 
kombinasi α-tomatine dengan dos rendah paclitaxel di dalam sel PC-3. Rawatan kombinasi 
α-tomatine dengan dos rendah paclitaxel merencatkan pertumbuhan sel PC-3 tanpa 
menjejaskan pertumbuhan sel prostat normal RWPE-1. Eksperimen in vitro menunjukkan 
bahawa induksi apoptosis oleh kombinasi α-tomatine dengan dos rendah paclitaxel telah 
diiringi dengan perencatan laluan pro-hidup phosphatidylinositol-3-kinase (PI3K)/ protein 
kinase B Akt yang merupakan mediator kepada pengaktifan NF-κB dan terlibat dalam 
resistan terhadap rawatan kemoterapi untuk kanser prostat. Rawatan kombinasi α-tomatine 
dengan dos rendah paclitaxel juga merencat pertumbuhan tumor subkutan PC-3 tanpa 
menjejaskan jumlah berat badan mencit. Analisis daripada sampel tumor PC-3 
menunjukkan peningkatan apoptosis di dalam sel tumor PC-3 dengan pengurangan 
ekspresi pengaktifan protein PI3K/Akt. Secara keseluruhannya, kajian kami telah 
membuktikan bahawa α-tomatine adalah ejen semulajadi yang berkesan untuk merencat 
pertumbuhan kanser prostat bebas androgen dan juga dapat meningkatkan keberkesanan 
rawatan paclitaxel apabila digunakan secara kombinasi dengan α-tomatine. Penggunaan α-
tomatine di dalam aplikasi klinikal kanser prostat perlu terus diterokai selanjutnya.  
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INTRODUCTION 
The prostate gland is an important organ of the male reproductive system.  Its 
development, growth and differentiation is dependent on androgens. Prostate 
adenocarcinoma is a common prostate malignancy afflicting men. It is also one of most 
frequently diagnosed cancer in men worldwide (Jemal et al., 2011). Most patients 
diagnosed with early stage localized prostate cancer can be cured by prostatectomy and 
radiation therapy. Nonetheless, a substantial fraction of patients with clinically localized 
prostate cancer will eventually experience tumor recurrence with metastasis after local 
therapy with surgery or radiation therapy (Boorjian et al., 2012). Primary tumor that has 
extended beyond the prostatic capsule following surgery or radiotherapy is generally 
incurable (Felici et al., 2012; Lassi & Dawson, 2009). Androgen deprivation therapy 
has been the mainstay of treatment for patients with advanced metastatic prostate cancer 
(Cannata et al., 2012). Unfortunately, many patients eventually fail this therapy and 
progress to a stage where the tumor growth becomes unresponsive to hormonal ablation. 
This stage is termed as androgen-independent or castration-resistant prostate cancer. 
Androgen-independent prostate cancer is an incurable disease with a median overall 
survival of 16-18 months (Amaral et al., 2012; Harris et al., 2009). It progresses to local 
invasion of the seminal vesicles, lymph nodes metastasis and eventually develops 
metastatic bone disease. Progression of prostate cancer to androgen independence is a 
main barrier of treatment due to the complex molecular mechanisms underlying the 
evolution of androgen independence. Therefore, there remains an urgent need to find 
more efficacious treatments for patients with metastatic androgen-independent prostate 
cancer.  
At present, treatment options for metastatic androgen-independent prostate 
cancer are limited. Systemic chemotherapy with docetaxel in combination with 
prednisone remains the first-line therapy for patients with symptomatic metastatic 
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androgen-independent prostate cancer, with response rates of approximately 50% 
(Dagher et al., 2004). The main obstacles in treating androgen-independent prostate 
cancer with taxane-based chemotherapy are inherent toxicity associated with their use 
and short-lived survival benefit of approximately 2 to 3 months largely due to 
chemoresistance (Dagher et al., 2004). Nonetheless docetaxel-based regimen produces a 
modest survival benefit in patients, but it is not a curative treatment approach and there 
is an enlarging subset of patients who exhibit disease progression following docetaxel 
treatment and require second-line therapy. Cabazitaxel is a novel semisynthetic taxane-
based drug that has been approved in combination of prednisone as second-line therapy 
for patients with docetaxel-refractory disease (de Bono et al., 2010; Pal et al., 2010; 
Paller & Antonarakis, 2011). Still, the use of cabazitaxel is associated with substantial 
toxicity, primarily related to myelosuppression (de Bono et al., 2010; Nightingale & 
Ryu, 2012). This highlights the pressing need to develop novel agents that can provide 
safer and more efficacious treatment to patients.  
The use of phytochemicals in cancer therapy is gaining significant interest 
owing to their multitarget mechanism of actions and lack of substantial toxicity. A 
number of preclinical studies have demonstrated the effectiveness of bioactive 
phytochemicals against human prostate cancer both in vitro and in vivo with lesser 
toxicity on normal cells, such as lycopene (Tang et al., 2005), resveratrol (Narayanan et 
al., 2004; Wang et al., 2008), genistein (Naik et al., 1994; Suzuki et al., 2002) and 
epigallocatechin gallate (ECGC) (Albrecht et al., 2008; Brusselmans et al., 2003; Lee et 
al., 2008; Luo et al., 2010). Some of these are being evaluated in clinical trials for 
prostate cancer treatment (Russo et al., 2010). These phytochemicals function as 
chemotherapeutic agents by interfering with multiple signaling pathways aberrant in 
prostate cancer. Moreover, bioactive phytochemicals also synergize with conventional 
anticancer drug to improve cancer therapeutic efficacy, but reduce the toxic side effects 
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on normal cells and delay resistance onset. This highlights the promising approach of 
using phytochemicals for treatment of human prostate cancer.  
Alpha (α)-tomatine is the major saponin in tomatoes (Lycopersicon esculentum). 
Previous investigations have reported its cytotoxic effect on different types of human 
cancer cells (Choi et al., 2012; Friedman et al., 2009; Lee et al., 2004), as well as its 
anti-metastasis mechanism on lung cancer and breast cancer cells in vitro (Shi et al., 
2012; Shieh et al., 2011; Shih et al., 2009). However, the therapeutic effect and 
molecular mechanism of α-tomatine on androgen-independent prostate cancer remain 
unknown. Issues that require further clarification are whether α-tomatine targets the 
highly aggressive and invasive phenotype of androgen-independent prostate cancer cells 
in vitro and in vivo, and if so what is the molecular target of α-tomatine, and finally 
does it have chemosensitizing effect on prostate cancer? This study first demonstrates 
the potent therapeutic effect of α-tomatine as single agent and in combination with 
paclitaxel against the highly aggressive human androgen-independent prostate cancer 
PC-3 cells in vitro and in vivo. This is followed by detailed investigations of the 
interference by α-tomatine of NF-κB and PI3K/Akt signaling pathways in prostate 
cancer. It is believed that data from the present study would deliver important insights 
into therapeutic potential of α-tomatine for the treatment androgen-independent prostate 
cancer to warrant further clinical investigations.  
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1.1 The human prostate gland  
1.1.1 Overview 
The prostate is a large sex gland found only in the male reproductive system. It 
is approximately the size of a walnut and is located below the bladder and in front of the 
rectum. The gland surrounds the ejaculatory ducts at the base of urethra. The main 
function of prostate gland is to secrete seminal fluid that nourishes and protects sperm 
cells. It is composed of both glandular tissue that produces prostatic secretion and 
muscle tissue that helps in male ejaculation (Amin et al., 2010).  
 
1.1.2 Macroscopic anatomy of prostate gland  
The prostate is made up of anterior, posterior, lateral and median lobes. McNeal 
(1981) has defined four anatomically and clinically distinct zones within the adult 
prostatic parenchyma: peripheral, central, transitional and periurethral zones (McNeal, 
1981). These zones are distinguished by specific architectural and stromal features, as 
well as their position relative to the urethra. Both ducts and acini are lined by secretory 
epithelium in all the zones. The peripheral zone, an outermost part which consists of 
70% part of normal prostate gland in an adult and comprises most of the glandular 
tissues. The central zone accounts for 25% of the normal prostate volume and surrounds 
the ejaculatory ducts, while the transition zone surrounds the urethra which comprise of 
5% of the prostatic glandular tissue and contains the mucosal glands. The minor zone is 
the periurethral zone, which only consists of mucosal and submucosal glands. McNeal 
classification of prostate morphology is an important determinant of pathological 
condition because the prostatic intraepithelial neoplasia (PIN) and prostate 
adenocarcinoma predominantly arise in the peripheral zone of human prostate gland, 
whereas the transition zone is the place of origin of benign prostatic hyperplasia (BPH) 
(McNeal, 1988a, 1992). 
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1.1.3 Histology of prostate gland 
Microscopically, prostate gland consists of two compartments: (1) a surrounding 
connective tissue, stroma, and (2) epithelial compartment which includes the exocrine 
glands with their associated ductal structures. Stromal-epithelial interaction via 
paracrine mechanism is crucial in human normal prostate morphogenesis (Cunha et al., 
1987). The stromal layer is composed of extracellular matrix, fibroblasts, lymphocytes, 
smooth muscle cells and neuromuscular tissues (Coffey, 1992). Stromal cells play a role 
in regulating the growth and function of epithelial cells by producing growth factor such 
as keratinocyte growth factor (KGF) (Cunha et al., 2004).  
The prostate epithelial cell compartment consists of three cell types: basal cells, 
luminal cells, and neuroendocrine cells. Androgens including testosterone and 
dehydroepiandrosterone (DHEA) are essential for proper growth and differentiation of 
human prostatic epithelium cells during development. Basal cell compartment represent 
a population of undifferentiated and proliferating cells which forms a continuous layer 
along basement membrane of each prostatic duct (Bonkhoff & Remberger, 1996; 
McNeal, 1988b).  Basal cells are characterized by their expression of cell surface 
marker CD44, p53 superfamily member p63, cytokeratins 5 and 14 (Brawer et al., 1985; 
Liu et al., 1997; Sherwood et al., 1990; Signoretti et al., 2000). It is believed that the 
presence of pluripotent stem cell population within the basal cell compartment gives 
rise to terminally differentiated luminal cells and neuroendocrine cells (McNeal, 1988b; 
Xue et al., 1998). Luminal cell is a fully differentiated secretory cell which represents 
the predominant cell type within the prostate epithelium (McNeal, 1988b). It forms a 
layer above basal cells. Secretory luminal cells represent the exocrine compartment of 
prostate which are responsible to produce prostate-specific secretory proteins including 
prostatic-specific antigen (PSA) and prostatic acid phosphatase (PAP). Unlike in basal 
cells, secretory luminal cells express androgen receptor, cell surface marker CD57, 
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cytokeratins 8 and 18 (Brawer et al., 1985; Lamb et al., 2010; Liu et al., 1997; 
Sherwood et al., 1990). As these cells express high levels of androgen receptor, 
therefore they rely on androgens for their survival. Neuroendocrine cells are the 
androgen-insensitive cells which constitute a relatively minor population within 
prostatic acini, and scattered throughout the basal layer (McNeal, 1988b). At the 
molecular level, neuroendocrine cell expresses serotonin, chromogranin A and various 
peptide hormones with potential growth modulating properties. Immunohistochemical 
analysis of keratins revealed that prostate cancer is predominantly composed of 
secretory luminal cells with dispersed neuroendocrine cells. However, several studies 
have also identified the existence of basal phenotype of androgen-independent 
intermediate amplifying cell population in androgen-independent prostate cancer cells 
(DU145 and PC-3) and also within hormone-escaped prostate tumors (van Leenders et 
al., 2001). It is believed that both basal progenitor and luminal cells can be 
oncogenically transformed to give rise to prostate tumors (Choi et al., 2012; Taylor et 
al., 2012). 
 
1.2 Prostate adenocarcinoma 
1.2.1 Overview of prostate abnormalities 
All men are at risk of prostatic problems, ranging from simple infection to 
cancer. Every man past of the age of 50 are advised to perform yearly prostate gland 
examination. The three most common prostatic problems are inflammation, 
enlargement and cancer.  
Prostatitis is an inflammation disease that occurs more often in men younger 
than 50 years of age, which can be a result of bacterial or nonbacterial infections 
(Stamey, 1980). In 1998, The International Prostatitis Collaborative Network (IPCN) 
organized by National Institute of Health (NIH) has documented the classification 
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system of prostatitis syndromes (Table 1.1). In general, bacterial prostatitis is 
characterized by positive cultures of urine or prostatic secretions, presence of 
inﬂammatory cells in prostatic secretions and symptoms of urinary tract infections. 
Non-bacterial prostatitis occurs in men with no history of urinary tract infection and 
negative bacterial cultures of urine and prostatic ﬂuid.  
 
Table 1.1 NIH Prostatitis Classification System (adapted from Krieger et al., 1999) 
 
 
 
 
 
 
 
 
Benign prostatic hyperplasia (BPH) is a non-malignant enlargement of prostate 
gland which usually occurs in aging males overs 50 years of age. This abnormality is 
due to hyperplastic changes of the epithelial and stromal cells in the transition zone of 
prostate gland (Lepor, 2005). It is characterized by nodules of glandular and stromal 
hyperplasia, as well as diffused non-nodular enlargement (Laczko et al., 2005). 
Senescence of prostate cells and age-related androgenic change which affect the 
prostate cell growth are the main factors that contribute to the development of BPH in 
aging males (Castro et al., 2003; Colombel et al., 1998; Zhang et al., 2006).   
Prostate adenocarcinoma is the most common malignancy afflicting men at 
present. It is a slow growing malignancy that is diagnosed almost exclusively in men 
over 50 years of age. This malignant tumor arises from glandular epithelium, and hence 
termed adenocarcinoma (adeno = gland) (Hill & Tannock, 1992; Pierce, 1998). As in 
Category Type 
I Acute bacterial prostatitis 
II Chronic bacterial prostatitis 
III 
IIIA 
IIIB 
Chronic prostatitis/ Chronic pelvic pain syndrome 
Inflammatory 
Non-inflammatory 
IV Asymptomatic inflammatory prostatitis 
 9 
 
the case of normal prostate development, prostate cancer cells also depend on 
androgens for growth and survival, and thus androgen deprivation therapy using 
chemical or surgical castration is the first-line of therapeutic intervention for androgen-
dependent tumors. Initial response to hormonal manipulation is favorable with a 
significant decline in prostate-specific antigen (PSA) levels in most of patients. 
Unfortunately, remission induced by hormonal treatment is usually short-lived (Singer 
et al., 2008). Malignancy eventually progresses to metastatic phase and develops 
resistance to further hormonal manipulation in most patients within 14-30 months after 
the initiation of therapy (Singer et al., 2008). The progression of prostate tumor to 
metastasis malignancy is accompanied by elevated serum PSA levels despite castration 
of the levels of serum testosterone and this is termed metastatic androgen-independent 
or castration-resistant prostate cancer.  
Transition of androgen-dependence to metastatic androgen-independence 
disease is usually provoked by androgen deprivation therapy, and secondary hormonal 
manipulation remains as the palliative benefit for patients but this clinical benefit is 
usually short-lived. In most cases, aggressive malignancy advances to local invasion of 
the seminal vesicles, lymph nodes metastasis and eventually develops metastatic bone 
disease which can be deadly. Today, progression of the disease to the metastatic 
androgen-independent state is the primary reason for prostate cancer-related deaths.  
 
1.2.2 Epidemiology of prostate cancer 
According to Global Cancer Statistics, prostate cancer is the second most 
frequently diagnosed cancer and the sixth leading cause of cancer death in men 
worldwide in 2008 (Jemal et al., 2011). There is more than 25-fold difference in the 
worldwide incidence of prostate cancer, with the highest rate recorded primarily in 
developed countries compared to developing countries (Jemal et al., 2011). 
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Epidemiology data suggests that increasing age, race and family history of the disease 
are the only well-established risk factors that contribute to the tumorigenesis of this 
heterogeneous disease. Approximately 97% of all prostate cancer cases occur in men 50 
years of age and older, and 60% of them are 65 years of age and older. The highest 
prevalence rate in the world is observed in males of African descent in the Caribbean 
region (Bock et al., 2009; Miller et al., 2003). Asian countries typically have lower 
prevalence rates compared to Western countries (United States and Europe).   
According to National Cancer Registry Report 2007, prostate cancer is the 
fourth most common cancer in Malaysian males, it accounts for 6.2 % of cancer cases 
in Malaysian males with the Chinese recording the highest incidence of prostate cancer 
compared to Malay and Indian (Omar & Tamin, 2011). The incidence of prostate cancer 
increases after the age of 45 years and 39.1 % of patients were diagnosed with stage IV 
prostate cancer in 2007 (Omar & Tamin, 2011).   
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1.2.3 Initiation, promotion and progression of prostate cancer  
   
  
 
Figure 1.1 Pathway for human prostate carcinogenesis (adapted from Abate-Shen & 
Shen, 2000).  
 
Prostate adenocarcinoma is a genetically and phenotypically heterogeneous 
disease. Prostate tumorigenesis is a multistage process involving cellular, biochemical 
and genetic alterations from an asymptomatic latent carcinoma to clinically metastatic 
prostatic malignancy. Over 95% of the prostate cancers are adenocarcinomas that arise 
from the epithelial lining of the prostate gland. Loss of normal glandular structure and 
destruction of basement membrane resulted from degradation of prostatic architecture 
occur during prostate tumorigenesis. Extensive studies have identified several important 
allelic losses of tumor suppressor genes and overexpressed oncoproteins associated with 
prostate carcinogenesis, and they are further discussed below.  
Initiation and development of prostate cancer from a low-grade latent carcinoma 
to a high-grade metastatic malignancy arises from cellular, biochemical and genetic 
alterations. PIN is considered as a putative premalignant lesion for clinically significant 
prostatic carcinoma (Bostwick, 1989; De Marzo et al., 2003; Epstein, 2009). It is 
composed of dysplastic cells with a luminal secretory cell phenotype, which expresses 
both PSA and androgen receptor (AR). Histological characteristic of PIN includes the 
appearance of luminal epithelial hyperplasia, reduction in basal cells, enlargement of 
nuclei and nucleoli, cytoplasmic hyperchromasia, and nuclear atypia (Bostwick, 1989). 
Normal 
epithelium 
Prostatic 
Intraperitoneal 
neoplasia (PIN) 
Prostate 
carcinoma 
Metastatic 
carcinoma  
Androgen-
independent 
carcinoma  
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PIN can be categorized into low-grade and high-grade based on the level of cell atypia 
(Ayala & Ro, 2007). The grade of PIN in prostate biopsy is strongly associated with 
susceptibility of epithelium cells to neoplastic transformation, and invasive prostate 
carcinoma (Bostwick & Qian, 2004; McNeal, 1989; McNeal & Bostwick, 1986). High-
grade PIN has been increasingly implicated as precursor of early invasive prostate 
carcinoma (Bostwick, 1995; McNeal & Bostwick, 1986). The continuum from low-
grade PIN to high-grade PIN and early invasive prostate carcinoma involves the 
progression of basal cell layer disruption, loss of secretory differentiation markers, 
nuclear abnormalities, increased microvessel density, variation in DNA content and 
allelic loss is implicated in initiation and progression of prostate cancer. Allelic loss of 
chromosome 8p12-21 (Chang et al., 1994; Macoska et al., 1995; Matsuyama et al., 
1994) and its potential candidate gene NKX3.1, a tumor suppressor gene is involved in 
the initiation of prostate carcinoma (Bhatia-Gaur et al., 1999; He et al., 1997). Loss of 
8p12-21 has been observed in both PIN lesions and early invasive carcinoma, indicating 
its role in the initiation stage of prostate carcinogenesis. In addition, nuclear 
overexpression of MYC oncoproteins due to genomic alteration of chromosome 8q24 
region is highly prevalent in both luminal cells of PIN and advanced prostate cancer, 
suggesting its involvement in the initiation and progression of human prostate cancer 
(Gurel et al., 2008). 
Deletion of a specific region of chromosome 10q and 13q in particular has been 
identified as one of the mechanisms of prostate cancer progression (Bergerheim et al., 
1991; Carter et al., 1990; Cooney et al., 1996; Li et al., 1998; Melamed et al., 1997). 
Phosphatase and tensin homolog (PTEN) gene maps to 10q23 and MXI1 (encodes a 
Myc-binding protein) gene maps to 10q24-q25 deletion on chromosome 10q are 
frequent events in the progression of prostate adenocarcinoma (Bubendorf et al., 1999; 
Di Cristofano & Pandolfi, 2000; Gray et al., 1995). Loss of heterozygosity at 
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chromosome 10q is less frequent in PIN lesions, but more frequently found in 
carcinoma compared to the loss of 8p. Loss of PTEN correlates with high Gleason score 
and advanced prostate cancer (McMenamin et al., 1999). Therefore it is considered to 
be a later event in prostate cancer progression (Ittmann, 1996; Trybus et al., 1996). 
PTEN functions as a negative regulator of Akt, loss of PTEN results in upregulation of 
Akt pro-survival signaling pathway which confers apoptosis-resistance phenotype to 
prostate cancer cells (Chen et al., 2006).  
Prostate cancer usually progresses to an androgen-independent, highly invasive 
malignancy with metastatic growth from an androgen-dependent, organ-confined 
disease. Indeed, analyses of human prostate cancer samples have shown that deletion of 
retinoblastoma (Rb) tumor suppressor gene that maps to chromosome 13q (Sharma et 
al., 2010), loss of deleted in malignant brain tumors 1 (DMBT1) tumor suppressor gene 
(Du et al., 2011), loss of heterozygosity at chromosome 17p deleted a locus for TP53 
tumor suppressor gene (Bookstein et al., 1993; Effert et al., 1993), overexpression of 
forkhead box protein M1 (FOXM1) (Chandran et al., 2007) and B cell leukeimia-2 
(Bcl-2) (Fleischmann et al., 2012; McDonnell et al., 1997) are predominately associated 
with the transition to metastatic androgen-independent stage with poor clinical outcome.  
 Despite significant allelic losses within several tumor suppressor genes and 
overexpression of oncoproteins, deregulation of AR signaling and altered apoptotic 
regulatory genes have been implicated in the mechanism of development of androgen-
independent prostate cancer. A majority of patients treated with androgen-ablation 
therapy ultimately develop androgen-ablation resistance with recurrence of highly 
aggressive and metastatic androgen-independent prostate cancer. Well-studied 
molecular processes contributing to aberrant AR signaling and progression of androgen-
independent prostate cancer include AR gene amplification, mutations, overexpression 
 14 
 
of AR, presence of constitutive AR splice variant, alteration in AR coregulator levels 
and crosstalk with other growth factor signaling pathways (Hu et al., 2010).  
 
1.2.4 Diagnosis and treatment of prostate cancer  
Common diagnostic methods for prostate cancer are digital rectal examination, 
measurement of serum PSA concentration, transrectal ultrasound and biopsy (Pinthus et 
al., 2007). PSA is a 34 kDa kallikrein-like serine protease secreted by epithelial cells of 
the prostate gland (Polascik et al., 1999). PSA is present in small quantities in 
the serum of men with healthy prostates, but is often elevated in the presence of prostate 
cancer or other prostatic disorders.  
Lack of sufficient sensitivity in detecting early stage of prostate cancer is the 
main disadvantage of PSA screening. PSA levels can also be increased by various 
physiological and benign conditions, such as urine retention, PIN, prostatitis, irritation, 
BPH, and recent ejaculation, giving a false positive result (Herschman et al., 1997; 
Nadler et al., 1995; Tchetgen & Oesterling, 1997). Hence, it cannot be used to reflect 
the presence of tumor accurately and has to be used in combination with other 
diagnostic techniques. Common diagnostic tests used in clinical practice to examine 
if cancer has spread within the prostate or to other parts of the body include 
radionuclide bone scan, magnetic resonance imaging, pelvic lymphadenectomy, seminal 
vesicle biopsy, and computed tomography scan.  
Treatment options for prostate cancer are dependent on the stage of prostate 
cancer. Primary therapies such as watchful waiting, surgery (radical prostatectomy), 
radiation therapy (external beam radiation and brachytherapy) are used to treat early 
stage localized prostate cancer (Davidson et al., 1996; Sailer, 2006). However, 30-40% 
of patients eventually develop recurrent or metastatic disease (Dillioglugil et al., 1997). 
In 1941, Charles Huggins discovered that deprivation of androgen caused regression of 
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hormone-responsive metastatic prostate cancer, as prostate cell growth is dependent on 
androgen hormone (Huggins & Hodges, 1941). Since then, hormone ablation therapies 
achieved either surgically with bilateral orchiectomy or medically with luteinizing 
hormone releasing hormone (LHRH) agonists or antagonist, or oral anti-androgens to 
attain maximal androgen blockage (MAB) have become the frontline treatment for 
androgen-sensitive metastatic prostate cancer (Loblaw et al., 2007). These hormonal 
manipulations dramatically suppress gonadal testosterone production, resulting in 
clinical remissions in the majority of patients (Bracarda et al., 2005). Side effects or 
complications of these treatments include urinary and erectile difficulties that adversely 
impact the quality of life. 
In androgen-independent metastatic prostate cancer or in the cases where 
androgen deprivation failed, effective treatment options remain limited. A vaccine-
based immune therapy with Sipuleucel-T has been approved by the United States (US) 
Food and Drug Administration (FDA) for treatment of asymptomatic or minimally 
symptomatic metastatic androgen-independent prostate cancer in April 2010 (Kantoff et 
al., 2010; Kawalec et al., 2012). Modest survival advantage with 4.1 month 
improvement in median overall survival and 22% reduction in risk of death were 
observed in the phase III clinical trial of sipuleucel-T in patients with asymptomatic or 
minimally symptomatic metastatic androgen-independent prostate cancer (Kantoff et al., 
2010). For patients with symptomatic metastatic androgen-independent prostate cancer 
which is progressing rapidly, systemic chemotherapy is now considered as the standard 
of care in these patients. A taxane-based drug, docetaxel in combination with 
prednisone is the current standard of care in first-line palliative chemotherapy treatment 
for metastatic hormone-refractory prostate cancer (Petrylak et al., 2004; Tannock et al., 
2004). Docetaxel is a semisynthetic derivative of paclitaxel. Both drugs are antimitotic 
agents, which impair the natural dynamics of microtubules and leading to mitotic block 
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and apoptosis (Jordan & Wilson, 2004). Chemotherapy with docetaxel regimen 
improves overall survival and effectively decreases PSA in patients suffering with 
advanced malignancy compared with mitoxantrone (Petrylak et al., 2004; Tannock et 
al., 2004). This regimen was approved by the US FDA in 2004. However, inherent 
toxicity associated with the use of docetaxel and short-lived survival benefit of 
approximately 2 to 3 months due largely to chemoresistance represent as treatment 
dilemmas (Chang, 2007; Dagher et al., 2004). Febrile or non-febrile neutropenia, 
anemia and associated myelotoxicity are the dose-limiting adverse effects of docetaxel 
regimen that can severely affect the quality of life and consequent survival in elderly 
patients (Engels & Verweij, 2005). Moreover, there is an ever enlarging subset of 
patients who exhibit clinical disease progression following taxane-based chemotherapy, 
and second-line therapy is required to control tumor growth. In 2010, the US FDA has 
approved cabazitaxel, a second-generation semisynthetic taxane in combination with 
prednisone for treatment of patients whose disease progresses to standard docetaxel-
based therapy (Bilusic & Dahut, 2011). It is the first approved chemotherapeutic drug 
which has shown an improvement in the overall survival benefit in the post-docetaxel 
setting (Bilusic & Dahut, 2011). Unfortunately, the use of cabazitaxel regimen in post-
docetaxel population is also associated with undesired adverse reactions, including renal 
failure, neutropenia, leukopenia, anemia, febrile neutropenia, diarrhea, fatigue, and 
asthenia (Bilusic & Dahut, 2011). Other treatment options for androgen-independent 
disease include secondary hormonal therapy with abiraterone acetate which has been 
shown to improve overall survival in patients with progression of metastatic androgen-
independent prostate cancer after docetaxel-based treatment (de Bono et al., 2011). 
Abiraterone acetate, an oral inhibitor of androgen biosynthesis is designed to further 
inhibit androgen-mediated signaling. It has been approved by US FDA for use in 
combination with prednisone for treatment in chemo-naive patients and also docetaxel-
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refractory patients. However, the survival benefit of this treatment approach for patients 
is modest and it should be noted that the use of abiraterone acetate can be associated 
with substantial toxicities (de Bono et al., 2011). Therefore, continued efforts are being 
focused on development of newer therapeutic agents offering efficacious and safe 
therapeutic treatment for patients with advanced prostate cancer, either use in frontline 
chemotherapeutic setting or perhaps in combination with taxane-based regimen. 
  
1.3 Potential therapeutic targets for prostate cancer intervention 
1.3.1 Overview 
Over the last decade, targeted therapies have emerged as a new and potential 
strategy for cancer treatment. The hallmarks of cancer are composed of six essential 
biological capabilities for development of human cancer (Hanahan & Weinberg, 2011). 
These include sustaining proliferative signaling, resisting cell death, evading growth 
suppressors, activating invasion and metastasis, enabling replicative immortality and 
inducing angiogenesis (Hanahan & Weinberg, 2011). Each hallmark is regulated by a 
number of parallel signaling pathways. Understanding the key signaling pathways 
implicated in cancer growth and progression is important for the development of 
mechanism-based targeted therapeutics.  
Signaling pathways of great importance are androgen-receptor (AR), nuclear 
factor-kappa B (NF-κB), and phosphoinositide 3-kinase (PI3K), because deregulation of 
these signaling pathways frequently occur during prostate cancer progression. Their key 
roles in the transition of prostate cancer to metastatic androgen-independent state and 
their therapeutic interventions are further discussed in the following section.  
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1.3.2 Androgen receptor (AR) 
Androgen receptor (AR) is a 110 kDa nuclear receptor, a member of steroid 
hormone receptor transcription factor family that mediates the actions of androgens 
(Lindzey et al., 1994). It is composed of three major domains: an N-terminal 
transcriptional activation domain, a central DNA-binding domain, and a C-terminal 
steroid-binding domain, localized in the cytoplasm of stromal and secretory epithelial 
cells (Chatterjee, 2003). AR signaling is important for the development and function of 
male reproductive organs, including the prostate and epididymis (McPhaul, 2002; Yeh 
et al., 2002). It is bound to heat-shock proteins (hsp) such as hsp56, hsp70 and hsp90 
during inactive state (Yeh et al., 1999). Upon activation by androgens such as 
testosterone and dihydrotestosterone (DHT), the heat shock proteins dissociate and 
release AR. AR then translocates into the nucleus, binds to the consensus sequence of 
androgen response elements (AREs) (Roche et al., 1992), and activates androgen 
responsive genes (ARGs) involved in diverse biological processes such as proliferation, 
differentiation, apoptosis, metabolism and secretion (Nelson et al., 2002).  
Importantly, AR signaling plays pivotal roles in the prostate carcinogenesis and 
progression to androgen-independent state, where at this point tumor becomes 
unresponsive to androgen ablation therapy. Overexpression of AR due to amplification 
of AR gene is one of the potential mechanisms that has been proposed to explain 
persistence AR signaling in androgen-independent prostate cancer, as about 30% of 
androgen-independent prostate cancer have demonstrated an increase in the expression 
of AR gene (Chen et al., 2004; Koivisto et al., 1997; Linja et al., 2001; Suzuki et al., 
2003; Visakorpi et al., 1995). This leads to constitutive activation of the receptor and 
increases the sensitivity of tumor cells to very low levels of androgens that are produced 
by the adrenal glands. A recent report also suggests that AR hyperactivation due to Rb 
depletion significantly contributes to the androgen-independent prostate cancer 
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transition (Sharma et al., 2010). Mutation in AR gene also allow it to be stimulated by 
other ligands such as anti-androgens and oestrogens, thereby contributing to androgen-
refractory prostate tumor growth (Culig et al., 1993; Gottlieb et al., 2012; Peterziel et 
al., 1995; Taplin et al., 1995). In addition, several studies have reported that the 
presence of crosstalk of AR transactivation with other key growth factor signaling 
events, such as epidermal growth factor receptor (EGFR), mitogen activated protein 
kinase (MAPK) and mitogen-activated/extracellular signal-regulated kinase kinase 1 
(MEKK1), PI3K and NF-κB pathways in the absence of androgen contributes to 
progression of prostate cancer (Abreu-Martin et al., 1999; Bonaccorsi et al., 2004; 
Culig, 2004; Culig et al., 2005; Lee et al., 2005; Peterziel et al., 1999). Other 
documented factors that drive aberrant AR signaling and leads to the progression of 
androgen-independent prostate cancer are the presence of constitutive AR splice variant 
(Sun et al., 2010), prostate cancer stem cells (Collins et al., 2005) and the alteration in 
the expression of coregulators of androgens involved in the regulation of androgen 
receptor-driven transcription (Comuzzi et al., 2004; Culig et al., 2004).  
Current androgen-ablation therapies which suppress AR signaling pathway 
either by blocking androgen synthesis or blocking androgenic effects have been the 
cornerstone of treatment for men with metastatic prostate cancer. While initial clinical 
responses to androgen-ablation therapies are favorable, a vast majority of patients with 
advanced tumors eventually develop androgen-independent prostate cancer which 
carries a much poorer prognosis. The resistance to androgen-ablation therapy acquired 
by tumor cells during androgen deprivation is one of the major challenges in the 
management of prostate cancer. Several second-line hormone manipulations with agents 
such as antiandrogens (flutamide, bicalutamide and nilutamide), ketoconazole and 
abiraterone acetate have been utilized for treatment of metastatic androgen-independent 
prostate cancer. However, the survival benefit of these treatment approaches for patients 
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are modest and their responses are usually associated with toxicities. Clearly, discovery 
of more effective AR inhibitors that will improve clinical outcome for prostate cancer is 
highly desired.   
 
1.3.3 Nuclear factor-kappa B (NF-κB) 
Aberrant regulation of nuclear-factor kappa B (NF-κB) is implicated in the 
development and perpetuation of a variety of human ailments including autoimmune 
disorders, cancer, pulmonary, cardiovascular, neurodegenerative, and inflammatory 
diseases (Ahn et al., 2007; Boissiere et al., 1997; Collister & Albensi, 2005; Sur et al., 
2008). Accumulating evidence suggests that the transcription factor NF-κB plays a 
pivotal role in prostate cancer growth, survival, angiogenesis and metastatic progression 
(Huang et al., 2001; Surh et al., 2002). NF-κB is an ubiquitous transcription factor that 
controls the expression of genes involved in diverse biological processes. It regulates 
the transcriptional activity of over 300 genes involved in growth regulation, 
immunoregulation, apoptosis, inflammation and carcinogenesis (Sethi & Tergaonkar, 
2009). It was discovered as a factor that binds to the promoter of the κ chain of 
immunoglobulins in B cells (Sen & Baltimore, 1986, 2006). Its activation is stimulated 
by a divergent of stimuli including pro-inflammatory cytokines, bacterial and viral 
proteins, carcinogens, tumor promoters, stress, lipopolysaccharide (LPS), 
chemotherapeutic drugs and ionizing radiation through a wide variety of pathways 
(Anto et al., 2002; Banerjee et al., 2002; Chen et al., 2002).  
In mammalian cells, NF-κB1 (also known as p50 and its precursor is p105), NF-
κB2 (also known as p52 and its precursor is p100), Reticuloendotheliosis (REL) A (also 
known as p65), RELB and c-REL are the five identified NF-κB family members, all of 
which can form homo- and heterodimeric complexes (Ghosh et al., 1998; Hayden & 
Ghosh, 2008). Under resting condition, NF-κB dimers are sequestered in cytoplasm and 
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prevented from DNA binding through the interactions with inhibitor of kappa B (IκB) 
proteins consisting of IκBα, IκBβ, IκBγ, IκBε and BCL-3 proteins (Gilmore, 2006; 
Perkins, 2007; Tergaonkar, 2006).  
Numerous stimuli activate NF-κB through IκB kinase (IKK)-dependent pathway. 
The IKK complex consists of 2 catalytic subunits, IKKα and IKKβ, and a non-
enzymatic regulatory subunit, IKKγ/ NEMO (Perkins, 2007; Scheidereit, 2006). The 
signaling of NF-κB is generally mediated through either the canonical (classical) and or 
non-canonical (alternative) pathway. The classical pathway is most widely implicated in 
human cancer because it is involved in the inhibition of programmed cell death under 
most conditions (Karin & Delhase, 2000; Karin & Lin, 2002), whereas the non-
canonical pathway is crucial for development of secondary lymphoid organs, survival 
and maturation of premature B cells (Bonizzi & Karin, 2004). In the classical pathway, 
NF-κB signaling is triggered in response to pro-inflammatory cytokines (e.g.: tumor 
necrosis factor-α, interleukin-1, pathogen-associated molecular patterns) and microbial 
or viral infections that activate IKKα /IKKβ heterodimers, leading to phosphorylation of 
IκB proteins at two crucial serine residues, followed by polyubiquitination by the SCF 
βTrCP
 (Skp1-Cul1-F box protein) E3 ubiquitin-ligase and degradation of IκB proteins by 
26S proteasome (Fuchs et al., 1999; Fuchs et al., 2004; Krappmann & Scheidereit, 
2005). This proteolysis allows nuclear translocation of classical NF-κB (p50/RELA), 
where the free NF-κB dimers function as a transcription factor that induce the 
expression of proinflammatory cytokines, chemokines, and factors for cell proliferation 
and survival (Hoffmann & Baltimore, 2006). A heterodimer of RelA and p50 is the 
most common combination in the canonical NF-κB signaling pathway. 
NF-κB can affect all six hallmarks of cancer as described by Hanahan and 
Weinberg (2011) through the transcriptional activation of genes associated with cell 
proliferation, angiogenesis, metastasis, tumor promotion, inflammation, and suppression 
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of apoptosis (Basseres & Baldwin, 2006; Burstein & Duckett, 2003; Dutta et al., 2006; 
Luo et al., 2005). Of great importance, constitutive NF-κB activation has been observed 
in androgen-independent prostate carcinoma cell lines and the degree of nuclear 
localization of NF-κB p65 correlated with tumor grade (Fradet et al., 2004; Surh et al., 
2002). Activation and localization of NF-κB represent independent risk factors for 
disease recurrence after radical prostatectomy (Domingo-Domenech et al., 2005; Fradet 
et al., 2004). Consistently, it has been reported that aberrant IKK activation leads to the 
constitutive activation of the NF-κB survival pathway in androgen-independent prostate 
cancer cells (Gasparian et al., 2002). Mutation of inhibitory protein IκBα (Wood et al., 
1998), increased level of pro-inflammatory cytokines (O'Connell et al., 1995) and 
proteosomal activity (Miyamoto et al., 1994) are observed in other types of human 
cancer with constitutively active NF-κB. In addition, NF-κB appears to mediate 
transforming growth factor-beta (TGF-β)-induced epithelial-to-mesenchymal-transition 
(EMT), which is a key process involved in metastatic prostate cancer (Zhang et al., 
2009). Hence, it is believed that constitutive NF-κB activation is one of the molecular 
factors involved in the transition toward metastatic androgen-independent prostate 
cancer.  
Owing to the ability of NF-κB to govern the expression of numerous genes 
involved in various human physiologies, targeting NF-κB signaling offers an attractive 
approach for therapeutic development. At present, more than 700 inhibitors of this 
transcription factor have been described, including natural agents, peptides, synthetic 
molecules, anti-inflammatory or immunosuppressive agents, viral and microbial 
proteins (Gupta et al., 2010). NF-κB signaling can be suppressed by targeting various 
steps of the pathway including upstream signaling of IKKs, IKKs, ubiquitination step, 
methylation step, nuclear translocation step and DNA binding step. Some molecules 
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target one specific step leading to NF-κB inactivation, while there are several inhibitors 
that target multiple steps in the signaling. 
To date, NF-κB inhibitors such as are non-steroidal anti-inflammatory drugs 
(NSAIDs), cyclosporine A and corticosteroids are currently used for treating 
inflammatory conditions. Unfortunately, these drugs are highly pleiotropic, lack 
specificity in attenuating NF-κB activity and consequently require high dosage, causing 
toxicity and adverse effects to patients. A number of clinical trials have been performed 
with several NF-κB inhibitors for cancer treatment but the most signiﬁcant clinical data 
have so far been obtained with bortezomib. Bortezomib is a proteasome inhibitor which 
was approved by the US FDA in 2003 for second-line therapy of patients with 
progressive multiple myeloma (Kane et al., 2003). It is a selective inhibitor of the 20S 
proteasome (Adams et al., 1999), that inhibits the NF-κB signaling by preventing IκBα 
degradation, and possesses potent anti-tumor activities against various human cancers 
(Lenz, 2003). The clinical efficacy of bortezomib for treatment of cancer has been 
thoroughly investigated in Phase I, II and III clinical trials. However, the use of 
bortezomib is hampered by its severe adverse side effects, unsatisfactory efficacy in 
treatment of solid tumors and development of drug resistance (Chen et al., 2011). 
Nevertheless emerging evidences have clearly indicated that NF-κB inhibition is a 
promising therapeutic strategy for treatment of prostate cancer, and this warrants further 
efforts to discover highly specific but less toxic NF-κB inhibitors for the treatment of 
prostate cancer.  
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1.3.4 Phosphoinositide 3-kinase (PI3K)/Protein kinase B (Akt) 
PI3K is a heterodimeric enzyme which plays a central role in several critical 
cellular processes for cancer survival, growth, metabolism and motility. In mammalian 
cells, there are multiple isoforms of PI3K and they are subdivided into three classes 
based on the difference in structure and function. Class IA PI3Ks is most widely 
implicated in human cancer (Courtney et al., 2010; Yuan & Cantley, 2008), and is 
composed of a 110 kDa (p110) catalytic subunit that confers enzyme activity, and a 85 
kDa (p85) regulatory subunit (Carpenter et al., 1990). PIK3CA, PIK3CB, and PIK3CD 
encode p110α, p110β, and p110δ, respectively, which represent the catalytic isoforms 
(Engelman et al., 2006). The regulatory isoforms, p85α, p85β, and p55δ, are the 
products of three genes, PIK3R1, PIK3R2, and PIK3R3 (Engelman et al., 2006). The 
activation of class IA PI3Ks by growth factor is mediated through receptor tyrosine 
kinases (RTKs) (Skolnik et al., 1991; Zhao & Vogt, 2008). Examples of RTK include 
platelet derived growth factor receptor (PDGFR), epidermal growth factor receptor 
(EGFR), and insulin-like growth factor receptor (IGFR). In response to ligand binding, 
the p85 regulatory subunit directly binds to phosphotyrosine residues on RTKs, the 
binding relieves its inhibitory effect on p110 catalytic subunit (Cuevas et al., 2001). Ras 
oncoprotein (Shaw & Cantley, 2006) and G-protein coupled receptors (Katso et al., 
2001) have also been shown to directly activate p110 action. p110 catalytic subunit 
catalyzes the production of PtdIns-3,4-P2 (PIP2) and PtdIns-3,4,5-P3 (PIP3) that 
function as second messenger to recruit Akt and phosphoinositide-dependent kinase 
(PDK) to the plasma membrane (Auger et al., 1989; Cantley & Neel, 1999; Carpenter et 
al., 1990; Whitman et al., 1988). Akt is phosphorylated and activated in the presence of 
PDK1 and PDK2. Activated Akt conveys signals through phosphorylating numerous 
substrates involved in the regulation of cell survival, proliferation and growth (Chan et 
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al., 1999; Duronio et al., 1998). Phosphatase and tensin homolog (PTEN), a tumor 
suppressor gene terminates PI3K signaling by dephosphorylating PIP3 to PIP2.  
Anti-apoptotic mechanism of activated Akt is multifactorial as it directly 
phosphorylates several substrates involved in cell death. Foremost among these 
downstream target substrates of Akt are BAD and NF-κB.  BAD is one of pro-apoptotic 
Bcl-2 family members, which promotes cell death by forming a heterodimer with the 
anti-apoptotic Bcl-2 family member Bcl-xL. Activated Akt inhibits apoptosis cell death 
by phosphorylating and inactivating BAD, causing its dissociation from the Bcl-xL, and 
in turn, restores anti-apoptotic function of Bcl-xL (Datta et al., 1997; del Peso et al., 
1997; Gross et al., 1999). Similarly, activation of Akt by growth signals can 
phosphorylate and activate NF-κB signaling through IKK-dependent pathway, which in 
turn transactivates a number of genes involved in cellular proliferation and apoptosis 
(Romashkova & Makarov, 1999). Furthermore, it has been shown that PI3K/Akt/NF-κB 
signaling mediates the process of chemoresistance and radioresistance in various tumor 
cells, as several genes such as cyclin D1, COX-2, Bcl-2, Bcl-xL, XIAP, and survivin are 
NF-κB effector genes (Catz & Johnson, 2001; Guttridge et al., 1999; Stehlik et al., 1998; 
Tamatani et al., 1999; Yamamoto et al., 1995; Zhu et al., 2001). Other Akt target 
substrates are pro-apoptotic protease caspase-9 and Forkhead family of transcription 
factors (FKHR), where phosphorylation of these substrates attenuates their pro-
apoptotic activities (Brunet et al., 1999; Cardone et al., 1998). Apart from its role in 
apoptotic machinery, Akt also affects cell growth and proliferation. Akt phosphorylates 
glycogen synthase kinase-3 beta (GSK-3β) on serine 9, thereby inactivating its kinase 
activity on cyclin D1 and resulting in cell proliferation (Diehl et al., 1998). Expression 
of cyclin kinase inhibitors such as p27kip1 and p21Cip/ WAF1 are also negatively 
regulated by activated Akt (Graff et al., 2000; Li et al., 2002). Mammalian target of 
rapamycin (mTOR), a serine/threonine kinase which is a downstream effector of Akt is 
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involved in cell growth (an increase in cell size and mass). Activated Akt promotes the 
growth function of mTOR by direct phosphorylation inhibiting tuberous sclerosis 
complex 2 (TSC2), a negative regulator of mTOR (Inoki et al., 2002). Activation of 
mTORC1 integrates the signals from nutrients and growth factors to initiate cell growth 
by regulating mRNA translation, ribosome biogenesis, autophagy and metabolism 
(Kunz et al., 1993; Sarbassov et al., 2005; Wullschleger et al., 2006).  
Deregulation of PI3K/Akt pathway is one of the most frequent occurrences in 
human cancers including prostate cancer (Kreisberg et al., 2004). A study reported that 
Akt and AR act synergistically to promote the initiation and progression of prostate 
cancer in vivo, and cause the resistance to androgen ablation therapy (Xin et al., 2006).  
To date, the main documented mechanisms of constitutive PI3K/Akt activation 
observed in human cancers are genetic mutation and amplification of the specific key 
components of the signaling and activation by RTKs (Engelman, 2009; Rodon et al., 
2013). Mutation in tumor suppressor gene PTEN which functions as a negative 
regulator of PI3K is commonly observed in prostate cancer samples (Cairns et al., 1997; 
Komiya et al., 1996; McMenamin et al., 1999; Rodon et al., 2013). A recent study 
revealed that sustained PI3K activity in PTEN-deficient prostate cancer cells (PC-3 and 
LNCaP) is mediated through constitutively active form of p110, and is independent of 
RTK and Ras (Jiang et al., 2010). Studies have shown that prostate epithelium with 
homozygous deletion of PTEN potentially develop aggressive prostate carcinoma 
(Trotman et al., 2003; Wang et al., 2003). Indeed, complete loss of PTEN is observed at 
highest frequencies in androgen-independent prostate cancer accompanied with higher 
Gleason scores (Bertram et al., 2006; Dreher et al., 2004; Li et al., 1997; McMenamin 
et al., 1999; Sansal & Sellers, 2004; Schmitz et al., 2007), and is correlated with the 
incidence of development of lymph node metastases (Schmitz et al., 2007).  
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To date, a number of potent PI3K pathway inhibitors with improved 
pharmacological properties have been investigated intensively in both in vitro and in 
vivo models of prostate cancer. The most well-studied PI3K pathway inhibitors are 
LY294002 (Renner et al., 2007), GSK690693 (Rhodes et al., 2008), wortmannin 
(Powis et al., 1994; Seol et al., 2005), celecoxib (Narayanan et al., 2006; Patel et al., 
2005; Zheng et al., 2007), and perifosine (Chee et al., 2007; Posadas et al., 2005). So 
far only perifosine and celecoxib have been investigated in the clinical settings for 
treatment of prostate cancer. However, these agents have limited use in clinical practice 
because they lack specificity in blocking the PI3K/Akt and thus cause devastating side 
effects to patients. Therefore, there remains a pressing need to discover new, more 
efficient and less toxic PI3K pathway inhibitor for treatment of prostate cancer.  
 
1.4 Phytochemicals for cancer treatment 
1.4.1 Overview 
Positive therapeutic outcomes of conventional cancer therapies such as surgery 
and chemo- and radiotherapy are often limited due to high toxicity and related side-
effects, as well as the development of multi-drug resistance. Therefore, there is a 
pressing need for new therapeutic strategies to ameliorate treatment efficacy but 
minimize toxicity to normal tissues.  
Increasing evidence suggest that phytochemicals with distinct anticancer activity 
could be considered as potential cancer chemotherapeutic agents (Cragg & Newman, 
2009). Phytochemicals are typically secondary metabolites produced by plants for 
specific functions. They are not essential for normal growth, development and 
reproduction of normal plant cells, but play a role in protecting the plant against any 
harm in ecological environment. Phytochemicals are of particular interest for use in 
preventing cancer prevention or treatment because of their potentially low toxicity 
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profiles, thus they could be administrated on a long-term basis to either prevent primary 
tumor formation or tumor growth without adversely affecting the normal tissues 
(Aggarwal et al., 2007). To date, numerous preclinical studies have identified a number 
of potential plant-derived agents with lesser toxicity as effective anticancer agents in 
vitro and in vivo, such as isothiocyanates, resveratrol, curcumin, sulforaphane, lycopene, 
genistein and epigallocatechin gallate (ECGC) (Russo et al., 2010). Anti-carcinogenic 
studies of these plant constituents showed that these phytochemicals either block tumor 
initiation or suppress tumor growth during the promotion stage of cancer development 
by modulating signals transduction essential for carcinogenesis. Furthermore, some of 
these bioactive phytochemicals such as genistein, curcumin, ECGC and lycopene have 
been shown to improve cancer therapeutic efficacy in association with classical 
chemotherapeutic drugs and the combined treatment can delay resistance onset (Li et al., 
2005; Notarbartolo et al., 2005; Stearns et al., 2010; Stearns & Wang, 2011; Tang et al., 
2011).  
Indeed, some of these phytochemicals have been evaluated in clinical trials for 
their efficacy in treating prostate cancer. The clinical data suggest phytochemicals 
represent good candidates for chemotherapeutic applications. For example, a mixture of 
green tea catechins was used in a chemoprevention trial on patients with premalignant 
lesion of prostate cancer (Bettuzzi et al., 2006). The development of prostate cancer 
from high grade PIN (premalignant lesion of prostate cancer) was 3% in the 
experimental group and 30% in the placebo group following one year treatments (600 
mg/day) (Bettuzzi et al., 2006). A follow-up update to this study reported that the 
chemopreventive effect of green tea catechins was long-lasting (Brausi et al., 2008). 
Nonetheless, two clinical studies have reported that green tea catechins have limited 
benefits in patients with androgen-independent prostate cancer, and the outcomes from 
these clinical trials do not merit further investigations (Choan et al., 2005; Jatoi et al., 
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2003). Clinical trials of lycopene conducted on the patients with localized prostate 
cancer show that lycopene supplementation reduced tumor growth and plasma PSA 
levels in the intervention group compared with the control group (Kucuk et al., 2002). 
However, lycopene has also been shown to have unfavorable responses for patients with 
androgen-independent prostate cancer and it also causes gastrointestinal side effects 
(Ansari & Gupta, 2004; Jatoi et al., 2007; Schwenke et al., 2009). Other 
phytochemicals such as genistein (deVere White et al., 2004; deVere White et al., 2010; 
Kwan et al., 2010; Lazarevic et al., 2011; Pendleton et al., 2008) and pomegranate 
(Paller et al., 2013; Pantuck et al., 2006) have also been clinically investigated in 
patients with localized or androgen-dependent prostate cancer, the outcome from these 
clinical trials suggest their positive effect in reducing serum PSA levels and/ or increase 
in the PSA doubling time. Despite some successful stories of using phytochemicals as 
potential treatment for androgen-dependent prostate cancer, there are rooms for the 
discovery of more bioactive phytochemicals for the development of effective drugs 
against aggressive form of androgen-independent prostate cancer. The continuing 
efforts to discover effective phytochemicals will certainly shed light on the 
improvement of androgen-independent prostate cancer and contribute to impressive 
therapeutic outcomes. 
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1.4.2 Alpha (α)-tomatine 
1.4.2.1 Chemical structure of α-tomatine 
 
 
Figure 1.2 Chemical structure of α-tomatine.  
 
 
 
Figure 1.3 Chemical structure of dehydrotomatine (adapted from Friedman et al., 2007).  
 
Glycoalkaloid is one of the naturally occurring N-containing secondary plant 
metabolites in Solanaceous plant species such as egg-plants, potatoes, and tomatoes 
(Lycopersicon esculentum). It is produced by plants in defense against phytopathogens.  
Fontaine et al. (1948) first isolated glycoalkaloids from tomatoes, known as tomatine 
(Fontaine et al., 1948).  Tomatine comprises of ~10:1 mixture of alpha (α)-tomatine and 
dehydrotomatine, and is present in all parts of the tomato plant (Friedman, 2004; 
Friedman et al., 1994; Kozukue et al., 2004). Alpha-tomatine consists of an aglycon 
moiety (tomatidine), and a tetrasaccharide moiety (β-lycotetrose) that contains two 
molecules of D-glucose and one each of D-galactose and D-xylose (Figure 1.2). The 
Double bond 
Empirical formula: C50H81NO21 
Empirical formula: C50H83NO21 
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chemical structure of dehydrotomatine is different from α-tomatine, where 
dehydrotomatine has a double bond in the steroidal ring B of the aglycon (Figure 1.3). 
Immature green tomatoes contain up to 500 mg of α-tomatine/ kg of fresh fruit weight. 
The compound is partly degraded by enzyme synthesized or activated during fruit 
maturation. As the tomato ripens until at maturity level, there is an approximately 5 mg 
of α-tomatine/ kg of fresh fruit weight in mature red tomatoes (Friedman & Levin, 
1995).  
 
1.4.2.2 Biological activities of α-tomatine 
Alpha-tomatine has been shown previously to possess beneficial role in some 
biological activities including anti-fungal (Ito et al., 2007; Sandrock & Vanetten, 1998), 
immune-stimulation (Heal & Taylor-Robinson, 2010; Morrow et al., 2004; Yang et al., 
2004) and cholesterol lowering activities (Friedman et al., 2000).  
Apart from these beneficial biological effects of α-tomatine, previous studies 
have shown that α-tomatine has in vitro cytotoxic effects against the growth of various 
human cancer cells, including colon cancer HT-29 (Choi et al., 2012; Friedman et al., 
2009; Lee et al., 2004), liver cancer HepG2 (Friedman et al., 2009), stomach cancer 
AGS (Friedman et al., 2009), gastric cancer KATO-III (Choi et al., 2012), leukemia 
MOLT-4 (Kúdelová et al., 2013), breast cancer MCF-7 (Friedman et al., 2009) and 
MDA-MB-231 cells (Choi et al., 2012). Based on data derived from in vitro 
cytotoxicity assay, the cytotoxic effect of α-tomatine against the cancer cells was 
stronger than dehydrotomatine (Friedman et al., 2009)  and its hydrolysis products (β1-
tomatine, γ-tomatine, δ-tomatine and tomatidine) (Choi et al., 2010; Lee et al., 2004).  
In vivo study by Friedman et al. (2007) showed that α-tomatine has protective effects 
against dibenzo[a,l]pyrene (DBP)-induced liver and stomach tumors in rainbow trout 
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without causing significant changes in total weight, liver weight, tissue morphology and 
mortality (Friedman et al., 2007).   
A more recent study reported that exposure of α-tomatine to human chronic 
myeloid leukemia K562 cell line and acute promyelocytic leukemia HL60 caused 
growth inhibition and apoptosis (Chao et al., 2012) which is mediated through the 
release of apoptosis-inducing factor (AIF) from the mitochondria into the nucleus and 
down-regulated the expression of survivin expression (Chao et al., 2012). The study 
also showed that α-tomatine significantly inhibited HL60 xenograft tumor growth 
without significant body weight loss in severe combined immunodeficiency (SCID) 
mice, accompanied by increased expression of apoptotic marker and decreased 
expression of survivin (Chao et al., 2012).  
In addition, a study has shown that glycoalkaloid α-tomatine inhibits invasion 
and migration of A549 cells at the sub-toxic concentration by reducing the activities of 
matrix metalloproteinase (MMP)-2 and MMP-9 (Shih et al., 2009). Further molecular 
study suggests that anti-metastasis mechanism of α-tomatine on A549 cells is related to 
its suppression effects on PI3K/Akt, extracellular signal-regulated kinases (ERK) 
signaling pathways, and the inhibition on binding activities of NF-κB and activated 
protein-1 (AP-1) transcription factors (Shih et al., 2009).  In a similar study, Shieh et al. 
(2011) reported the anti-metastatic activity of α-tomatine on NCI-H460 cells by 
downregulation of MMP-7 expression. It is proposed that the mechanism of anti-
metastasis effect occurs through the inactivation of focal adhesion kinase 
(FAK)/PI3K/Akt signaling pathway and reducing NF-κB DNA binding activity (Shieh 
et al., 2011). A more recent study also revealed that α-tomatine suppressed the 12-O-
tetradecanoylphorbol-13-acetate (TPA)-induced invasion and migration by blocking the 
protein kinase C alpha (PKC-α)/ERK signaling followed by NF-κB dependent MMP-
2/9 activation on breast cancer MCF-7 cells (Shi et al., 2012). However, the mechanism 
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of inhibitory effect of α-tomatine on NF-κB DNA binding activity is not reported. 
These studies proposed that α-tomatine as an anti-metastatic agent against human lung 
and breast adenocarcinoma.   
The present study aimed to investigate the therapeutic efficacy of α-tomatine as 
single agent and in combination with taxane-based regimen for treatment of androgen-
independent prostate cancer. Previous studies have demonstrated the cytotoxic effect of 
α-tomatine on different types of human cancer cells in vitro, as well as its anti-
metastatic mechanism on lung and breast cancer cells having wild-type p53 and PTEN 
tumor suppressor gene. However, the susceptibility of p53/PTEN null androgen-
independent prostate adenocarcinoma PC-3 cells to the anti-cancer effect of α-tomatine 
and the related molecular mechanism remain to be investigated. It is worth noting that 
different types of human cancer exhibit different histopathologies, genetic and 
epigenetic alterations, which actually contributes to variable drug response or efficacy. 
Similarly, there is no one universal chemotherapy drug that is used to treat all types of 
human cancer at present, and each chemotherapy agent is uniquely effective against 
specific types of cancer. Therefore, it is essential to further explore the potential of α-
tomatine to combat other types of incurable human cancer including androgen-
independent prostate cancer.  
Androgen-independent prostate cancer PC-3 cells derived from patients with 
prostate cancer bone metastasis are used as a model test system in the present study 
because of their highly aggressive proliferative nature. Our preliminary study showed 
that AR null PC-3 cells were more sensitive to growth inhibition by α-tomatine 
compared to wild-type p53 and AR expressing androgen-dependent prostate cancer 
LNCaP cells. PC-3 cell line is used in the present study as it closely mimics the castrate 
resistant stage of human prostate which is clinically more relevant in discovery of novel 
therapeutics for androgen-independent prostate cancer. It is expected that findings from 
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the present study would provide important insights into the therapeutic potential of α-
tomatine in androgen-independent prostate cancer that warrants further clinical 
investigations. More importantly, this will also be the first reported study to investigate 
the in vitro and in vivo chemosensitizing anti-cancer efficacy of α-tomatine with taxane-
based agent.   
 
1.5 Research objectives 
The overall objective of the proposed investigation is to investigate the anti-
cancer effect of α-tomatine on the growth of human androgen-independent PC-3 
prostate cancer cells. The specific aims of the study are: i) To investigate the in vitro 
anti-cancer effect of α-tomatine on the growth of PC-3 cancer cells, ii) To elucidate the 
molecular mechanism underlying  cytotoxicity of α-tomatine on PC-3 cells, iii) To 
examine the anti-tumor efficacy of α-tomatine on the subcutaneous and orthotopic 
tumor growth in immunodeficient mice, and iv) To investigate the in vitro and in vivo 
synergistic anti-cancer effect of α-tomatine in combined with paclitaxel against PC-3 
cells.  
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CHAPTER 2 
IN VITRO ANTICANCER ACTIVITY OF ALPHA-
TOMATINE ON ANDROGEN-INDEPENDENT 
PROSTATE CANCER PC-3 CELLS 
 
 
 
 
The contents in this chapter have been published in Lee, S. T., Wong, P. F., Cheah, S. 
C., Mustafa, M. R. (2011). Alpha-tomatine induces apoptosis and inhibits nuclear 
factor-kappa B activation on human prostatic adenocarcinoma PC-3 Cells. PLoS ONE, 
6(4), e18915.  
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2.1 Abstract 
Alpha-tomatine is the major saponin in tomato (Lycopersicon esculentum). This study 
investigates the chemopreventive potential of α-tomatine on androgen-independent 
human prostatic adenocarcinoma PC-3 cells. Treatment of highly aggressive human 
prostate cancer PC-3 cells with α-tomatine resulted in a concentration-dependent 
inhibition of cell growth with a half-maximal efficient concentration (EC50) value of 
1.67 ± 0.3 µM. It is also less cytotoxic to normal human liver WRL-68 cells and normal 
human prostate RWPE-1 cells. Assessment of real-time growth kinetics by cell 
impedance-based Real-Time Cell Analyzer (RTCA) showed that α-tomatine exhibited 
its cytotoxic effects against PC-3 cells as early as an hour after treatment. The inhibitory 
effect of α-tomatine on PC-3 cancer cell growth was mainly due to induction of 
apoptosis as evidenced by positive Annexin V staining and decreased in mitochondrial 
membrane potential but increased in nuclear condensation, polarization of F-actin, cell 
membrane permeability and cytochrome c expressions. Results also showed that α-
tomatine induced activation of caspase-3, -8 and -9, suggesting that both intrinsic and 
extrinsic apoptosis pathways are involved. Furthermore, nuclear factor-kappa B (NF-κB) 
nuclear translocation was inhibited, which in turn resulted in significant decreases in 
NF-κB/p50 and NF-κB/p65 in the nuclear fraction of the treated cells compared to the 
control untreated cells. These results provide further insights into the molecular 
mechanism of the anti-proliferative actions of a-tomatine. Alpha-tomatine induces 
apoptosis and inhibits NF-kB activation on prostate cancer cells. These results suggest 
that α-tomatine may be beneficial for protection against prostate cancer development 
and progression.  
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2.2 Introduction 
Prostate cancer is one of the leading causes of death in men worldwide with 
major mortality due to advanced stage of the cancer where androgen-independent cells 
become unresponsive to hormone ablation therapy (Jemal et al., 2011). There is a 
pressing need to identify alternative chemopreventive measures as surgery and current 
chemotherapeutic strategies can be ineffective against the aggressive form of prostate 
cancer (Neergheen et al., 2010; Russo, 2007; Surh, 2003).  
Failure of cells to undergo apoptotic cell death contributes to the development of 
cancers, hence treatment that induces apoptosis would be a promising anticancer 
strategy (Hanahan & Weinberg, 2011; Tan et al., 2009). Natural products are important 
sources of new and less toxic anticancer agents. A variety of dietary agents such as 
resveratrol, curcumin, sulforaphane, gingerol, indole-3 carbinol, withanolide and green 
tea catechins can induce apoptosis and are effective against various human cancer cells 
tested (Khan et al., 2008, 2010; Martin, 2006; Nobili et al., 2009; Tan et al., 2009). 
These also have an added advantage of lesser toxicity compared to current standard 
therapeutic drugs (Dorai & Aggarwal, 2004). 
The present work investigates the chemopreventive potential of α-tomatine 
against prostate cancer cells. Alpha-tomatine is the major saponin in tomato 
(Lycopersicon esculentum). It possesses anti-fungal (Ito et al., 2007; Sandrock & 
Vanetten, 1998), immune-stimulation (Heal & Taylor-Robinson, 2010; Morrow et al., 
2004; Yang et al., 2004) and cholesterol lowering activities (Friedman et al., 2000). It is 
protective against dibenzo[a,l]pyrene (DBP)-induced liver and stomach tumors in 
rainbow trout (Friedman et al., 2007) and also promotes anti-proliferative effects 
against human colon HT-29, liver HepG2, breast MCF-7 and stomach AGS cancer cells 
(Friedman et al., 2009; Lee et al., 2004). Thus far, it is only known that α-tomatine acts 
on phosphoinositide 3-kinase/ protein kinase B (PI3K/Akt) and extracellular signaling-
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regulating kinase (ERK) signaling pathways in lung adenocarcinoma A549 cells (Shih 
et al., 2009). The present study, hence, seeks to investigate the effect of α-tomatine on 
the growth of human prostatic adenocarcinoma PC-3 cells and to identify its potential 
growth inhibitory mechanism. Results from the present study would provide new 
insights into the beneficial role of -tomatine for prevention of prostate cancer 
development and progression. 
 
2.3 Materials and Methods 
2.3.1 Phytochemicals, standard drug and reagents 
Alpha-tomatine (purity > 97%) was purchased from Tokyo Chemical Industry (Tokyo, 
Japan). Paclitaxel from Ascent Scientific (Weston-SuperMare, UK), a standard drug 
used in chemotherapy regimen for prostate cancer was used as positive control in this 
study. Curcumin (Merck, Germany) was used as positive control in NF-κB translocation 
assay. Dimethyl sulfoxide (DMSO) and tumor necrosis factor-alpha (TNF-α) were 
purchased from Sigma Aldrich (St. Louis, MO). Both the tested compound and positive 
controls were prepared in 100% DMSO, stored at -20°C, and then diluted as needed in 
cell culture medium. Penicillin/ streptomycin, Dulbecco Modified Eagle Medium 
(DMEM), Roswell Park Memorial Institute (RPMI 1640), keratinocyte growth medium, 
fetal bovine serum (FBS) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenytetrazolium 
bromide (MTT) were purchased from Invitrogen (Carlsbad, CA). 
 
2.3.2 Cell lines 
Prostate cancer PC-3 (CRL-1435), normal human liver WRL-68 (CL-48) and normal 
human prostate epithelial RWPE-1 (CRL-11609) cells were obtained from the 
American Type Culture Collection (Manassas, VA) and cultured in RPMI-1640, 
DMEM and keratinocyte growth medium, respectively. Both RPMI-1640 and DMEM 
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were supplemented with 10% heat-inactivated FBS, 100 U/mL penicillin and 100 
μg/mL streptomycin. Cells were cultured at 37 ºC in a humidified atmosphere of carbon 
dioxide–air (5:95).  
 
2.3.3 In vitro cytotoxicity screening 
Briefly, adherent cells were seeded in sterile 96-wells plates at optimum cell density. 
After 18–24 hours, cells were treated with increasing concentrations (0.16 - 5.0 μM) of 
α-tomatine for 24 hours. Cells treated with 0.2% DMSO was used as vehicle control. 
Following treatment, cells were incubated in the dark with 2 mg/ml MTT at 37°C for 2 
hours, then the medium was carefully removed and 100 μl of DMSO was added to 
dissolve the formazan crystals formed. Absorbance was measured at 570nm in a plate 
reader. Cell viability was calculated using the following formula: (mean absorbance in 
test wells)/ (mean absorbance in control well) x 100%. Dose-response curves were 
plotted using GraphPad Prism 4 (GraphPad Software Inc., San Diego, CA). Half 
maximal effective concentration (EC50) values were determined using non-linear 
regression model with sigmoidal dose response (variable slope) following the algorithm 
of GraphPad Prism 4. 
 
2.3.4 Real time cell proliferation analysis 
Real time growth kinetics of PC-3 cells was examined by impedance-based Real-Time 
Cell Analysis (RTCA) system (Roche Diagnostic, Mannheim, Germany). RTCA 
utilizes E-plate which contains inter-digitated micro-electrodes on the bottom of the 
plate that detect local ionic changes as cells proliferate and is measured as electrode 
impedance. Briefly, 50 μl of medium was added in 16-wells E-plate and background 
readings were recorded. Cell suspension (50 μl) at cell density of 1.25 x 104 cells/well 
was added to each well of the E-plate. The attachment, spreading and proliferation of 
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the cells were monitored every 5 minutes intervals. When the cells entered logarithmic 
growth phase, they were treated with 100 μl of α-tomatine at various concentrations and 
continuously monitored every 10 minutes for up to 72 hours. Cells treated with 0.2% of 
DMSO was used as vehicle control and monitored in parallel with the α-tomatine and 
paclitaxel-treated cells. Cell sensor impedance was expressed as an arbitrary unit called 
the cell index. The cell index at each time point was defined as (Rn – Rb) / 15, where Rn 
is the cell-electrode impedance of the well and the Rb is the background impedance of 
the well with the media alone. Growth curves were normalized to the cell index at the 
last measured time point before compound addition for each well.  
 
2.3.5 Annexin V/propidium iodide (PI) double staining assay 
Apoptosis-mediated cell death of tumor cell was examined by a double staining method 
using FITC-labeled Annexin V/ PI apoptosis detection kit (BD Bioscience, San Jose, 
CA) according to the manufacturer’s instructions. Briefly, control and α-tomatine-
treated cells were collected, washed in cold phosphate-buffered saline (PBS) twice, 
stained with fluoresceinisothiocyanate (FITC)-conjugated annexin V and PI dyes. The 
externalization of phoshotidylserine and the permeability to PI were evaluated by FACS 
Calibur flow cytometer (BD Bioscience, San Jose, CA). Data from 10,000 gated events 
per sample were collected. Cells in early stages of apoptosis were positively stained 
with annexin V; whereas, cells in late apoptosis were positively stained with both 
annexin V and PI. 
 
2.3.6 Multiparameter high content screening (HCS) assays 
HCS (Cellomics Inc, Pittsburgh, PA, USA) enables concurrent quantitative 
measurement of multiple independent cellular phenotypes using fluorescent probes. 
Both Cellomics multiparameter cytotoxicity and apoptosis HitKit
 
(Pittsburgh, PA, USA) 
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were used to examine cellular changes in the α-tomatine-treated PC-3 cells. 
Multiparameter cytotoxicity HitKit
 
contains four fluorescent dyes, i.e. blue fluorescent 
Hoechst 33342, membrane permeability, mitochondrial membrane potential, and 
cytochrome c dyes. They respectively detect changes in nuclear morphology (nuclear 
condensation), membrane permeability, mitochondrial membrane potential and 
expression of cytochrome c. The multiparameter apoptosis kit quantifies three 
fundamental parameters related to the process of apoptosis, i.e. (i) nuclear condensation, 
detected by the blue fluorescent nuclear dye, Hoechst 33342; (ii) F-actin content, 
detected by green fluorescent Alexa Fluor 488 Phalloidin stain; (iii) mitochondrial 
membrane potential, based on the uptake of MitoTracker Red into mitochondria of cells. 
Briefly, PC-3 cells were seeded overnight at density of 8000 cells/well into flat-
bottomed 96-well plates (Perkin-Elmer Inc., Wellesley, MA, USA). Following 
treatment with different concentrations of α-tomatine (0.25 to 2.0 μM), fixation and 
staining for imaging analysis of the PC-3 cells were performed according to the 
manufacturer’s instructions. Cells treated with 0.2% DMSO and 5.0 μM paclitaxel were 
used as negative and positive controls, respectively. Plates were analyzed using Thermo 
Scientific ArrayScan VTI HCS Reader (Cellomics Inc, Pittsburgh, PA, USA). This is a 
computerized automated fluorescence imaging microscope that automatically identifies 
stained cells and measures the intensity and distribution of fluorescence in individual 
cells. Images for each fluoroprobe were acquired at different channels using suitable 
filters with 20x objective at fixed exposure time. The Cell Health Profiling 
BioApplication software was used for image acquisitions and analysis. For each well, at 
least 25 fields, corresponding to at least 500 cells were automatically acquired and 
analyzed. All experiments were performed in triplicate. Cell average intensity (Mean) 
under the modified object mask within selected range in each channel was used as assay 
indicator, and reported as average fluorescence intensity.  
 42 
 
Cell cycle phase distribution of α-tomatine-treated cells was determined using 
Cellomics Cell Cycle BioApplication as described previously (Chassoux et al., 1999).  
It applies similar principles as fluorescence-activated cell sorting (FACS) in assessing 
cell cycle distribution where the intensity of Hoechst stained nucleus is deemed 
proportional to the cell’s DNA content. Total fluorescence intensity of the dye from the 
nucleus of each cell typically exhibits a bimodal distribution. The first peak typically 
contains cells with 2N DNA content (G0/G1phase), the second peak with a double 
intensity of the first, contains cells with 4N DNA content (G2/M phase). Under normal 
conditions, there are more cells in the G0/G1 versus the G2/M phase. The region 
between these two peaks represents cells with DNA content between 2N and 4N (S 
phase) which are cells in the process of doubling their DNA. Cells found with DNA < 
2N distribution are usually apoptotic cells. To identify the range of each of the DNA 
content categories, the software first identifies 2N (G0/G1 phase) and 4N (G2/M phase) 
DNA content peaks using vehicle control cells. Then, it automatically classified each 
cell’s nuclear total intensity into one of the categories of DNA content: sub-G0 
(DNA<2N), G0/G1 (DNA~2N), S (2N<DNA>4N) and G2/M (DNA~4N) phases in -
tomatine-treated cells. The percentage of each cell cycle phase for vehicle control, 
paclitaxel-treated cells and α-tomatine-treated cells were then reported.   
 
2.3.7 Caspase activity  
The activities of caspase-3, -8 and -9 were measured using the fluorometric assay kit 
(Calbiochem, USA) following the protocol of the manufacturer. Briefly, cells were 
treated with α-tomatine (2.0 μM). After treatment, the cells were harvested using 
trypsinization and cell lysates were prepared as described (Roy et al., 2005). The cell 
lysates were mixed with reaction buffer and 10 μl of fluorogenic peptide substrate: Ac-
DEVD-AMC (caspase-3), Ac-IETD-AMC (caspase-8) and Ac-LEHD-AMC (caspase-
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9), and incubated for 2 hours at 37°C in the dark. Inhibitors (caspase-8: z-IETD-FMK; 
caspase-9: z-LEHD-FMK; caspase-3-like: DEVD-CHO) were added 30 minutes before 
addition of fluorogenic substrate. Wells containing 50 μl of sample buffer, 50 μl of 
assay buffer and 10 μl of substrate were used as blank. Purified caspase was used as 
positive control while untreated cell extract was used as negative control. Fluorescence 
was then measured at excitation of 390 nm and emission of 500 nm. Fold-increase in 
the protease activity was determined by comparing the levels of the treated cells with 
untreated controls. 
 
2.3.8 NF-κB translocation assay 
NF-κB translocation in PC-3 cells was examined using NF-κB activation HCS kit 
which contains Hoechst 33342 and Alexa Fluor 488 conjugated anti-NF-κB dyes. PC-3 
cells were seeded into sterile flat-bottomed 96-well plates (Perkin-Elmer Inc., 
Wellesley, MA, USA) at 8000 cells/well (100μl/well). After 18–24 hours, cells were 
treated with different concentrations of α-tomatine for 30 minutes, followed by 
treatment with 10 ng/ml TNF-α for another 30 minutes. Cells pre-treated with 0.2% 
DMSO and 50 μM curcumin were used as negative and positive inhibitor controls, 
respectively. Fixation, permeabilization and immunofluorescence staining of cells were 
performed according to the manufacturer’s instructions. For target translocation analysis, 
cells stained with Hoechst dye were identified as objects in channel 1 and an adjustable 
mask called Circ was created around every nucleus. In non-activated cells, Alexa Fluor 
488-stained NF-κB was detected in channel 2 in the cytoplasm where an annular region 
called Ring was defined beyond the nuclear region. Images were acquired using suitable 
filters with 20x objective at fixed exposure times. For each well, at least 500 cells were 
automatically acquired and analyzed. The output feature 
MEAN_CircRingAvgIntenDiffCh2 represents the difference between the intensity of 
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nuclear and cytoplasmic NF-κB associated fluorescence (Nuc-Cyto Diff), reported as 
translocation parameter, as previously described (Ding et al., 1998).  
 
2.3.9 NF-κB/p50 and NF-κB/p65 transcription factor assay 
PC-3 cells at 70-80% confluence were treated with α-tomatine for 30 minutes, followed 
by treatment with TNF-α (10 ng/ml) for another 30 minutes. The cells were then 
washed with PBS and the both nuclear and cytoplasmic fractions of the treated cells 
were extracted using nuclear extraction kit (Cayman Chemical, Ann Arbour, MI). 
Concentrations of the active forms of NF-κB/p50 and NF-κB/p65 in the both fractions 
were measured using Cayman NF-κB/p50 and NF-κB/p65 ELISA kits (Ann Arbour, MI) 
according to the instructions of the manufacturer. The differences in NF-κB/p50 and 
NF-κB/p65 levels between the nuclear and cytoplasmic fractions were reported.  
 
2.3.10 Statistical analysis 
All assays were conducted in at least three separate experiments. Results are expressed 
as the mean value ± standard error of mean (SEM). Statistical analysis was performed 
with one-way analysis of variance (ANOVA), with Dunnett’s Multiple Comparison 
Test to identify between-group differences using GraphPad Prism software (version 4.0; 
GraphPad Software Inc., San Diego, CA). Statistical significance is expressed as *p < 
0.05; **p < 0.01; ***p < 0.001. Log EC50 calculations were performed using the built-
in algorithms from dose-response curves with variable slope.  
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2.4 Results 
2.41 Alpha-tomatine dose-dependently inhibits proliferation of PC-3 cancer cells 
To evaluate the effect of α-tomatine on cell viability of PC-3, WRL-68 and RWPE-1 
cells, MTT assay was performed. Treatment of α-tomatine to PC-3 cells resulted in a 
significant dose-dependent (from 0.16 to 5.0 μM) inhibition of cell growth (Figure 2.1). 
The EC50 value at 24 hours post-treatment with α-tomatine for PC-3 cells was estimated 
at 1.67 ± 0.3 μM. Alpha-tomatine only caused cytotoxicity towards normal prostate 
RWPE-1 cells at highest concentration (5.0 μM) of α-tomatine, with EC50 value of 3.85 
± 0.1 μM (Figure 2.1). Normal human liver WRL-68 cells treated with the highest 
concentration of -tomatine tested (5.0 M) resulted in ~35% of nonviable cells and 
this suggest that -tomatine is less cytotoxic against WRL-68 cells when compared to 
PC3 cells (Figure 2.1). The EC50 values of -tomatine towards WRL-68 cells (>5 M) 
and RWPE-1 (3.85 ± 0.1 μM) and were higher than that of PC-3 cells (1.67 ± 0.3 M), 
suggesting the selective cytotoxicity of -tomatine towards prostate cancer PC-3 cells.  
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Figure 2.1 The effect of α-tomatine on cell viability of PC-3, WRL-68 and RWPE-1 
cells. Cells were treated with α-tomatine for 24 hours and cell proliferation was 
measured using MTT reduction assay. Each value represents the mean ± SEM of three 
independent experiments, performed in triplicates. EC50 values of α-tomatine on PC-3 
cancer cell, WRL-68 normal cells and RWPE-1 normal prostate cells at 24 hours 
treatment were 1.67 ± 0.3 M, > 5.0 M and 3.85 ± 0.1 μM, respectively. 
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2.42 Real-time growth kinetics analysis of α-tomatine using cell impedance-based 
analyzer  
The dynamics of PC-3 cells proliferation on the 16-wells E-plates were monitored at 
every 5 minutes interval from the time of plating until the cells entered the logarithmic 
growth phase, following which the cells were treated with different concentrations of α-
tomatine. After treatment, cell index values were acquired at every 10 minutes interval 
for 72 hours. It was observed that a rapid decrease in cell index value occurred as early 
as an hour after treatment with 5.0 μM and 2.5 μM of α-tomatine on PC-3 cells (Figure 
2.2A), suggesting that PC-3 cells were dying from the treatment with these 
concentrations. PC-3 cells treated at lower concentrations (0.16 - 1.25 M) of -
tomatine were proliferating in parallel to cells treated with vehicle control as indicated 
with increase in cell index values. In contrast, WRL-68 cells treatment with α-tomatine 
showed no reduction in cell index values even at the highest tested concentration of 5.0 
M compared to control levels and it exhibited a continuous rise in cell index values 
throughout the 72 hours of treatment (Figure 2.2B). This showed that WRL-68 cells 
growth was not affected by -tomatine. Treatment with 2.5 μM -tomatine initially 
inhibited normal prostate RWPE-1 cell proliferation but eventually recovered to the 
level of vehicle control cells (Figure 2.2C). Treatment with higher concentration (5.0 
M), however, decreased the cell index values suggesting that -tomatine inhibited the 
proliferation of RWPE-1 cells at high concentration. These data suggested that -
tomatine at low concentration (2.5 M) can inhibit the growth of PC-3 prostate cancer 
cells but not the normal prostate RWPE-1.  
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Figure 2.2 Dynamic assessment of cell viability after treatment with α-tomatine. 
Normalized cell index measured over 72 hours on (A) prostate cancer PC-3, (B) human 
normal liver WRL-68 and (C) human normal prostate RWPE-1 cells. Briefly, cells at 
logarithmic growth phase were treated with α-tomatine and cell index values were 
recorded every 10 minutes intervals using RTCA DP system. Cells treated with 5.0 μM 
paclitaxel and 0.2% DMSO were used as positive and negative controls, respectively. A 
change in impedance as the cells spread on the E-plate was displayed as cell index value. 
Plotted cell index values were normalized to the last time point before addition of 
treatment.
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2.43 Alpha-tomatine induces apoptosis on PC-3 cancer cells 
To determine if -tomatine induces apoptosis in PC-3 prostate cancer cells, annexin 
V/propidium iodide (PI) double staining assay and flow cytometry analysis were 
performed. Treatment with 2.0 μM -tomatine for 1, 3, 6 and 24 hours resulted in a 
gradual increase in early apoptotic cells (annexin V positive only) from 2.07 ± 0.12 % 
to 5.00 ± 0.97 %, 14.57 ± 1.55 %, and 21.50 ± 2.48 %, respectively (Figure 2.3, black 
bars). The late apoptotic cells (annexin V and PI positive) were also increased 
significantly, from 2.63 ± 0.56 % to 4.00 ± 0.93 %, 6.93 ± 1.3 %, and 16.9 ± 1.92 % 
(Figure 2.3, white bars). Positive control cells treated with 5.0 μM paclitaxel for 24 
hours also resulted in 7.13 ± 0.75 % of early apoptotic cells (Figure 2.3, black bars) and 
21.53 ± 1.74 % of late apoptotic cells (Figure 2.3, white bars) in the culture compared 
with only 0.23 ± 0.09 % of early apoptotic cells (Figure 2.3, black bars) and 0.37 ± 0.12 
% of late apoptotic cells (Figure 2.3, white bars) in the negative control cells treated 
with 0.2% DMSO. Hence, these results showed that α-tomatine inhibited PC-3 cells 
growth by inducing apoptosis in these cells.  
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Figure 2.3 Annexin V/PI double staining assay. Cells were exposed to either 0.2% 
DMSO (vehicle control), 5.0 µM paclitaxel (positive control), or α-tomatine for the 
indicated time. The treated cells were stained with annexin V and PI and then subjected 
to flow cytometric analysis. The percentages of early apoptotic cells (annexin V 
positive, PI negative) and late apoptotic cells (annexin V and PI positive) observed at 
different incubation time with α-tomatine are shown. Results are presented as the mean 
± SEM of three independent experiments. Statistical significance is expressed as **p < 
0.01; *p < 0.05 versus vehicle control. 
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2.44 Multiparametric HCS assays 
To further confirm the induction of apoptosis by α-tomatine, the treated cells were 
examined for cellular changes associated with apoptosis using HCS analysis. Treatment 
with 2.0, 1.0 and 0.5 M -tomatine resulted in approximately 95%, 83% and 20% cell 
loss, respectively (Figure 2.4A). In comparison, positive control cells treated with 5.0 
M paclitaxel resulted in only 45% cell loss and none from the vehicle control cells 
(Figure 2.4A). The α-tomatine treated cells also exhibited a concentration-dependent 
increase in nuclear chromatin staining with Hoechst 33342 (Figures 2.4B and 2.5C), 
suggesting an increase in nuclear condensation. Increased in nuclear chromatin staining 
with Hoechst 33342 was also observed in the paclitaxel positive control cells (Figure 
2.4B and 2.5B) whereas the fluorescent intensity was significantly lower and healthy 
nuclear morphology was observed in the vehicle control cells (Figures 2.4B and 2.5A). 
Membrane permeability of the treated cells also increased significantly as evidenced by 
high fluorescent intensity in the cytoplasm of -tomatine (Figure 2.4C and 2.5C) and 
paclitaxel- treated cells (Figure 2.4C, and 2.5B) compared to the vehicle control 
(Figures 2.4C and 2.5A). A reduction in mitochondrial membrane potential is observed 
in both paclitaxel (Figure 2.4D and 2.5B) and α-tomatine (Figure 2.4D and 2.5C) 
treated cells compared to intact mitochondrial membrane potential of the vehicle control 
cells (Figure 2.4D and 2.5A). More specific apoptosis indicators such as release of 
cytochrome c and F-actin polarization or cleavage were found increased in a 
concentration-dependent manner in the cytoplasm of PC-3 treated cells, with the highest 
increase observed at 2.0 µM -tomatine (Figure 2.4E, 2.4F and 2.5C). These results 
further confirmed that -tomatine inhibited PC-3 cell growth by inducing apoptosis. 
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Figure 2.4 HCS analysis of apoptosis associated cellular morphology on α-tomatine 
treated PC-3 cells. PC-3 cells were treated with different concentrations of α-tomatine 
(0.5 - 2.0 μM). Cell morphology changes associated with apoptosis such as (A) 
percentage of dead cells, (B) alterations in nuclear condensation, (C) membrane 
permeability, (D) mitochondrial membrane potential, (E) expression of cytochrome c 
and (F) F-actin contents are reflected by the average fluorescence intensity detected. 
Cells treated with 0.2% DMSO and 5.0 μM paclitaxel were used as negative and 
positive controls, respectively. All measured parameters were expressed as average 
fluorescent intensities and averaged for at least 500 cells per well. Data is representative 
of three independent experiments. Statistical significance is expressed as **p < 0.01; *p 
< 0.05 versus vehicle control. 
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Figure 2.5 Cytotoxic and pro-apoptotic effects of α-tomatine on PC-3 cells. PC3 cells 
were treated for 24 hours with (A) 0.2% DMSO, (B) 5.0 μM paclitaxel, and (C) 2.0 μM 
α-tomatine. The treated cells were examined for nuclear condensation using blue 
Hoechst 33342 stain, changes in membrane permeability using a green fluoroprobe, 
mitochondrial membrane potential using MitoTracker Red CMXRos dye, and 
cytochrome c expression using a blue green fluoroprobe. Scale bar indicates 20 μm. 
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2.45 Alpha-tomatine-induced apoptosis in PC-3 cells is not associated with cell 
cycle arrest 
To determine whether induction of apoptosis in PC-3 cells by α-tomatine could be 
related to the cell cycle arrest, cell cycle distribution of the treated cells was assessed by 
labelling the cell’s DNA with blue fluorescent Hoechst 33342 stain, whose intensity is 
proportional to the cell’s DNA content. The sub-G0 population representing apoptotic 
cells in the 2.0 M -tomatine treated cells was markedly increased (95%) compared to 
positive control cells treated with paclitaxel (40%, Figure 2.6A). This increase was 
reflected by significant reduction in cells at G0/G1 (Figure 2.6B), S (Figure 2.6C), and 
G2/M phases (Figure 2.6D). No significant changes in the percentage of population of 
cells in other phases were observed in 0.5 and 1.0 M treated cells, suggesting that 
induction of apoptosis was not mediated by cell cycle arrest. 
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Figure 2.6 Cell cycle distribution of α-tomatine-treated PC-3 cells. The percentage of α-
tomatine-treated cells at (A) Sub-G0, (B) G0/G1, (C) S, and (D) G2/M phases of PC-3 
cells. Each bar represents the mean ± SEM of data from three independent experiments. 
Statistical significance is expressed as **p < 0.01 versus vehicle control.
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2.46 Alpha-tomatine induces caspases activation 
Caspases are present in the proforms (inactive) and become active after site-specific 
cleavage to participate in the process of apoptosis. To determine whether caspases are 
involved in apoptosis induction by -tomatine, the protein levels of active caspases in 
-tomatine-treated cells were evaluated. Activation of the executioner procaspase-3 by 
α-tomatine was found to be time-dependent (Figure 2.7A). Caspase-3 activity was 
significantly elevated at the first hour of treatment and progressed to a maximal level 
(6-fold over vesicle control) after 24 hours of incubation (Figure 2.7A). High levels of 
pro-caspase-8 and pro-caspase 9 were detected as early as 1 hour after the addition of α-
tomatine, and reached a maximal level at 6 hours of incubation where the high levels of 
caspase 8 and 9 persisted over 24 hours of incubation (Figure 2.7B and 2.7C). These 
findings suggest that α-tomatine activated caspase-3, caspase-8 and caspase-9 as early 
as 1 hour after treatment. Cell permeable-specific inhibitors of caspase-3-like (DEVD-
CHO, Figure 2.7A), caspase-8 (z-IETD-FMK, Figure 2.7B) and caspase-9 (z-LEHD-
FMK, Figure 2.7C) were added into α-tomatine treatment to determine whether the 
activation of caspase-3, -8 and -9 by α-tomatine can be blocked by these inhibitors. In 
the presence of inhibitors, fold increase of caspase-3 (Figure 2.7A), caspase-8 (Figure 
2.7B) and caspase-9 (Figure 2.7C) were reduced. These results further confirmed the 
activation of caspase-3, -8 and -9 by α-tomatine in PC-3 cells.  
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Figure 2.7 Effect of α-tomatine on caspases activation. Fold increase of the levels of (A) 
caspase-3, (B) caspase-8, and (C) caspase-9 in PC-3 cells treated with 2.0 μM α-
tomatine, compared to vehicle control. The caspase activities were determined in the 
presence or absence of specific inhibitors in time course manner. The fluorescence 
intensity was measured at excitation wavelength of 390nm and emission wavelength of 
500nm. The increase of protease activities was determined by comparing the levels in 
α-tomatine treated PC-3 cells with the vehicle control. Each bar represents the mean ± 
SEM of data from three independent experiments. Statistical significance is expressed 
as **p < 0.01; *p < 0.05 versus vehicle control. 
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2.47 Alpha-tomatine inhibits TNF-α-induced NF-κB nuclear translocation 
It has been shown that activation of NF-κB blocks apoptosis and promotes cell 
proliferation (Karin & Greten, 2005). We assessed whether -tomatine inhibits 
activation of NF-κB induced by the inflammatory cytokine, TNF- using Alexa Fluor 
488-conjugated anti-NF-κB antibody. In cells treated with medium only (Figure 2.8A 
and 2.8Bii), high fluorescent intensity of NF-κB was found in cytoplasm but dimly in 
nuclei, indicating that NF-κB was not activated under resting condition. Following 
stimulation with TNF-α alone, NF-κB fluorescent intensity significantly increased in 
nuclei, suggesting that TNF-α stimulation resulted in NF-κB activation and 
translocation from cytoplasm into nuclei occurred in the stimulated cells (Figure 2.8A 
and 2.8Bi). However, in PC-3 cells treated with curcumin, a known inhibitor of NF-κB 
activation, it was observed that significant inhibition of TNF-α-induced NF-κB nuclear 
translocation as evidenced by low nuclear NF-κB-related fluorescence intensity (Figure 
2.8A). Similarly, α-tomatine also inhibited TNF-α-induced NF-κB activation in a dose-
dependent manner with strong inhibition observed at 2.0 μM treatment (Figure 2.8A, 
and 2.8Biii). These results showed that -tomatine inhibits NF-κB activation.  
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Figure 2.8 The inhibitory effect of α-tomatine on TNF-α-induced NF-κB nuclear 
translocation. PC-3 cells were pretreated with α-tomatine for 30 minutes and followed 
by 10 ng/ml of TNF-α stimulation for 30 minutes. (A) Cells treated with 50 μM 
curcumin and medium only were used as positive NF-κB inhibitor and negative control, 
respectively. Cells were fixed, immunostained with anti-NF-κB antibody, and 
counterstained with Hoechst 33342. NF-κB nuclear translocation index was measured 
using Thermo Scientific ArrayScan VTI HCS Reader and expressed as the difference 
between nuclear and cytoplasmic NF-κB related fluorescence intensity. Each bar 
represents the mean ± SEM of data in triplicate. Statistical significance is expressed as 
**p < 0.01; *p < 0.05 versus cells cells treated with TNF-α alone. (B) Images of PC-3 
cells treated with 10 ng/mL TNF-α alone (i), medium only (ii), and 2.0 µM of α-
tomatine pretreatment before 10 ng/ml TNF-α stimulation (iii). Control and treated PC-
3 cells were stained with Hoechst (blue) and the Alexa Fluor 488-conjugated anti-NF-
κB antibody (green). Images were acquired for each fluorescence channel, using 
suitable filters with 20x objective. Scale bar indicates 20 μm. 
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2.48 Alpha-tomatine treatment inhibits NF-κB/p50 and NF-κB/p65 nuclear 
translocation 
To further confirm TNF-α-induced NF-κB activation was inhibited in α-tomatine 
treated PC-3 cells through the inhibition of NF-κB nuclear translocation, NF-κB/p50 
(Figure 9A) and NF-κB/p65 (Figure 2.9B) in nuclear and cytoplasmic fractions of the 
treated cells were measured by ELISA. Pretreatment with 2.0 μM of α-tomatine resulted 
in significant decreased in both NF-κB/p50 (Figure 2.9A) and NF-κB/p65 (Figure 2.9B) 
level in nuclear fractions, compared to cells treated with TNF-α control (Figure 2.9A 
and 2.9B). These results showed that α-tomatine inhibits TNF-α-induced NF-κB 
activation by inhibiting nuclear translocation of NF-κB/p50 and NF-κB/p65 in the 
treated PC-3 cells. 
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Figure 2.9 Comparison of NF-κB/p50 and NF-κB/p65 protein levels between nuclear 
and cytoplasmic fraction. PC-3 cells were treated with 0.5, 1.0, 2.0 µM α-tomatine for 
30 minutes, followed by treatment with 10 ng/ml TNF-α for another 30 minutes. 
Nuclear and cytoplasmic fractions of the PC-3 treated cells were extracted, the 
concentration of the active form of (A) NF-κB/p50 and (B) NF-κB/p65 in both fractions 
were measured with ELISA kits. Differences of NF-κB/p50, NF-κB/p65 in the nuclear 
and cytoplasmic fractions are reported. Each bar represents the mean ± SEM of data in 
triplicate. Statistical significance is expressed as **p < 0.01; *p < 0.05 versus cells 
treated with TNF-α control. 
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2.5 Discussion 
Alpha-tomatine was reported to inhibit growth of human colon HT-29, liver 
HepG2, breast MCF-7 and stomach AGS cancer cells (Friedman et al., 2009; Lee et al., 
2004) but its anti-proliferative mechanisms require further definition. The present study 
reports that -tomatine inhibits NF-κB activation and induces apoptosis on androgen-
independent human prostatic adenocarcinoma PC-3 cells. The EC50 of α-tomatine 
towards PC-3 cells was estimated at 1.67 ± 0.3 μM and this value is comparable to 
earlier studies on different cancer cell lines (Friedman et al., 2009; Lee et al., 2004). 
Dynamic assessment by xCelligence system showed that -tomatine is a fast-acting 
compound, inhibiting the cancer cells proliferation as early as an hour after treatment 
with 2.5 and 5.0 M -tomatine and its growth suppressive effect was not fully 
reversible as the cancer cell proliferation failed to recover throughout 72 hours of 
treatment. It is also less cytotoxic against human liver normal cells and human prostate 
normal cells. Although our data showed that α-tomatine inhibited the growth of normal 
prostate RWPE-1 cells at high concentration (5.0 μM), where utilization of high dose of 
α-tomatine can be a key consideration for cancer treatment, earlier in vivo studies 
showed no apparent toxic effects in rainbow trout (Friedman et al., 2007) and does not 
affect body and liver weights of mice (Friedman, 2002; Friedman et al., 1996).  
Flow cytometry analysis of annexin V/PI staining showed that -tomatine 
conspicuously induced apoptosis. This observation was confirmed by multiparametric 
cell-based HCS analysis that showed morphological features characteristic of apoptotic 
cell death such as nuclear condensation, loss of membrane symmetry, polarization of F-
actin, release of cytochrome c and reduction in mitochondrial membrane potential. 
Disruption of the mitochondrial membrane potential is an early event in apoptosis and 
triggers release of cytochrome c and other apoptogenic molecules from the 
mitochondria to the cytosol (Ly et al., 2003). These apoptogenic molecules contribute 
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to the activation of caspases and subsequent cell death. More intensive molecular 
studies indicate that apoptotic cell death can be triggered either through receptor 
(extrinsic)-mediated pathway where the ligand-receptor binding activates caspase-8 or 
the mitochondrial (intrinsic)-mediated pathway where cytochrome c is released from the 
mitochondrial and activates caspase-9 (Mishra & Kumar, 2005; Schneider & Tschopp, 
2000). Both of these mechanisms will eventually merge and lead to the hierarchical 
activation of the downstream caspase-3, 6 and 7, which are responsible for the 
characteristic apoptosis-associated morphological changes such as chromatin 
condensation, membrane blebbing, and loss of overall cell shape (Hengartner, 2000; 
Stroh & Schulze-Osthoff, 1998). The present study demonstrated that treatment with -
tomatine increased activities of caspase-3 and -9 and caused depolarization of 
mitochondrial membrane potential and release of cytochrome c. These results suggest 
that induction of apoptosis is mediated through the intrinsic pathway. Pro-caspase-8 is 
an intracellular component that directly communicates with the death domain of cell 
membrane receptors and its activation in the -tomatine-treated cells suggests that 
apoptosis is also mediated through the extrinsic pathway which perhaps merged with 
the intrinsic pathway and activated the executioner caspase 3. Consistent with these data, 
addition of cell permeable-specific inhibitors of caspase-8 (z-IETD-FMK), caspase-9 
(z-LEHD-FMK), or caspase-3-like (DEVD-CHO) enzymes revealed that addition of 
caspase inhibitors completely decreased -tomatine-induced activation of caspase-3, -8 
and -9, confirmed the role of caspase-3, -8 and -9 in α-tomatine-induced apoptosis. 
Curcumin is an example of dietary agent that mediates apoptosis via both intrinsic and 
extrinsic pathways (Karunagaran et al., 2005). 
Alpha-tomatine could also significantly alter polymerization of actin filaments 
in the treated PC-3 cells. This observation is in line with reports that showed 
polymerization or cleavage of actin cytoskeleton during the early and late phases of 
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apoptosis (Brown et al., 1997; Gourlay & Ayscough, 2005a, 2005b; Posey & Bierer, 
1999). Cisplatin, a well-known anticancer drug is an example of drug that induces F-
actin damage prior to changes in nuclear morphology (Kruidering et al., 1998).  
While the present study found no evidence of cell cycle arrest by -tomatine, 
there are evidence that suggest induction of apoptosis could be mediated through the 
inhibition of nuclear factor-kappa B (NF-κB) signaling pathway. Constitutive NF-κB 
activation has been observed in many types of cancer, including androgen-independent 
prostate cancer (Karin & Greten, 2005). Overexpression of NF-κB/p65 protein was 
found in the nuclear fraction of prostate cancer clinical specimens (Fradet et al., 2004; 
Ross et al., 2003), suggesting the pathophysiological role for NF-κB in prostate cancer 
progression. Constitutive activation of NF-κB in tumor cells could promote cancer cells 
survival by blocking apoptosis and promote cancer cells growth through angiogenesis, 
metastasis and invasion (Millera et al., 2010). Accumulating evidence indicate that 
constitutive activation of NF-κB in tumor cells always contribute to chemoresistance 
and radioresistance, and represents an independent risk factor for recurrence after 
radical prostatectomy (Domingo-Domenech et al., 2005; Fradet et al., 2004; Li & Sethi, 
2010). Hence, targeting the NF-κB signaling pathway remains an attractive therapeutic 
option for prostate cancer. Treatment of PC-3 cells with -tomatine resulted in a strong 
inhibition of NF-κB activation, which was consistent with a decrease in nuclear levels 
of NF-κB/p65 and NF-κB/p50. The ability of α-tomatine in inhibiting NF-κB activation 
by blocking the nuclear translocation of NF-κB/p65 and NF-κB/p50 transcription 
factors suggests its promising role in prostate cancer prevention. Inhibition of NF-κB 
activation could indirectly contribute to the pro-apoptotic action of -tomatine on PC-3 
cells as NF-κB controls the transcription of anti-apoptotic and cell proliferation genes, 
essential for the survival of cancer cells (Sethi & Tergaonkar, 2009). 
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2.6 Conclusion 
In summary, these results show that α-tomatine has good potential as dietary 
phytochemical with pro-apoptosis activity. Alpha-tomatine can be further explored for 
its therapeutic potential in the treatment of cancers where constitutive activation of NF-
κB and apoptosis resistance remains a major concern in cancer chemotherapy. To 
establish the relevance of in vitro findings, further study is underway to investigate in 
vivo anti-tumor and NF-κB activities of α-tomatine using prostate xenograft cancer 
model.  
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CHAPTER 3 
ALPHA-TOMATINE ATTENUATION OF IN VIVO 
GROWTH OF SUBCUTANEOUS AND ORTHOTOPIC 
XENOGRAFT TUMORS OF HUMAN OF PROSTATE 
CARCINOMA PC-3 CELLS IS ACCOMPANIED BY 
INACTIVATION OF NUCLEAR FACTOR-KAPPA B 
SIGNALING 
 
 
 
 
The contents in this chapter have been published in Lee, S. T., Wong, P. F., He, H., 
Hooper, J. D., Mustafa, M.R. (2013). Alpha-tomatine attenuation of in vivo growth of 
subcutaneous and orthotopic xenograft tumors of human prostate carcinoma PC-3 cells 
is accompanied by inactivation of nuclear factor-kappa B signaling. PLoS ONE, 8(2), 
e57708.  
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3.1 Abstract 
Nuclear factor-kappa B (NF-κB) plays a role in prostate cancer and agents that suppress 
its activation may inhibit development or progression of this malignancy. Alpha (α)-
tomatine is the major saponin present in tomato (Lycopersicon esculentum) and we have 
previously reported that it suppresses tumor necrosis factor-alpha (TNF-α)-induced 
nuclear translocation of NF-κB in androgen-independent prostate cancer PC-3 cells and 
also potently induces apoptosis of these cells. However, the precise mechanism by 
which α-tomatine suppresses NF-κB nuclear translocation is yet to be elucidated and the 
anti-tumor activity of this agent in vivo has not been examined. In the present study we 
show that suppression of NF-κB activation by α-tomatine occurs through inhibition of 
inhibitor of kappa B alpha (IκBα) kinase (IKK) activity, leading to sequential 
suppression of IκBα phosphorylation, IκBα degradation, NF-κB/p65 phosphorylation, 
and NF-κB p50/p65 nuclear translocation. Consistent with its ability to induce apoptosis, 
α-tomatine reduced  TNF-α induced activation of the pro-survival mediator Akt and its 
inhibition of NF-κB activation was accompanied by significant reduction in the 
expression of NF-κB-dependent anti-apoptotic (c-IAP1, c-IAP2, Bcl-2, Bcl-xL, XIAP 
and survivin) proteins. We also evaluated the antitumor activity of α-tomatine against 
PC-3 cell tumors grown subcutaneously and orthotopically in mice. Our data indicate 
that intraperitoneal administration of α-tomatine significantly attenuates the growth of 
PC-3 cell tumors grown at both sites. Analysis of tumor material indicates that the 
tumor suppressing effects of α-tomatine were accompanied by increased apoptosis and 
lower proliferation of tumor cells as well as reduced nuclear translocation of the p50 
and p65 components of NF-κB. Our study provides first evidence for in vivo antitumor 
efficacy of α-tomatine against the human androgen-independent prostate cancer. The 
potential usefulness of α-tomatine in prostate cancer prevention and therapy requires 
further investigation.   
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3.2 Introduction 
Prostate cancer is the second most frequently diagnosed cancer and the sixth 
leading cause of cancer death in men worldwide (Jemal et al., 2011). As progression of 
this malignancy is dependent on the androgen receptor, therapies that target activating 
ligands (the hormones testosterone and dihydrotestosterone) produce response rates in 
patients of up to 95% (Bracarda et al., 2005). Unfortunately, nearly all prostate cancer 
patients develop hormone-refractory prostate cancer (Bracarda et al., 2005). For these 
patients curative treatments are not available and docetaxel-based chemotherapy 
provides palliation with response rates of approximately 50% and median survival of 18 
to 20 months with survival benefit of about 2 months (Dagher et al., 2004). For patients 
with hormone-refractory prostate cancer, low toxicity molecular targeting strategies are 
needed.  
 Accumulating evidence suggests that the transcription factor nuclear factor-
kappa B (NF-κB) plays a pivotal role in prostate cancer growth, survival, angiogenesis 
and metastatic progression (Huang et al., 2001; Jin et al., 2008; Surh et al., 2002; 
Sweeney et al., 2004; Yemelyanov et al., 2006). NF-κB consists of a p50/p65 
heterodimer that is masked by the inhibitor of NF-κB, inhibitor of kappa B alpha (IκBα) 
that causes its retention in the cytoplasm under resting condition. Various stimuli, 
including tumor necrosis-alpha (TNF-α), phorbol ester and lipopolysaccharides (LPS), 
result in IκBα kinase (IKK) activation, which mediates IκBα phosphorylation at Ser32 
and Ser36 followed by its ubiquitination and proteasome-mediated degradation. This 
releases the NF-κB p50/p65 heterodimer, which then translocates to the nucleus, where 
it binds to consensus sequence motifs to induce gene transcription. It has been 
demonstrated that NF-κB is constitutively activated in androgen-insensitive prostate 
carcinoma cells, and overexpression of NF-κB p65 protein was found in the nuclear 
fraction of prostate cancer clinical specimens (Fradet et al., 2004; Surh et al., 2002), 
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suggesting a role for NF-κB in prostate cancer progression. Consistently, it has been 
reported that aberrant IKK activation leads to the constitutive activation of the NF-κB 
survival pathway in androgen-independent prostate cancer cells (Gasparian et al., 2002). 
In addition, activation and localization of NF-κB represent independent risk factors for 
disease recurrence after radical prostatectomy (Domingo-Domenech et al., 2005; Fradet 
et al., 2004). Hence, effective inhibition of NF-κB could be a promising strategy for 
treatment of prostate cancer and prevention of relapse. 
Alpha (α)-tomatine is the major saponin in tomato (Lycopersicon esculentum). 
Previous studies have reported its immunopotentiating (Heal & Taylor-Robinson, 2010; 
Morrow et al., 2004; Yang et al., 2004) and in vitro anti-cancer activities (Friedman, 
2004; Friedman et al., 2009; Shieh et al., 2011; Shih et al., 2009). It also has protective 
effects against dibenzo[a,l]pyrene (DBP)-induced liver and stomach tumors in rainbow 
trout without causing significant changes in total weight, liver weight, tissue 
morphology and mortality (Friedman et al., 2007).  Thus far, the mechanism by which 
α-tomatine mediates its anti-prostate cancer effect is not well understood. Our previous 
study reported the pro-apoptotic effect of α-tomatine against androgen-independent 
human prostatic adenocarcinoma PC-3 cells through the inhibition of TNF-α-induced 
NF-κB nuclear translocation (Lee et al., 2011). In the present study, the mechanism of 
the inhibition of α-tomatine on NF-κB signaling pathway is further characterized. For 
the first time, this study demonstrates the potent anti-tumor activity of α-tomatine 
against human androgen-independent prostate cancer in vivo.  
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3.3 Materials and Methods 
3.3.1 Ethics statement 
Experiments with mice were performed in accordance with the protocol approved by 
the University of Queensland Animal Ethics Committee (AEC Approval Number: 
MMRI/210/10). 
 
3.3.2 Materials  
Alpha-tomatine was purchased from Tokyo Chemical Industry (Tokyo, Japan). 
Dimethyl sulfoxide (DMSO), TNF-α, fetal bovine serum (FBS), 3,3,5,5 
tetramethylbenzidine (TMB), Calpain Inhibitor I, ALLN (N-acetyl-leucyl-leucyl-
norleucinal) and anti-human beta (β)-actin antibody were purchased from Sigma 
Aldrich (St. Louis, MO). Penicillin/ streptomycin, Roswell Park Memorial Institute 
(RPMI-1640) media and 0.4% trypan blue solution were purchased from Invitrogen 
(Carlsbad, CA). Protein A/G plus agarose beads, Akt inhibitor VIII, and antibodies 
against p65, p50, IκBα, Akt, IKKα, and IKKβ were obtained from Santa Cruz 
Biotechnology, CA. The glutathione S-transferase-IκBα (GST-IκBα) fusion protein and 
polyvinylidene fluoride (PVDF) membrane were purchased from Millipore (Bedford, 
MA). Kinase buffer, antibodies against phospho-specific IκBα (Ser32/36), phospho-
specific p65 (Ser536), phospho-specific Akt (Ser473), B cell leukaemia-2 (Bcl-2), B 
cell leukemia-x long (Bcl-xL), cellular inhibitor of apoptosis 1 (c-IAP1), cellular 
inhibitor of apoptosis 2 (c-IAP2), survivin, X-linked inhibitor of apoptosis (XIAP), 
histone H3, cleaved Poly (ADP-ribose) polymerase (PARP) and cleaved caspase-3 
antibodies were purchased from Cell Signaling (Beverly, MA). Antibodies against Ki-
67 and proliferating cell nuclear antigen (PCNA) were purchased from BD Biosciences 
(San Diego, CA).  
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3.3.3 Cell lines 
The prostate cancer PC-3 cell line was purchased from the American Type Culture 
Collection (Manassas, VA). Luciferase-expressing prostate cancer PC-3 cell line was a 
kind gift of Dr. Patrick Ming Tat Ling, Queensland University of Technology, Australia. 
Both PC-3 and luciferase-expressing PC-3 cells were cultured in RPMI-1640 
supplemented with 10% FBS, 100 U/mL penicillin and 100 μg/mL streptomycin. Cells 
were cultured at 37 ºC in a 5% CO2 humidified incubator.  
 
3.3.4 Cell treatment and fractionation 
For the in vitro assays, PC-3 cells at 70-80% confluence were treated with α-tomatine (2 
µM) for 30 minutes, and then exposed to10 ng/ml TNF-α for various time periods. Akt 
inhibitor VIII (10 µM) which inhibits activation of Akt as evidenced by reduced 
phosphorylation of this kinase at Thr308 and Ser473 (Barnett et al., 2005) was used as 
inhibitor control for studying the effect of α-tomatine on Akt activation as described 
previously (Estrada et al., 2010). Both nuclear and cytoplasmic fractions of treated and 
vehicle control cells were isolated using a nuclear extraction kit (Cayman Chemical, 
Ann Arbour, MI) according to the manufacturer’s instructions. Briefly, cells were 
harvested using a cell scrapper then pelleted by centrifugation at 4ºC before two washes 
with ice-cold PBS supplemented with phosphatase inhibitor solution at 4°C. Pelleted 
cells were swollen for 15 minutes in ice-cold hypotonic buffer supplemented with 
complete protease and phosphatase inhibitors. 10 % Nonidet P-40 assay reagent was 
then added and cytosolic fractions were collected by brief centrifugation. Pellets were 
resuspended in ice-cold complete nuclear extraction buffer then vortexed on ice for 30 
seconds at highest setting. These cell pelleting and vortexing steps were repeated for a 
total of 6 cycles. The final pellet was resuspended then centrifuged at 14,000 x g for 10 
minutes at 4°C. The supernatants containing nuclear fractions were collected.  
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3.3.5 Cell viability analysis 
Cell viability was examined using a trypan blue exclusion assay as described previously 
(Husain et al., 2011). Briefly, cells in control and treated groups were harvested, stained 
with 0.4% trypan blue solution and total viable cells were counted using hemacytometer. 
The proportion of viable cells was calculated by dividing the number of viable test cells 
by the number of viable control cells at the end of each experimental treatment.  
 
3.3.6 IκBα kinase assay 
The effect of α-tomatine on TNF-α-induced IKK activation was analyzed as described 
previously (Sethi et al., 2007). Briefly, PC-3 cells were preincubated with either 2 µM 
α-tomatine or 0.1% DMSO (vehicle) for 30 minutes, and then treated with 10 ng/ml 
TNF-α for the indicated times. IKK complex was immunoprecipitated from whole cell 
extracts using antibodies against IKKα and IKKβ. Protein A/G plus agarose beads were 
added and incubated at 4°C for overnight. The beads were washed with lysis buffer and 
resuspended in a kinase buffer before GST-IκBα as IKK substrate was added. After 
incubation at 30°C for 30 minutes, the reaction was terminated by addition of 
Laemmli’s loading buffer and heated at 100°C for 5 minutes. Western blot analysis was 
performed to detect phosphorylated-IκBα (p-IκBα) and to determine the total amounts 
of IKKα and IKKβ in each sample. To determine whether α-tomatine directly targets 
IKK, IKKα and IKKβ immunoprecipitated from 10 ng/ml TNF-α and 0.1% DMSO 
(vehicle) treated cells. In vitro kinase assay was performed in the absence or presence of 
indicated concentrations of α-tomatine at 30°C for 30 minutes.   
 
3.3.7 Subcutaneous and orthotopic implantation of PC-3 cells  
Male BALB/c nude mice (6 weeks old) were purchased from the Animal Resources 
Centre (Canning Vale, Western Australia). For subcutaneous tumor growth study, 
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luciferase-expressing PC-3 prostate cancer cells (1 x 10
6
 in 0.1 ml Dulbecco’s PBS) 
were inoculated subcutaneously into the lower flanks of each mouse. On day 7 after 
cancer cell inoculation, each mouse had one palpable tumor and were randomly 
assigned to four groups (n = 8/group). These groups of mice were then given 
intraperitoneal injections of vehicle solution, 10 mg/kg docetaxel, 5 mg/kg α-tomatine 
or 10mg/kg α-tomatine thrice a week for an additional 3 weeks. All the mice were 
monitored weekly for tumor growth and body weight. Tumor dimensions were 
measured with calipers and volume calculated using a standard formula: (length x 
width
2
) x 0.5 (Plymate et al., 2003). The experiment was terminated 28 days after 
cancer cell inoculation at which time bioluminescent signals of tumors in live mice 
were captured on a Xenogen IVIS Spectrum imaging system (Alameda, CA, USA) 
using Live Imaging Acquisition and Analysis software.  Briefly, mice were injected 
intraperitoneally with luciferin potassium salt, anesthetized and luminescence images 
acquired. Luminescence signal intensity was quantified as region of interest analysis of 
total photons per second for each tumor. Tumors were excised, washed with ice-cold 
phosphate buffered saline (PBS) and stored at -80°C until examined by Western blot 
analysis. 
Orthotopic growth of PC-3 cells was performed as described previously (Luk et al., 
2011). Briefly, under a dissecting microscope (Olympus, Tokyo, Japan), the prostate of 
6 weeks old anesthetized SCID mice were exposed through a surgical incision and 2 x 
10
5
 cells in 10 µl Dulbecco’s PBS injected into the dorsal prostate. Organs were then 
replaced, and the abdomen was closed in two layers with silk sutures. Five days after 
implantation, mice were randomly assigned to two groups that received vehicle solution 
or 10 mg/kg α-tomatine intraperitoneally thrice a week for 14 days (n = 6 per group). 
Body weight was measured weekly. Bioluminescent signal of the PC-3 cell tumor in 
each mouse was measured at the end of the study using a Xenogen IVIS Spectrum 
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imaging system as described above. All mice were then sacrificed by cervical 
dislocation.  
 
3.3.8 Tissue processing and protein extraction  
For protein analysis of mouse tumors, tissues were minced, suspended in tissue protein 
extraction reagent (Thermo-Fisher Scientific, Waltham, MA) supplemented with 
complete protease and phosphatase inhibitors, and homogenized using a gentleMACS 
Dissociator (Miltenyi Biotec, Germany). The homogenized tissue was transferred to a 
pre-chilled microcentrifuge tube, incubated on ice for 30 minutes and then centrifuged 
at 15,000 x g for 20 minutes at 4°C. The supernatant containing total cellular proteins 
was collected for Western blot analysis. Nuclear proteins were extracted using a nuclear 
extraction kit according to the manufacturer’s instructions. Briefly, hypotonic buffer 
supplemented with 1 mM DTT and 0.01% Nonidet P-40 per gram of tissues was added 
to minced tissues, which were then homogenized with a gentleMACS Dissociator 
followed by incubation on ice for 15 minutes. Cytoplasmic proteins were separated by 
centrifugation. The pellets were resuspended in ice-cold complete nuclear extraction 
buffer then vortexed on ice for 30 seconds at highest setting. These cell pelleting and 
vortexing steps were repeated for a total of 6 cycles. The suspensions were then 
centrifuged at 14,000 x g for 10 minutes at 4°C and supernatants containing nuclear 
fractions were collected for Western blot analysis. 
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3.3.9 Western blot analysis  
Protein samples were separated by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and then transferred onto PVDF membranes which were 
probed with primary antibodies, followed after washes by horseradish peroxidase-
conjugated secondary antibodies and visualized colorimetrically after further washes 
using TMB solution. Protein bands were visualized and quantified using a gel 
documentation system (BioRad, Richmond, Calif).  
 
3.3.10 Statistical analysis 
All assays were performed on at least three separate occasions. Results are expressed as 
the mean value ± standard error of the mean (SEM). Statistical analysis was performed 
with one-way analysis of variance, with Dunnett’s Multiple Comparison Test to identify 
between-group differences using GraphPad Prism software (version 5.0; GraphPad 
Software Inc., San Diego, CA). For in vivo tumor growth experiments, statistical 
significance of differences in tumor volume, body weight and total bioluminescence 
intensity between control and treatment groups was assessed by two-way ANOVA 
(GraphPad Software Inc., version 5.0, San Diego, CA), with p values < 0.05 considered 
significant. Statistical significance is expressed as *p < 0.05; **p < 0.01; ***p < 0.001. 
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3.4 Results 
3.41 Alpha-tomatine inhibits constitutive and TNF-α-induced nuclear 
translocation of NF-κB p50/p65 and phosphorylation of NF-κB p65 
We previously showed that -tomatine inhibited the growth of androgen-independent 
human prostatic adenocarcinoma PC-3 in vitro with the half maximal effective 
concentration (EC50) value of 1.67 ± 0.3 M (Lee et al., 2011). At this chosen dose, α-
tomatine was shown to be less cytotoxic to human normal prostate RWPE-1 (EC50 = 
3.85 ± 0.1 µM) and normal liver WRL-68 cells (EC50  > 5 µM). Treatment with 2 M α-
tomatine induces apoptosis and inhibits the TNF--induced NF-κB nuclear 
translocation on PC-3 cells (Lee et al., 2011). In the present study, the mechanism of -
tomatine in inhibition of NF-κB activation was investigated by analyzing its effect on 
phosphorylation and translocation of NF-κB sub-units in prostate cancer PC-3 cells. PC-
3 cell line has been shown to harbor constitutive basal activity of NF-κB due to aberrant 
IKK activation (Gasparian et al., 2002). As shown in Figure 3.1A, the basal 
phosphorylation of NF-κB p65 was suppressed by 30 minutes treatment of 2 µM α-
tomatine (first lane in right upper panel). The time-dependent phosphorylation of NF-
κB p65 induced by TNF-α over a 60 minutes period was also completely suppressed by 
pretreatment of cells with 2 µM α-tomatine (Figure 3.1A, right upper panel). 
Examination of treated and control cell populations using a trypan blue exclusion assay 
indicated that the concentration of α-tomatine and TNF-α used and the time of exposure 
had minimal effect on cell viability (Figure 3.1B). In addition to the observed loss of 
p65 phosphorylation, α-tomatine reduced basal nuclear levels of NF-κB p50/p65 
subunits (Figure 3.1C, right upper and middle panels, first lane versus third lane) and 
also suppressed TNF-α induced nuclear translocation of NF-κB p50/p65 subunits 
(Figure 3.1C, right upper and middle panels, second lane versus forth lane). These 
findings indicate that -tomatine impairs the constitutive basal and TNF-α-induced 
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phosphorylation of NF-κB p65 which in turn prevents the nuclear translocation of NF-
κB p50 and p65.  
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Figure 3.1 Effect of α-tomatine on constitutive and TNF-α-induced phosphorylation of 
p65 and nuclear translocation of NF-κB p50/p65. (A) PC-3 cells at 70-80% confluency 
were treated with either 0.1% DMSO (vehicle) or 2 µM α-tomatine in DMSO for 30 
minutes, followed by treatment with 10 ng/ml TNF-α for the indicated times. 
Cytoplasmic extracts were analyzed by Western blot analysis using an antibody against 
the phosphorylated form of p65. (B) Cell viability was assessed by counting cells that 
excluded trypan blue using a hemocytometer. (C) Effect of α-tomatine on nuclear and 
cytoplasmic levels of NF-κB p50 and p65 in human prostate cancer PC-3 cells. Nuclear 
and cytoplasmic fractions extracted from PC-3 cells treated either 0.1% DMSO or 2 µM 
α-tomatine in DMSO for 30 minutes, followed by treatment with 10 ng/ml TNF-α for 
the 30 minutes were analyzed by Western blot analysis with antibodies against NF-κB 
p50 and p65 proteins. β-actin and histone H3 proteins were loading control for 
cytoplasmic and nuclear extracts, respectively. Graphical representation of densitometry 
analysis of NF-κB p50 and p65 Western blot analyses from three independent 
experiments are shown below each panel. The ratio of the signal intensity of each 
protein to loading control was normalized to the vehicle control.  Statistical significance 
is expressed as ***p < 0.001; **p < 0.01; *p < 0.05 versus vehicle control. 
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3.42 Alpha-tomatine inhibits constitutive and TNF-α-dependent IκBα 
phosphorylation and degradation 
The translocation of NF-κB to the nucleus is preceded by the phosphorylation, 
ubiquitination and proteolytic degradation of IκBα (Zandi et al., 1997). To determine 
whether the observed inhibition of constitutive and TNF-α-induced NF-κB nuclear 
translocation caused by -tomatine was due to inhibition of IκBα degradation, we 
pretreated cells with α-tomatine and then exposed them to TNF-α stimulation for time 
periods up to 60 minutes. TNF-α induced IκBα degradation in control cells as early as 5 
minutes after stimulation (Figure 3.2A, left upper panel). In contrast, in α-tomatine-
pretreated cells, expression of IκBα was sustained under both basal and TNF-α 
stimulated conditions (Figure 3.2B, right upper panel). The effect of α-tomatine on the 
constitutive basal and TNF-α-induced phosphorylation of IκBα was examined using an 
antibody that detects IκBα phosphorylated at Ser32 and Ser36. Calpain inhibitor ALLN 
was used to prevent degradation of phosphorylated IκBα. As shown in Figure 3.2B, the 
basal constitutive phosphorylation of IκBα in PC-3 was attenuated by α-tomatine (first 
lane in right upper panel). Western blot analysis indicated that TNF-α further induced 
basal phosphorylation of IκBα as early as 5 minutes post-stimulation (Figure 3.2B, left 
upper panel), but α-tomatine completely suppressed this event (Figure 3.2B, right upper 
panel). These results indicate that α-tomatine inhibits the basal and the TNF-α-induced 
phosphorylation of IκBα which in turn prevents the degradation of IκBα as well as 
subsequent nuclear translocation of NF-κB. 
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3.43 Alpha-tomatine inhibits the constitutive and TNF-α-induced IKK activation 
IKK complex is the central regulator of NF-κB activation which phosphorylates and 
induces degradation of IκBα. TNF-α induces IκBα phosphorylation and degradation via 
activation of the IKK complex (Zandi et al., 1997). To determine if pretreatment with 
-tomatine affects IKK activation, in vitro kinase assays were performed using 
immunoprecipitated components of the IKK complex, and GST-IκBα as the IKK 
phosphorylation substrate. The phosphorylated substrate was detected by western 
blotting analysis using a phosphospecific anti-IκBα antibody.  As shown in Figure 3.2C, 
TNF-α treatment further stimulated basal IKK activity as an increase phosphorylated-
IκBα was detected as early as 5 minutes after treatment and remained detectable 10 
minutes later (Figure 3.2C, left upper panel). In contrast, phosphorylated-IκBα was not 
detected in cells treated with 2 µM α-tomatine (Figure 3.2C, first lane in right upper 
panel), and α-tomatine pretreatment also strongly blocked TNF-α-induced IKK 
activation as no phosphorylated-IκBα was detectable (Figure 3.2C, right upper panel). 
Western blot analysis demonstrated that TNF-α and α-tomatine had no effect on the 
expression of the components of the IKK complex, IKKα or IKKβ (Figure 3.2C), 
indicating that -tomatine blocked the basal and TNF-α-induced phosphorylation of 
IκBα by attenuating the action of IKK rather than by causing degradation of this kinase.  
In a second set of experiments, we assessed whether α-tomatine suppressed IKK 
activity by directly binding to IKK by using IKKα and IKKβ immunoprecipitated from 
cells treated with TNF-α. The kinase reaction mixture was incubated with increasing 
concentrations of α-tomatine (1, 2 and 5 μM). As shown in Figure 3.2D, whereas TNF-
α caused an increase in phosphorylation of IκBα, this was not reduced by inclusion of 
increasing concentrations of α-tomatine. This suggests that while -tomatine efficiently 
inhibits IKK-mediated phosphorylation of IκBα, it did not do this by directly inhibiting 
IKK.  
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3.44 Alpha-tomatine inhibits TNF-α-induced Akt activation 
It has been reported that the serine-threonine kinase Akt can activate IKK (Ozes et al., 
1999). To gain insight into whether this pathway may be relevant in the constitutive and 
TNF-α–induced activation of NF-κB signaling, we pretreated PC-3 cells with 2 µM α-
tomatine for 30 minutes then exposed these cells to TNF-α for time periods up to 15 
minutes. In control experiments cells were treated with an Akt inhibitor, Akt inhibitor 
VIII, at 10 µM for 3 hours as described previously (Estrada et al., 2010). As shown in 
Figure 3.2E, TNF-α stimulated the basal Akt activation in a time-dependent manner 
(left upper panel), α-tomatine suppressed both basal and TNF-α-induced Akt activation 
as effectively as Akt inhibitor VIII with no significant effect on the expression of total 
Akt protein (right upper and lower panels). This result revealed that α-tomatine impairs 
the basal and TNF-α-induced IKK activation by suppressing Akt activation.  
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Figure 3.2 Effect of α-tomatine on IκBα Kinase activity. (A) Cells were grown to 70–
80 % confluence, treated with either 0.1% DMSO (vehicle) or 2 µM α-tomatine in 
DMSO for 30 minutes, followed by treatment with 10 ng/ml of TNF-α for the indicated 
times. The presence of IκBα was detected by Western blot analysis. (B) To determine 
whether α-tomatine inhibits IκBα degradation by blocking IκBα phosphorylation, cells 
were treated with either 0.1% DMSO (vehicle) or 2 µM α-tomatine in DMSO for 30 
minutes, followed by 50 μg/ml calpain inhibitor ALLN for 30 minutes, and then treated 
with 10 ng/ml of TNF-α for the times indicated. Anti-phospho-IκBα Western blot 
analysis was performed on cytoplasmic extracts. β-actin served as a loading control. (C) 
PC-3 cells were preincubated with either 2 µM α-tomatine or 0.1% DMSO (vehicle) for 
30 minutes, and then treated with 10 ng/ml TNF-α for the indicated times. IKKα and 
IKKβ were immunoprecipitated from lysates from cells and in vitro kinase assays were 
performed using GST-IκBα as substrate. Western blot analysis was performed to detect 
phosphorylated IκBα. (D) IKK complex immunoprecipitated from vehicle and TNF-α-
treated PC-3 cell extracts with an anti-IKKα and IKKβ antibodies was assayed for IKK 
activity. The kinase reaction mixture was incubated with α-tomatine as indicated.  The 
expressions of phosphorylated IκBα, total IKKα and IKKβ were examined by Western 
blot analysis. (E) PC-3 cells were pretreated with 2 µM α-tomatine for 30 minutes, and 
then treated with 10 ng/ml TNF-α  for the indicated times. Lysates extracted from cells 
treated with 10 µM Akt inhibitor VIII for 3 hours serve as inhibition control. The 
expressions of phosphorylated IκBα, total IKKα and IKKβ were examined by Western 
blot analysis. Graphical representation of densitometry analysis of phospho-Akt 
Western blot analysis from three independent experiments is shown below the panel. 
The ratio of the signal intensity of each protein to loading control was normalized to the 
vehicle control. Statistical significance is expressed as ***p < 0.001; **p < 0.01; *p < 
0.05 versus vehicle control. 
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3.45 Alpha-tomatine represses TNF-α-induced NF-κB dependent expression of 
pro-survival proteins  
Several studies have indicated that the transcription factor NF-κB regulates the 
expression of proteins implicated in facilitating tumor cell survival including Bcl-2, 
Bcl-xL, c-IAP, survivin and XIAP (Aggarwal, 2004; Plati et al., 2011). Accordingly, 
we next examined whether α-tomatine inhibition of NF-κB nuclear translocation is 
accompanied by alterations in the expression of these pro-survival proteins. In these 
experiments cells were pretreated with α-tomatine (2 µM) for 30 minutes before 
induction of TNF-α-induced effects for 6 hours. This time period was selected to permit 
accumulation of levels of pro-survival proteins sufficient for Western blot analysis. As 
during this time period α-tomatine treatment resulted in varying levels of cell rounding 
and detachment in treated and control cells, both adherent and non-adherent cells were 
collected for protein extraction. As shown in Figure 3.3, Western blot analysis revealed 
that TNF-α induced marked upregulation of c-IAP1 and c-IAP2 while increases in 
expression of Bcl-xL, survivin and XIAP were also apparent but at lower levels and 
Bcl-2 expression was marginally increased in response to this cytokine. It was striking 
that α-tomatine caused sharp down-regulation of each of these mediators of cell survival 
under basal conditions as well as completely blocking TNF-α-induced upregulation of 
each protein (Figure 3.3). These data indicate that, consistent with its ability to inhibit 
TNF-α-induced NF-κB nuclear translocation, α-tomatine blocks the expression of the 
pro-survival mediators typically upreguated by this cytokine.  
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Figure 3.3 α-tomatine represses TNF-α-induced NF-κB dependent expression of pro-
survival proteins. PC-3 cells grown to 70–80 % confluence were treated with either 
0.1% DMSO or 2 µM α-tomatine for 30 minutes, 10 ng/ml TNF-α was then added and 
the cells were incubated for a further 6 hours. Whole-cell extracts were prepared, and 
were analyzed by Western blot analysis using antibodies against Bcl-2, Bcl-xL, c-IAP1, 
c-IAP2, XIAP and survivin. The results shown here are representative of three 
independent experiments. 
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3.46 Alpha-tomatine attenuates growth of PC-3 cell xenograft tumors in mice  
To examine the effect of α-tomatine on tumor growth in vivo, we challenged PC-3 cell 
tumors grown subcutaneously in mice. In these experiments tumors were allowed to 
establish for 1 week before being challenged 3 times per week for 3 weeks with α-
tomatine (5 or 10 mg/kg/mouse) or the prostate cancer therapeutic docetaxel (10 
mg/kg/mouse) (Tang et al., 2011) and vehicle solution. Figure 3.4A shows that 10 
mg/kg α-tomatine was as efficient as 10 mg/kg docetaxel at retarding growth of PC-3 
cell subcutaneous mouse tumors. In addition, there was also a marked decrease in tumor 
volume in response to lower dose of α-tomatine (5 mg/kg). Specifically, 3 weeks after 
the commencement of drug challenge the average tumor volume in vehicle control mice 
(1000 ± 180 mm
3
), was approximately 1.4 fold higher as compared to mice treated with 
5 mg/kg α-tomatine (720 ± 60mm3), and approximately 4.7 fold higher compared with 
mice treated with 10 mg/kg of α-tomatine (210 ± 35 mm3) or docetaxel (183 ± 32 mm3) 
(Figure 3.4A). Of note, α-tomatine treatment at both 5 mg/kg (Figure 3.4B, blue) and 10 
mg/kg (Figure 3.4B, green) did not provoke body weight loss in contrast with docetaxel 
(Figure 3.4B, red) which caused a reduction in body weight of ~10% more than those 
seen in untreated tumor bearing mice (Figure 3.4B, black). In fact, both control and 
docetaxel treatment groups showed a trend of decreasing body weight after 14 days of 
cancer cells inoculation, potentially due to high tumor burden and toxicity of docetaxel, 
respectively (Figure 3.4B). Consistent with the tumor volumes determined from caliper 
measurements, the intensity of bioluminescence measured on day 28 was significantly 
lower in both docetaxel and 10 mg/kg α-tomatine treatment groups (Figure 3.4C and 
3.4D). These results suggest that α-tomatine retards the growth of PC-3 cell 
subcutaneous xenograft tumors at an effective dose of 10 mg/kg. 
We also used an orthotopic mouse model to examine the effect of α-tomatine on 
prostate tumor growth. In this experiment, PC-3 cell tumors were allowed to grow in 
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mice for 5 days before thrice weekly treatment for 2 weeks with 10 mg/kg α-tomatine. 
As shown in Figure 3.5A, and consistent with the data obtained from the xenograft 
mouse model, α-tomatine significantly suppressed the tumorigenicity of PC-3 cell 
orthotopic tumors. In addition, the total body weight of mice was not adversely affected 
by α-tomatine treatment (Figure 3.5B). The images in Figure 3.5C shows strong 
bioluminescent signal from the prostate of control mice, demonstrating that the tumor 
cells were successfully implanted. In addition, 4 out of 6 α-tomatine treated mice 
showed only weak bioluminescent signals and another 2 mice had no signal. These 
findings demonstrate that α-tomatine has potent anti-tumor effects against mouse 
xenograft and orthotopic PC-3 cell tumors.  
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Figure 3.4 Anti-tumor activity of α-tomatine against subcutaneous PC-3 cell tumors. 
Luciferase expressing PC-3 cell xenograft tumors established in male nude mice (n = 8 
per treatment group) for 1 week were treated thrice weekly for 3 weeks with vehicle, 
docetaxel (10 mg/kg) or α-tomatine (5 or 10 mg/kg). (A) Graph of tumor volume in 
each treatment group versus the number of days after initial injection of PC-3 cells. (B) 
Graph of mean body weight for each treatment group versus the number of days after 
initial injection of PC-3 cells. (C) Bioluminescence intensities emitted from PC-3 cell 
xenograft tumors at the end of the experiment for each treatment group. (D) 
Bioluminescence images of PC-3 subcutaneous xenografts. The first row shows the 
vehicle control group; middle row shows the docetaxel treatment group; bottom row 
shows the 10 mg/kg α-tomatine treatment group. Each bar or point represents the mean 
± SEM of data (n=8). Statistical significance is expressed as ***p < 0.001; **p < 0.01; 
*p < 0.05 versus vehicle control. 
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Figure 3.5 Anti-tumor activity of α-tomatine against orthotopic PC-3 cell tumors. 
Luciferase expressing PC-3 cell orthotopic tumors established in male SCID mice (n = 
6 per treatment group) for 5 days were treated thrice weekly for 2 weeks with vehicle or 
α-tomatine (10 mg/kg). (A) Bioluminescence intensities emitted from PC-3 cell 
orthotopic tumors for each treatment group after 14 days of treatment. (B) 
Bioluminescent images at the end of the experiment of SCID mice carrying orthotopic 
tumors of luciferase expressing PC-3-luc cells. The upper row shows the vehicle control 
group, whereas the bottom row shows the α-tomatine (10 mg/kg) treatment group. (C) 
Graph of mean body weight for each treatment group versus the number of days after 
initial injection of PC-3 cells. Each bar or point represents the mean ± SEM of data 
(n=6). Statistical significance is expressed as **p < 0.01 versus vehicle control.  
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3.47 Alpha-tomatine reduces expression of proliferation markers, increases 
expression of apoptosis markers and inhibits nuclear translocation of NF- κB in 
xenograft tumors 
To examine the mechanism by which α-tomatine suppressed the growth of PC-3 cell 
tumors in mice, we next examined tumor tissue recovered from mice carrying 
subcutaneous tumors for expression of markers of proliferation (PCNA and Ki-67) and 
apoptosis (cleaved PARP and cleaved caspase-3). This analysis was not possible for 
orthotopic tumors as insufficient material was available for the α-tomatine treated mice. 
As shown in Figure 3.6, Western blot analysis of lysates from six independent tumor 
samples indicated that while both markers of proliferation (PCNA and Ki-67)  
decreased in response to α-tomatine treatment (Figure 3.6A and 3.6B), levels of both 
markers of apoptosis (cleaved PARP and caspase-3) increased (Figure 3.6C and 3.6D). 
These data suggest that both anti-proliferative and pro-apoptotic effects of α-tomatine 
contribute to the reduced growth of PC-3 cell tumors in mice. As NF-κB translocation 
to the nucleus is important for promoting increased cell proliferation and survival and 
we have shown that this translocation event is reduced in vitro by α-tomatine, we were 
interested to examine recovered subcutaneous mouse tumors for localization of NF-κB. 
As shown in Figure 3.6E, Western blot analysis from six independent tumor samples 
indicated that there was a distinct decrease in the levels of NF-κB components in the 
nucleus of tumor cells in response to α-tomatine treatment. These data suggest that the 
anti-tumor effects of α-tomatine in vivo may be due to its ability to block the 
proliferative and anti-apoptotic effects of NF-κB signaling by reducing its translocation 
to the nucleus.  
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Figure 3.6 Western blot analysis of PCNA, Ki-67, cleaved-PARP, cleaved-caspase-3 
and NF-κB in PC-3 tumor tissues samples. (A-D) PC-3 tumors excised from mice 
treated with vehicle, 5 mg/kg or 10 mg/kg of α-tomatine were lysed and examined by 
Western blot analysis. Representative images are shown. Markers of proliferation 
(PCNA and Ki-67). Markers of apoptosis (cleaved PARP and cleaved caspase-3). β-
actin was used as loading control. (E) Western blot analysis on nuclear extracts probing 
for NF-κB p50 and p65 levels. Equal loading of protein was confirmed by stripping and 
reprobing the blots with histone H3 antibody. Graphical representation of densitometry 
analysis of each Western blot data from six independent tumor samples is shown below 
each panel. The ratio of the signal intensity of each protein to loading control was 
normalized to the vehicle control.  Statistical significance is expressed as ***p < 0.001; 
*p < 0.05 versus vehicle control. 
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3.5 Discussion 
We provide the first evidence that the saponin α-tomatine can efficiently inhibit 
the growth of prostate cancer tumors in vivo without inducing overt toxicity. Our 
analysis of recovered mouse tumors suggest that mechanistically α-tomatine mediates 
its anti-prostate cancer effects in vivo by blocking, at least in part, the proliferative and 
anti-apoptotic effects of NF-κB signaling by reducing translocation of this protein 
complex to the nucleus. Our detailed in vitro analyses indicate that α-tomatine 
suppression of NF-κB activation occurs through indirect inhibition of IKK kinase 
activity, leading to suppression of IκBα phosphorylation and degradation, NF-κB/p65 
phosphorylation and NF-κB p50/p65 nuclear translocation. Consistent with its ability to 
induce apoptosis, α-tomatine inhibition of NF-κB activation in vitro was accompanied 
by significant reduction in expression of TNF-α induced pro-survival mediators c-IAP, 
Bcl-2, Bcl-xL, survivin and XIAP.  
The NF-κB signaling pathway is an important target for disease treatment 
because its dysregulation is required for inappropriate inflammatory responses as well 
as cancer and other ailments (Sethi & Tergaonkar, 2009). In response to most activating 
stimuli, NF-κB signaling occurs through sequential activation of IKK, phosphorylation 
of IκBα at serine 32 and 36, leading to its degradation, and the nuclear translocation of 
NF-κB where it regulates transcription of a range of genes including those that promote 
cell proliferation and survival (Karin & Lin, 2002). Consistent with our data from α-
tomatine, suppression of NF-κB activation has been shown to be a critical mechanism 
of action of several plant-derived anticancer agents, such as curcumin, lycopene, 
silibinin, genistein, resveratrol and green tea polyphenols (Gupta et al., 2010). In the 
present study, we showed that α-tomatine is an indirect inhibitor of IKK.  Presumably, 
α-tomatine inhibits upstream signaling components that lead to activation of the IKK 
complex, such as Akt serine-threonine kinase, NF-κB inducing kinase, mitogen-
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activated/extracellular signal-regulated kinase kinase 1 (MEKK1), MEKK3, TGF 
activated kinase 1 (TAK1) and glycogen synthase kinase-3 beta (Aggarwal et al., 2004; 
Hoeflich et al., 2000; Lee et al., 1998; Sakurai et al., 1999; Yang et al., 2001).  Indeed, 
we found that α-tomatine inhibits TNF-α-induced Akt activation, although further 
experiments are needed to address if this effect is responsible for the changes we 
observed in phosphorylation and translocation of NF-κB components or the anti-tumor 
actions of α-tomatine against subcutaneous and orthotopic tumors grown in mice. These 
results are in agreement with those of previous studies that suggest that α-tomatine 
suppresses invasion and migration of human lung cancer cells in vitro through the 
inhibition of the Akt (Shieh et al., 2011; Shih et al., 2009). As conventional 
chemotherapeutic agents, including docetaxel target normal as well as tumor cells and 
lead to deleterious effects for prostate cancer patients there is a pressing need to identify 
less toxic agents to control this disease. In recent years, a number of naturally occurring 
dietary agents of reduced toxicity have been reported to induce apoptosis and inhibit 
tumor growth, highlighting the promise of using naturally derived agents for 
chemotherapy and chemoprevention of prostate and other cancers (Cragg et al., 2009; 
Khan et al., 2010; Nobili et al., 2009).  
 Furthermore, it is also possible that an inhibitor of NF-κB activation could be an 
adjuvant for overcoming tumor resistance to radiation and chemotherapies, such as 
paclitaxel, doxorubicin, 5-fluorouracil, and vinca alkaloids (vinblastine and vincristine), 
that occur via NF-κB activation (Das & White, 1997; Uetsuka et al., 2003; Wang et al., 
2003). It is thought that this induced resistance in a wide variety of tumor cells occurs 
via induction of NF-κB effector genes, including Bcl-2 (Catz & Johnson, 2001), Bcl-xL 
(Tamatani et al., 1999), survivin (Zhu et al., 2001), XIAP (Stehlik et al., 1998), c-IAP1 
(Gill et al., 2009) and c-IAP2 (Gill et al., 2009) that are known to mediate protective 
responses to chemotherapeutic agents and radiation. Therefore, targeting NF-κB 
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through the actions of α-tomatine, which we have shown to block NF-κB activation and 
transcription of NF-κB effector genes, may result in improvements in treatment of 
prostate cancer. In support of this, other dietary agents, including resveratrol, curcumin, 
genistein, (−) epigallocatechin gallate and soya isoflavone that can block various steps 
leading to NF-κB activation and sensitize tumor cells to the beneficial effects of 
chemotherapeutic drugs and radiation in treatment of cancer (Akimoto et al., 2001; 
Fulda & Debatin, 2004; Komatsu et al., 1997; Kunnumakkara et al., 2009; Li et al., 
2005; Sandur et al., 2009; Zoberi et al., 2002).  
 We previously reported that -tomatine induces caspase-dependent death of PC-
3 cells in vitro accompanied by increased caspase-3 activity and the release of 
cytochrome c (Lee et al., 2011). Caspases have been shown to be involved in apoptosis 
through activation of PARP downstream molecule (Kaufmann et al., 1993). Importantly, 
here we have demonstrated the pro-apoptotic effect of α-tomatine in vivo by showing a 
significant increase in the cleavage of PARP and caspase-3 in α-tomatine-treated tumors. 
In addition, our data show that α-tomatine elicits anti-proliferative effects in vivo as we 
observed reduced levels of the markers of proliferation Ki-67 and PCNA. Our data from 
PC-3 tumors also suggest that these pro-apoptotic and anti-proliferative effects of α-
tomatine are mediated, at least in part, by reduced nuclear translocation of NF-κB p50 
and p65. Indeed our in vitro studies clearly demonstrate that α-tomatine is very effective 
at blocking activation and translocation of the components of the NF-κB complex 
providing support for the possibility that this mechanism is also important for its effects 
in vivo against prostate cancer PC-3 cell tumors. 
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3.6 Conclusion 
 In summary, we present the first evidence that α-tomatine is an effective anti-
tumor compound against prostate cancer xenograft and orthotopic tumors. This agent 
may prove to be useful in the prevention and treatment of androgen-independent 
prostate cancer and this warrants further investigation.  
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CHAPTER 4 
ALPHA-TOMATINE SYNERGISES WITH PACLITAXEL 
TO ENHANCE APOPTOSIS OF ANDROGEN-
INDEPENDENT HUMAN PROSTATE CANCER PC-3 
CELLS IN VITRO AND IN VIVO 
 
 
 
 
The contents in this chapter have been published in Lee, S. T., Wong, P. F., Hooper, J. 
D., Mustafa, M. R. (2013). Alpha-tomatine synergises with paclitaxel to enhance 
apoptosis of androgen-independent human prostate cancer PC-3 cells in vitro and in 
vivo. Phytomedicine, 20(14), 1297-1305.  
 
 
 
 
 
 
 
 111 
 
4.1 Abstract 
Alpha (α)-tomatine, a major saponin found in tomato has been shown to inhibit the 
growth of androgen-independent prostate cancer PC-3 cells. The effects of α-tomatine 
in combination with the chemotherapeutic agent paclitaxel against PC-3 cells were 
investigated in the present study. Combined treatment with a sub-toxic dose of α-
tomatine and paclitaxel significantly decreased cell viability with concomitant increase 
in the percentage of apoptotic PC-3 cells. The combined treatment, however, had no 
cytotoxic effect on the non-neoplastic prostate RWPE-1 cells. Apoptosis of PC-3 cells 
was accompanied by the inhibition of PI3K/Akt pro-survival signaling, an increase in 
the expression of the pro-apoptotic protein BAD but a decrease in the expressions of 
anti-apoptotic proteins, Bcl-2 and Bcl-xL. Results from a mouse xenograft model 
showed the combined treatment completely suppressed subcutaneous tumor 
growth without significant side effects. Consistent with its in vitro anti-cancer effects, 
tumor materials from mice showed increased apoptosis of tumor cells with reduced 
protein expression of activated PI3K/Akt. These results suggest that the synergistic anti-
cancer effects of paclitaxel and α-tomatine may be beneficial for refractory prostate 
cancer treatment. 
 
4.2 Introduction 
Prostate cancer is the second most frequently diagnosed cancer and the sixth 
leading cause of cancer death in men worldwide (Jemal et al., 2011). The majority of 
patients with advanced prostate cancer respond well to initial treatment with anti-
hormonal therapies, but almost all of these patients will eventually develop hormone-
refractory prostate cancer and bone metastatic disease (Bracarda et al., 2005). Taxane-
based drugs such as paclitaxel and docetaxel are potent chemotherapeutic agents used 
for the treatment of hormone-refractory prostate cancer (Mancuso et al., 2007). These 
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drugs are microtubule inhibitors which bind to β-tubulin resulting in microtubule 
stabilization, disruption of mitosis and ultimately apoptosis (Schiff et al., 1979). The 
main limitations of taxane-based drugs include inherent toxicity associated with their 
use and short-lived survival benefit of approximately 2 to 3 months largely due to 
chemoresistance (Chang, 2007; Dagher et al., 2004).  Accordingly, there remains an 
unmet need for the identification and development of novel agents that can be used to 
improve the treatment outcomes of chemotherapy.  
We are interested in the utility of naturally occurring plant compounds as agents 
to safely augment the anti-cancer activity of standard chemotherapies. Alpha (α)-
tomatine, a major saponin present in tomato has been shown to have potent in vitro and 
in vivo anti-tumor activity against human prostate cancer PC-3 cells (Lee et al., 2011; 
Lee et al., 2013). These reports indicate that α-tomatine-induced apoptosis of PC-3 cells 
is mediated, at least in part, through the inhibition of nuclear factor-kappa B (NF-κB) 
nuclear translocation (Lee et al., 2011; Lee et al., 2013). In the present study, we 
examined the ability of α-tomatine to augment the anti-cancer actions of a taxane-based 
drug, paclitaxel. Accordingly, we sought to examine the effect of the combined α-
tomatine and paclitaxel treatment on constitutively active phosphoinositide 3-kinase 
(PI3K)/Akt signaling, which is an upstream mediator of NF-κB and confers 
chemoresistance in advanced prostate cancer (Lee et al., 2004; Madrid et al., 2000).  
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4.3 Materials and Methods 
4.3.1 Materials  
Alpha-tomatine was purchased from Tokyo Chemical Industry (Tokyo, Japan). 
Dimethyl sulfoxide (DMSO), fetal bovine serum (FBS), 3,3,5,5 tetramethylbenzidine 
(TMB), paclitaxel and anti-human beta (β)-actin antibody were purchased from Sigma-
Aldrich (USA). Penicillin/streptomycin, Roswell Park Memorial Institute (RPMI-1640), 
keratinocyte growth medium, fetal bovine serum (FBS) and 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenytetrazolium bromide (MTT) were purchased from Invitrogen (USA). An 
antibody against Akt was obtained from Santa Cruz Biotechnology, USA. An Akt 
kinase assay kit, phosphospecific anti-Akt (Ser473), phosphospecific anti-PI3K p85 
(Tyr458)/p55 (Tyr199), anti-PI3K, anti-Bcl-2, anti-Bcl-xL, anti-BAD, anti-cleaved Poly 
(ADP-ribose) polymerase (PARP), and anti-cleaved caspase-3 antibodies were 
purchased from Cell Signaling Technologies (USA). Antibody against proliferating cell 
nuclear antigen (PCNA) was purchased from BD Biosciences (USA).  
 
4.3.2 Cell lines 
Androgen-independent prostate cancer PC-3, androgen-dependent prostate cancer 
LNCaP and non-neoplastic human prostate epithelial RWPE-1 cell lines were obtained 
from the American Type Culture Collection. The luciferase-expressing PC-3 cell line 
was a kind gift from Dr. Patrick Ming Tat Ling, Queensland University of Technology, 
Australia. PC-3, LNCaP and luciferase-expressing PC-3 cells were cultured in RPMI-
1640 supplemented with 10% FBS, 100 U/mL penicillin and 100 μg/mL streptomycin. 
RWPE-1 cells were cultured in keratinocyte growth medium. All cells were maintained 
at 37ºC in a 5% CO2 humidified incubator.  
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4.3.3 In vitro cytotoxicity assay 
Briefly, 18–24 hours after seeding, adherent cells in sterile 96-wells plates were treated 
for 24 hours with α-tomatine and paclitaxel alone or in combination at concentrations 
shown in the relevant figure legend. Cell viability was determined following 24 hours 
treatment using the MTT assay as described previously (Lee et al., 2011).  
 
4.3.4 Assessment of the effect of combined drug treatments in PC-3 cells 
The effect of combined treatment of α-tomatine and paclitaxel was quantified by 
determining the combination index (CI) according to the algorithm of Chou and Talalay 
(Chou, 2010) using CalcuSyn software (Biosoft, Inc., Cambridge, United Kingdom). A 
CI value of 1 indicates an additive effect whereas < 1 represents synergism and >1 
antagonism (Chou, 2010).  
 
4.3.5 Cell cycle analysis  
Cell cycle distribution was examined by propidium iodide (PI) staining of nuclei acids 
using a BD Cycletest Plus DNA Reagent Kit as described previously (Dasmahapatra et 
al., 2004).  
 
4.3.6 Assessment of apoptosis by annexin V/propidium iodide (PI) double staining 
assay 
Apoptosis-mediated death of tumor cells was examined by a double staining method 
using a fluoresceinisothiocyanate (FITC)-labeled annexin V/PI apoptosis detection kit 
(BD Bioscience, San Jose, CA) as described in our previous paper (Lee et al., 2011). 
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4.3.7 Cell lysis  
PC-3 cells at 70-80% confluence were treated with vehicle solution, 1 µM α-tomatine, 5 
nM paclitaxel or α-tomatine and paclitaxel in combination. Protein extraction was 
performed as described in our previous paper (Lee et al., 2013). 
 
4.3.8 Western blot analysis  
Separation of proteins by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE), immunoblotting, and densitometric scanning of the membranes were 
performed as described in our previous paper (Lee et al., 2013). Signal intensity of the 
respective protein was normalized to loading control and expressed as a percentage of 
vehicle treated control.   
 
4.3.9 Assessment of Akt kinase activity 
Akt kinase activity was quantified using an Akt kinase assay kit (Cell Signaling 
Technology, Inc.), following the instructions of the manufacturer. Protein lysates from 
treated PC-3 cells were incubated overnight with an immobilized anti-phospho-Akt 
monoclonal antibody (bead conjugate). The enzymatic activity of immunoprecipitated 
phosphorylated Akt was then assessed in vitro using the supplied glycogen synthase 
kinase (GSK)-3α/β fusion protein as substrate, in the presence of ATP. Phosphorylation 
of GSK-3α/β was detected using an anti-phospho-GSK-3α/β antibody. The signal 
intensity of phospho-GSK-3α/β was normalized to total GSK-3α/β and presented as a 
percentage of vehicle treated control.  
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4.3.10 Growth of subcutaneous PC-3 cell tumors in mice 
Experiments with mice were performed in accordance with a protocol approved by the 
University of Queensland Animal Ethics Committee. Male BALB/c nude mice (6 weeks 
old) were purchased from the Animal Resources Centre (Canning Vale, Western 
Australia). Luciferases-expressing PC-3 cells were inoculated subcutaneously into the 
lower flanks of each mouse as described in our previous paper. On day 7 after cancer 
cell inoculation, each mouse had one palpable tumor and were randomly assigned to 
four groups (n = 6/group). These groups of mice were then given intraperitoneal 
injections of vehicle solution, 5 mg/kg paclitaxel, 5 mg/kg α-tomatine or 5 mg/kg α-
tomatine + 5 mg/kg paclitaxel thrice weekly for an additional 3 weeks. The mice were 
monitored weekly for tumor growth and body weight. Tumor dimensions were 
measured with calipers and the tumor volumes were calculated using a standard formula: 
(length x width
2
) x 0.5 (Plymate et al., 2003). The experiment was terminated 28 days 
after cancer cell inoculation, from which the time bioluminescent signals of tumors in 
live mice were first captured using a Xenogen IVIS Spectrum imaging system (USA) as 
described in our previous paper (Lee et al., 2013). 
 
4.3.11 Tissue processing and protein extraction  
Tissue processing and protein extraction were performed as described in our previous 
paper (Lee et al., 2013).   
 
4.3.12 Statistical analysis 
In vitro assays were performed in at least three separate experiments. Results are 
expressed as the mean value ± standard error of the mean (SEM). Statistical analysis 
was performed with one-way analysis of variance (ANOVA), with Dunnett’s Multiple 
Comparison Test to identify between-group differences using GraphPad Prism software 
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(San Diego, CA). For in vivo tumor growth experiments, statistical significance of the 
differences in tumor volume, body weight and total bioluminescence intensity between 
control and treatment groups was assessed by two-way ANOVA using GraphPad Prism 
software (San Diego, CA), with p values < 0.05 considered significant. Statistical 
significance is expressed as ***, p<0.001; **, p<0.01; *, p<0.05.  
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4.4 Results 
4.4.1 Alpha-tomatine acts synergistically with paclitaxel to inhibit the in vitro 
growth of PC-3 cells          
The in vitro growth inhibitory effects of α-tomatine and paclitaxel on prostate cancer 
cells was firstly evaluated as single agent at concentrations of 0.5, 1, 2 and 4 µM for α-
tomatine and 2.5, 5, 10, 25 and 50 nM for paclitaxel on PC-3 and LNCaP cancer cells. 
The α-tomatine concentrations were chosen based on our previous report of half 
maximal concentration (EC50) in PC-3 cancer cells at 1.67 ± 0.3 µM (Lee et al., 2011). 
As shown in Figure 4.1A, the growth of PC-3 and LNCaP cells were significantly 
inhibited by α-tomatine in a dose-dependent manner. Treatment with α-tomatine for 24 
hours inhibited the proliferation of LNCaP cells with an EC50 value of 2.65 ± 0.1 µM. 
PC-3 cells, hence, were more sensitive to growth inhibition by α-tomatine compared to 
LNCaP cells.  
Paclitaxel inhibited the proliferation of PC-3 and LNCaP cells in a dose-dependent 
manner, with an EC50 at 32.11 ± 4.39 nM for PC-3 cells and 44.80 ± 2.49 nM for 
LNCaP cells at 24 hours exposure (Figure 4.1B). We next tested the effect of combined 
drug treatment at sub-maximal levels of toxicity (1 µM α-tomatine and 5 nM paclitaxel) 
on PC-3, LNCaP and non-neoplastic prostate RWPE-1 cells. MTT assay revealed that 
this combination of treatment doses resulted in greater growth inhibition with PC-3 cell 
viability reduced to ~50% (Figure 4.1C). In contrast, the combined treatment reduced 
LNCaP cell viability to only ~30% (Figure 4.1C). Viability of non-neoplastic prostate 
cells was largely unaffected by single agent or combined drug treatments (Figure 4.1C). 
These results showed that a greater anti-proliferative effect of α-tomatine was observed 
in paclitaxel-treated PC-3 cells compared to treatments using α-tomatine or paclitaxel 
alone and in the treated LNCaP cells. Hence, subsequent mechanistic and animal studies 
were performed only on PC-3 cells.  
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Chou-Talalay method was used to determine whether the combined drugs action are 
antagonistic, additive or synergistic (Chou, 2010). CI values obtained using this method 
were plotted and tabulated in Figure 4.1D. These compounds were found to act 
synergistically against PC-3 cells at the dose of 1 µM α-tomatine and 5 nM paclitaxel 
with a CI value of 0.691 (Figure 4.1D).  
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Figure 4.1 Effect of α-tomatine and paclitaxel on growth of PC-3, LNCaP and RWPE-1 
cells in vitro. Dose–dependent cytotoxicity of (A) α-tomatine and (B) paclitaxel in PC-3 
and LNCaP cancer cells. (C) Cytotoxic effect of combined 1 µM α-tomatine and 5 nM 
paclitaxel (PTX) treatment in PC-3, LNCaP and RWPE-1 cells. Data are shown as 
mean ± SEM of three independent experiments. Statistical significance is expressed as 
***p < 0.001; **p < 0.01; *p < 0.05 versus vehicle control. (D) Top, Isobologram 
analysis of the cytotoxicity of α-tomatine and paclitaxel (PTX) treatments alone or in 
combination. Bottom, CI values determined from the formula described in Materials 
and Methods. 
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4.4.2 Induction of apoptosis by α-tomatine and paclitaxel in PC-3 cells 
Paclitaxel is known to induce G2/M cell cycle arrest (Horwitz, 1992). To examine 
whether the synergistic effect of paclitaxel and α-tomatine is due to enhancement of 
paclitaxel-induced G2/M arrest by α-tomatine, we performed flow cytometric analysis 
of PI-stained PC-3 cells to evaluate the effect of single agent and combination 
treatments on cell cycle distribution. Combined treatment of α-tomatine and paclitaxel 
abrogated the G2/M arresting effects of individual paclitaxel treatment. The combined 
treatment, however, resulted in an increased distribution of cell in sub-G0 phase (50.23 
± 9.86%), compared to 5.39 ± 2.51% and 13.38 ± 3.22% in cells treated with 1 µM α-
tomatine and 5 nM paclitaxel alone, respectively (Figure 4.2A), suggesting that there is 
an increase in apoptotic population.  
We next performed annexin V/PI double staining of the treated PC-3 cells to assess the 
proportion of cells progressing through the phases of apoptotic cell death. In these 
analyses, cells in the early stages of apoptosis were stained positively with annexin V, 
whereas cells in late stages of apoptosis were stained positively with both annexin V 
and PI. As shown in Figure 4.2B, PC-3 cells treated with α-tomatine in combination 
with paclitaxel showed a marked increase in cells in both the early (17.83 ± 3.07 %) and 
late (24.12 ± 2.96%) stages of apoptosis compared to cells treated with only α-tomatine 
(early 4.73 ± 2.25%; late 2.18 ± 1.13%) or paclitaxel (early 6.75 ± 3.26%; late 5.92 ± 
1.97%). Taken together, these results showed that combined α-tomatine and paclitaxel 
treatment induces more cell death than the individual agents.  
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Figure 4.2 Effect of α-tomatine and paclitaxel (PTX) on cell cycle distribution and 
apoptosis of PC-3 cells. (A) The percentages of PC-3 cells at sub-G0, G0/G1, S and 
G2/M phases 24 h after drug treatments. (B) Flow cytometric analysis of apoptotic PC-3 
cells using annexin V/PI double staining following 24 hours with the indicated 
treatments. Data are shown as means ± SEM of three independent experiments. 
Statistical significance is expressed as ***p < 0.001; *p < 0.05 versus vehicle control.  
(A) (B) 
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4.4.3 Synergism of α-tomatine and paclitaxel growth inhibition is accompanied by 
the inhibition of PI3K/Akt signaling and altered expression of downstream 
regulators of apoptosis 
We have previously shown that α-tomatine inhibited nuclear translocation of NF-κB in 
PC-3 cells (Lee et al., 2011). To extend this analysis, we investigated the effect of this 
combined α-tomatine and paclitaxel treatment on PI3K/Akt, an important determinant 
of chemoresistance and upstream mediator of NF-κB (Lee et al., 2004; Madrid et al., 
2000). The enzymatic activity of Akt was firstly examined by an in vitro kinase assay 
using a GSK-3α/β fusion protein as substrate. PC-3 cells were treated with 1 µM α-
tomatine, 5 nM paclitaxel or in combination for 3 hours before the onset of apoptosis.  
Treated and control cell populations were examined using trypan blue exclusion assay 
which indicated that this exposure had minimal effect on cell viability (Appendix A). 
Western blot analysis showed that combined α-tomatine and paclitaxel treatment caused 
a marked reduction in phospho-GSK-3α/β levels (Figure 4.3A, left) where Akt activity 
was reduced by ~60% (Figure 4.3A, right). In contrast, single agent treatment with α-
tomatine and paclitaxel caused ~28% reduction and ~30% increase in Akt activity, 
respectively (Figure 4.3A). We also directly assessed the effect of α-tomatine and 
paclitaxel on Akt activation by detection of phospho-Akt and total Akt on PC-3 cell 
lysates. As shown in Figure 4.3B, combined α-tomatine and PTX treatment reduced the 
phosphorylated Akt levels by ~50%, which is close to the 60% reduction in cells treated 
with PI3K inhibitor wortmannin (1 µM). The effects in this assay of the individual 
agents on Akt activation (Figure 4.3B), paralleled closely the effects observed from our 
in vitro kinase assay using a GSK-3α/β fusion protein as substrate (Figure 4.3A).  
We also examined the direct effect of these agents on PI3K, an upstream regulator of 
Akt by Western blot analysis. As shown in Figure 4.3C, the effects of single agent 
treatment with α-tomatine and combined treatment were similar to those observed for 
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Akt activity (Figure 4.3A, 4.3B), whereas single agent treatment with 5 nM paclitaxel 
produced no significant change in the protein expression of phospho-PI3K (Figure 
4.3C).  In addition, neither single agent nor combination treatments had any effect on 
the levels of total Akt and PI3K (Figure 4.3B, 4.3C).  
As we observed that the combined treatment inhibited the constitutive PI3K/Akt 
activation in PC-3 cells, we were interested in the effect of this combination on 
downstream regulators of apoptosis including BAD, Bcl-xL and Bcl-2. In cells treated 
with combined treatment of α-tomatine and paclitaxel for 8 hours, the expressions of 
anti-apoptosis proteins Bcl-2 and Bcl-xL were significantly downregulated (Figure 4.4A, 
4.4Bi, 4.4Bii). However, there was no significant change in the expressions of Bcl-2 
and Bcl-xL in response to either single agent treatment (Figure 4.4A, 4.4Bi, 4.4Bii). 
Conversely, the expression of the pro-apoptotic protein BAD increased in PC-3 cells 
treated with combined treatment of α-tomatine and paclitaxel (Figure 4.4A, 4.4Biii).  
These data suggest that combined treatment with α-tomatine and paclitaxel promotes 
apoptosis of PC-3 cells by reducing the constitutive PI3K/Akt activity, thereby reducing 
the expression of Bcl-xL and Bcl-2 pro-survival proteins, and increasing the expression 
of BAD pro-apoptosis mediator.  
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Figure 4.3 Inhibitory effect of α-tomatine and paclitaxel (PTX) on PI3K/Akt activity. 
Protein expressions of (A) phospho-GSK-3α/β (B) phospho-Akt and (C) phospho-PI3K 
in PC-3 cells treated with the indicated treatments. Bar graphs show densitometry 
analysis of each Western blot data of three independent experiments. Data are shown as 
means ± SEM. Statistical significance is expressed as ***p < 0.001; **p < 0.01; *p < 
0.05 versus vehicle control. 
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Figure 4.4 Effect of α-tomatine and paclitaxel (PTX) on the expression of apoptosis 
mediators in PC-3 cells. (A) Protein expressions of Bcl-2, Bcl-xL and BAD in PC-3 
cells treated with the indicated treatments. (B)(i-iii) Densitometry analysis of each 
Western blot data of three independent experiments. Data are shown as means ± SEM. 
Statistical significance is expressed as ***p < 0.001 versus vehicle control. 
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4.4.4 Alpha-tomatine enhances the anti-tumorigenic effects of the paclitaxel 
against PC-3 tumor xenografts in nude mice 
By the end of the experiment, combined treatment of α-tomatine (5 mg/kg) and 
paclitaxel (5 mg/kg) caused  a marked reduction of PC-3 cell tumor volume and 
bioluminescent signal, whereas individual treatments with α-tomatine and paclitaxel 
had much less pronounced effects (Figure 4.5A-C). More importantly, none of the 
treatments caused a reduction in mouse body weight (Figure 4.5D). Taken together, 
these results suggest that α-tomatine improves the efficacy of paclitaxel in inhibiting 
PC-3 cell tumor growth in vivo.  
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Figure 4.5 Alpha-tomatine potentiates paclitaxel (PTX) in inhibiting the growth of 
subcutaneous PC-3 tumors in mice. (A) Tumor volumes in each treatment group are 
presented as growth curves. (B) Endpoint bioluminescence intensities of tumors in each 
treatment group. (C) Representative bioluminescence images of PC-3 subcutaneous 
xenografts. (D) Graph of mean body weight for each treatment group versus the number 
of days after initial injection of PC-3 cells. Each point or bar represents the mean ± 
SEM of data (n = 6 per group). Statistical significance is expressed as ***p < 0.001; ** 
p < 0.01 versus vehicle control.  
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4.4.5 Combined α-tomatine and paclitaxel treatment inhibits PI3K/Akt signaling 
and increases apoptosis in PC-3 xenograft tumors 
To further assess the effect of the combination treatment on the in vivo growth of PC-3 
cell mouse xenograft tumors, we examined tumor tissues recovered from mice for the 
expression of a marker of proliferation (PCNA) and apoptosis (cleaved PARP and 
cleaved caspase-3). Lysates from six independent tumor samples indicated that while 
PCNA expression decreased in response to the combination treatment (Figure 4.6A), 
the levels of cleaved PARP and caspase 3 had increased (Figure 4.6B, 4.6C), compared 
to those treated with single agents. These data showed that anti-proliferative and pro-
apoptotic effects of the combination treatment contribute to the reduced growth of PC-3 
cell tumors in mice. 
As we have shown that constitutive activation of PI3K/Akt signaling is reduced in vitro 
by the combined treatment, we also examined the tumors recovered from mice for the 
expression of phospho-PI3K, phospho-Akt and its downstream molecule BAD. As 
shown in Figure 4.6D and 4.6E, there was a distinct decrease in the levels of phospho-
PI3K and phospho-Akt in tumor cells in response to the combined treatment, whereas 
the expression of BAD increased in response to the combined treatment (Figure 4.6F). 
These findings support the proposal that the in vivo anti-tumor effect of combined α-
tomatine and PTX is accompanied with the inhibition of pro-survival PI3K/Akt 
signaling. 
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Figure 4.6 Impact of paclitaxel (PTX) and α-tomatine on PI3K/Akt signaling in 
subcutaneous PC-3 cell tumors. Western blot analysis of (A) PCNA, (B) cleaved 
caspase-3, (C) cleaved PARP, (D) phospho-Akt, (E) phospho-PI3K and (F) BAD in PC-
3 tumor tissues samples. Graphical representation of densitometry analysis of each 
Western blot data from six independent tumor samples is shown below each panel. Data 
are shown as means ± SEM. Statistical significance is expressed as ***p < 0.001 versus 
vehicle control. 
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4.5 Discussion 
Preclinical in vitro and in vivo studies have indicated that phytochemicals, such 
as genistein and lycopene can enhance the anti-tumor activity of chemotherapeutic 
agents (Hwang et al., 2005; Tang et al., 2005). The use of phytochemicals and 
chemotherapeutic agents in combination has the advantage of low toxicity and 
potentiation of the actions of toxic chemotherapies thereby providing the opportunity to 
use chemotherapeutic agents at lower concentrations with fewer unwanted side-effects. 
We have shown that the tomato saponin, α-tomatine significantly enhanced the in vitro 
and in vivo anti-tumor activity of paclitaxel. In particular, α-tomatine acted 
synergistically in vitro with paclitaxel to significantly reduce the viability of PC-3 
prostate cancer cells without impacting the viability of non-neoplastic prostate RWPE-1 
cells. In addition, α-tomatine potentiated the action of paclitaxel in vivo causing 
regression of PC-3 xenograft tumors in mice without negatively impacting the weight of 
these animals. These data are suggestive that α-tomatine may be beneficial in clinical 
settings when combined with conventional chemotherapeutic agents such as paclitaxel. 
Drug resistance promoted by activation of pro-survival pathways and 
inactivation of pro-apoptotic mechanisms is a major problem for treatment of advanced 
prostate tumors (Seruga et al., 2011). Paradoxically, it is known that several 
conventional chemotherapeutic drugs, including paclitaxel promotes survival signaling 
implicated in the development of resistance to chemotherapy (Li & Sethi, 2010). This 
scenario limits the effectiveness of the chemotherapies and necessitates increases in the 
dosage or a change in the drug treatment. Accumulating evidence has indicated that 
activation of the PI3K/Akt pathway in advanced prostate cancer is implicated in the 
acquisition of resistance to chemotherapeutic drugs (Lee et al., 2004; McCubrey et al., 
2006). Previous studies also suggested that activated Akt mediates paclitaxel-induced 
resistance and thus inhibition of Akt may synergistically increase paclitaxel sensitivity 
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(Kim et al., 2007; Weng et al., 2009). Consistent with the previous reports, we observed 
that paclitaxel increased pro-survival Akt activity and promoted the cell survival 
without affecting the abundant expressions of anti-apoptotic Bcl-2 and Bcl-xL proteins 
in PC-3 cells. More importantly, the constitutively active PI3K/Akt signaling in PC-3 
cells due to the loss of phosphatase and tensin homolog (PTEN), a critical negative 
regulator of PI3K/Akt (Huang et al., 2001), was most efficiently suppressed by 
combination treatment with paclitaxel and α-tomatine.  Taken together, our data denote 
that α-tomatine-mediated sensitization of PC-3 cells to paclitaxel involves down-
regulation of both constitutive and paclitaxel-induced Akt activity by α-tomatine. 
Consistent with our findings, α-tomatine has previously been shown to have anti-
metastatic effect on lung cancer cells via inactivation of PI3K/Akt signaling (Shieh et 
al., 2011; Shih et al., 2009). Therefore, therapeutic targeting of PI3K/Akt by α-tomatine 
presents a promising approach to cancer therapy.  
Deregulated anti-apoptotic proteins Bcl-2 and Bcl-xL have been shown to 
function as oncoproteins in the development of androgen-independent prostate cancer 
and chemoresistance in prostate cancer (Catz & Johnson, 2003; Lebedeva et al., 2000). 
Our data indicate that the increased susceptibility of PC-3 cells caused by combined 
paclitaxel and α-tomatine treatment was accompanied with down-regulation of the Akt-
regulated anti-apoptotic proteins Bcl-2 and Bcl-xL and increased expression of the pro-
apoptotic protein BAD. These data are consistent with report showing that Akt 
upregulates expression of Bcl-2 through cAMP-response element-binding protein 
(Pugazhenthi et al., 2000). Previous study demonstrated that PTEN suppresses the Bcl-2 
through inhibiting Akt activity and thereby induces the chemosensitivity (Huang et al., 
2001). As constitutively active PI3K/Akt and abundant Bcl-2 protein expression were 
observed in untreated PTEN null PC-3 cells, reduction of PI3K/Akt activity by α-
tomatine may therefore induce chemosensitization of the PC-3 cells to paclitaxel-
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induced apoptosis accompanied with downregulation of Bcl-2 protein expression. In 
addition, activated Akt is known to prevent cell death by phosphorylating several 
apoptosis regulating proteins including pro-apoptotic Bcl-2 family member BAD, 
leading to its disassociation from the anti-apoptotic Bcl-2 family member Bcl-xL, and 
in turn, promotes survival (Datta et al., 1997). Conversely, disruption of this pro-
survival pathway will induce the dephosphorylation of BAD leading to the formation of 
a heterodimer with Bcl-xL and inhibit the anti-apoptosis function of Bcl-xL and thus 
trigger cell death (Yang et al., 1995). We therefore propose that the enhanced apoptotic 
effect by the combination of α-tomatine and paclitaxel is attributed to the down-
regulation of Akt-regulated pro-survival proteins and upregulation of Akt-regulated pro-
apoptotic proteins.  
 
4.6 Conclusion 
In conclusion, this study demonstrated that α-tomatine, a phytochemical from 
tomatoes, improves the ability of paclitaxel to induce in vitro and in vivo death of 
androgen-independent prostate cancer PC-3 cells. Our data suggest that this compound 
has the ability to potentiate sub-lethal doses of paclitaxel to toxic levels, indicating the 
potential of α-tomatine as an adjunct to taxane-based chemotherapy for the treatment of 
prostate cancer.  
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Morbidity and mortality from androgen-independent prostate cancer remain a 
significant health care problem. Patients with androgen-independent prostate cancer 
have poor prognosis and are more likely to die from complications of metastatic disease. 
Systemic chemotherapy with docetaxel in combination with prednisone represents the 
standard first-line treatment. However, chemoresistance, short-lived clinical benefit, and 
the drug-associated toxicities have limited its clinical application. Discovery of less 
toxic, more selective and effective agents for combating this malignant form of prostate 
cancer is highly desirable. Increasing evidence suggests that phytochemicals with 
distinct anticancer activity are part of cancer therapeutic arsenal, because of their 
greater efficacy and potentially low toxicity profiles. Alpha-tomatine, a dietary saponin 
readily available in tomato has gained much research interest. The anti-cancer activities 
of α-tomatine have been reported against several cancer cells in recent years. As yet, no 
anticancer activity and chemosensitizing effect of α-tomatine on the androgen-
independent prostate cancer has been documented. The present study describes the 
therapeutic potential of α-tomatine as single agent and in combination with a 
chemotherapeutic agent for treatment of androgen-independent prostate cancer.  
Initial study showed that α-tomatine suppresses the growth of two prostate 
cancer cell lines but is more potent in suppressing growth of AR-deficient PC-3 cells 
than the AR-expressing LNCaP cells. The higher sensitivity of α-tomatine in PC-3 
compared to LNCaP cells reflects the involvement of AR-independent mechanism in 
the growth inhibitory effect of α-tomatine on androgen-independent prostate cancer PC-
3 cells. Interestingly, this glycoalkaloid is less cytotoxic to both normal prostate 
epithelial (RWPE-1) and liver (WRL-68) cells, suggesting its specificity for the cancer 
cells. The cytotoxicity of α-tomatine on the growth of PC-3 cells is attributed to its pro-
apoptotic action, as manifested by positive Annexin V staining and decreased in 
mitochondrial membrane potential but increased in nuclear condensation, polarization 
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of F-actin, cell membrane permeability, cytochrome c expressions and also caspases 
activation. Notably, PC-3 cell line is null of p53 tumor suppressor gene, the anti-cancer 
activity of α-tomatine is independent of p53 status in PC-3 cells, suggesting the 
involvement of p53-independent apoptosis. Since p53 abnormalities are usually 
responsible in conferring resistance to cancer chemotherapy and radiotherapy, α-
tomatine is believed to exert apoptotic action in androgen-independent prostate cancer 
cells without conferring resistance to the patients throughout the treatment.  
Constitutively active NF-κB inflicted by aberrant IKK activation and upstream 
signal transduction pathways such as PI3K/Akt is one of hallmarks of androgen-
independent prostate cancer that confers pro-survival benefit in cancer cells through 
transcriptional activation of genes involved cell proliferation and anti-apoptosis. The 
present study demonstrates that the in vitro pro-apoptotic action of α-tomatine in PC-3 
cells is mediated, at least in part, by attenuation of basal constitutive and inducible NF-
κB activation through indirect inhibition of IKK kinase activity. Indeed, the attenuation 
of kinase activity of IKK by α-tomatine is attributed to its suppression on Akt activation. 
Akt is the main downstream target of PI3K and upstream kinase of IKK. Suppression of 
constitutively active Akt by α-tomatine shuts down the NF-κB pro-survival signal 
which in turn induces apoptotic machinery in PC-3 cancer cells. Importantly, inhibitory 
effect of tomatine is not limited to basal constitutive NF-κB activation, but α-tomatine 
also exerts suppressive effect on TNF-α-induced NF-κB activation. It has been shown 
that secretion of inflammatory cytokine TNF-α by macrophages and other stromal cells 
within prostate microenvironment favor tumor growth and metastatic progression 
through activating NF-κB pro-survival signaling. Elevated serum TNF-α levels in 
patients with androgen-independent prostate cancers, increased expression of TNF-α 
and nuclear expression of NF-κB in prostate tumors imply the role of TNF-α-mediated 
NF-κB signaling in the growth of androgen-independent prostate cancer. Taken together, 
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these data underscore the fact that α-tomatine overcomes both basal constitutive and 
TNF-α-induced NF-κB activation through inhibition of Akt, thereby leading to 
downregulation of NF-κB-regulated anti-apoptotic gene products and consequently 
apoptosis in PC-3 cells.  
Most of the compounds that show prominence in in vitro cytotoxicity studies are 
ineffective when tested in vivo. This is because the dosage, absorption, bioavailability, 
route of administration and metabolism of the drug affect drug effectiveness and 
potency in human body. Of therapeutic interest, this study also demonstrates the potent 
anti-tumor activity of α-tomatine against PC-3 tumor in both subcutaneous and 
orthotopic tumor xenograft mouse models. The noteworthy findings in the present study 
are that a non-toxic dose of intraperitoneal injection of α-tomatine inhibits the growth of 
both subcutaneously and orthotopically implanted human prostate adenocarcinoma PC-
3 xenograft in immunodeficiency mice. Orthotopic xenograft model which mimics the 
microenvironment and circulation of primary tumors in humans is another avenue to 
study the intervention of a potential anticancer agent in the preclinical setting. 
Suppressive effect of α-tomatine against PC-3 tumors grown subcutaneously and 
orthotopically in vivo therefore provide merit for further clinical investigations. The 
inhibitory effect of α-tomatine on the in vivo growth of PC-3 tumor is also associated 
with the increased in apoptosis and decreased in NF-κB nuclear translocation. These in 
vivo data strengthen the notion that α-tomatine, by blocking on anti-apoptotic 
machinery, can be developed as novel treatment for androgen-independent prostate 
cancer.   
Chemoresistance promoted by activation of pro-survival pathways and 
inactivation of pro-apoptotic mechanisms remains a critical challenge in the 
management of androgen-independent prostate cancer. The use of phytochemicals and 
chemotherapeutic agents in combination has the advantage of low toxicity and 
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potentiation of the actions of toxic chemotherapies, thereby providing the opportunity to 
use chemotherapeutic agents at lower concentrations with fewer side-effects. Findings 
from the present study further revealed the ability of α-tomatine to augment the anti-
cancer actions of paclitaxel against PC-3 cells in vitro and in vivo. In vitro study first 
demonstrated that sub-toxic dose of α-tomatine potentiates the pro-apoptotic action of 
paclitaxel without increasing cytotoxicity to normal prostate RWPE-1 cells, and 
isobologram analysis of the enhanced efficacy obtained by combining α-tomatine and 
paclitaxel indicates synergism. Interestingly, in vivo xenograft study further revealed the 
effectiveness of sub-toxic dose of α-tomatine in augmenting the anti-tumor action of 
low-dose paclitaxel. The co-administration of α-tomatine and paclitaxel significantly 
retard the growth of PC-3 xenograft tumors in mice without negatively impacting the 
weight of these animals. Consistent with our previous observation showing that 
cytotoxic dose of α-tomatine suppresses NF-κB activation by inhibiting Akt, α-tomatine 
at sub-toxic dose has synergistic effects with paclitaxel in suppressing upstream 
mediator of NF-κB, PI3K/Akt. It is believed that α-tomatine at sub-toxic dose partially 
suppresses the constitutively activated PI3K/Akt in PC-3 cells, thereby increases the 
susceptibility of PC-3 cells to paclitaxel-induced apoptosis.  
Findings from present study are in agreement with the previous reports by Shih 
et al. (2009) and Shieh et al. (2011), where sub-toxic dose of α-tomatine suppresses 
invasion and migration of lung cancer cells having the wild-type PTEN tumor 
suppressor gene through inactivating PI3K/Akt signaling and reducing NF-κB DNA-
binding activity. It is known that PTEN negatively regulates the PI3K/Akt signaling, 
and deregulated PI3K/Akt signaling through loss of PTEN occurs frequently in 
androgen-independent prostate cancer. The present study provides further evidence that 
α-tomatine can also suppress constitutively activated PI3K/Akt signaling in PTEN-
deficient PC-3 cells. As emerging evidence have clearly indicated that deregulation of 
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PI3K/Akt and NF-κB signaling pathways are implicated in androgen-independent 
prostate cancer and confer chemoresistance, one implication of these observations is 
that hampering of these oncogenic signalings in PC-3 by α-tomatine represents a 
promising therapeutic strategy for androgen-independent prostate tumor and improving 
the efficacy of chemotherapy.  
In summary, both in vitro and in vivo findings of the present study buttress high 
therapeutic potential of α-tomatine for treatment of androgen-independent prostate 
cancer. Findings from this preclinical study warrant for further clinical investigations of 
the efficacy and safety profile of α-tomatine for treatment of androgen-independent 
prostate cancer. Moreover, combining α-tomatine with paclitaxel may provide clinical 
benefit for men with androgen-independent prostate cancer. It can be used as adjuvant 
that potentiates the cytotoxic effects of paclitaxel given at sub-toxic levels as well as to 
alleviate paclitaxel-associated side effects. Lastly, these preclinical findings also open 
doors to future pharmacokinetic studies and clinical investigations of α-tomatine for 
treatment of androgen-independent prostate cancer.  
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APPENDIX 
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Appendix A. Cell viability of PC-3 cells in response to 3 hours exposure of the 
indicated treatments using trypan blue exclusion dye assay. Data are shown as means ± 
SEM. 
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Abstract
Background: Alpha-tomatine (a-tomatine) is the major saponin in tomato (Lycopersicon esculentum). This study investigates
the chemopreventive potential of a-tomatine on androgen-independent human prostatic adenocarcinoma PC-3 cells.
Methodology/Principal Findings: Treatment of highly aggressive human prostate cancer PC-3 cells with a-tomatine
resulted in a concentration-dependent inhibition of cell growth with a half-maximal efficient concentration (EC50) value of
1.6760.3 mM. It is also less cytotoxic to normal human liver WRL-68 cells and normal human prostate RWPE-1 cells.
Assessment of real-time growth kinetics by cell impedance-based Real-Time Cell Analyzer (RTCA) showed that a-tomatine
exhibited its cytotoxic effects against PC-3 cells as early as an hour after treatment. The inhibitory effect of a-tomatine on
PC-3 cancer cell growth was mainly due to induction of apoptosis as evidenced by positive Annexin V staining and
decreased in mitochondrial membrane potential but increased in nuclear condensation, polarization of F-actin, cell
membrane permeability and cytochrome c expressions. Results also showed that a-tomatine induced activation of caspase-
3, -8 and -9, suggesting that both intrinsic and extrinsic apoptosis pathways are involved. Furthermore, nuclear factor-kappa
B (NF-kB) nuclear translocation was inhibited, which in turn resulted in significant decreased in NF-kB/p50 and NF-kB/p65 in
the nuclear fraction of the treated cells compared to the control untreated cells. These results provide further insights into
the molecular mechanism of the anti-proliferative actions of a-tomatine.
Conclusion/Significance: a-tomatine induces apoptosis and inhibits NF-kB activation on prostate cancer cells. These results
suggest that a-tomatine may be beneficial for protection against prostate cancer development and progression.
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Introduction
Prostate cancer is one of the leading causes of deaths in men
worldwide with major mortality due to advanced stage of the
cancer where androgen-independent cells become unresponsive to
hormone ablation therapy [1,2]. There is a pressing need to
identify alternative chemopreventive measures as surgery and
current chemotherapeutic strategies can be ineffective against the
aggressive form of prostate cancer [3–5].
Failure of cells to undergo apoptotic cell death contributes to the
development of cancers, hence treatment that induces apoptosis
would be a promising anticancer strategy [6,7]. Natural products are
important sources of new and less toxic anticancer agents. A variety of
dietary agents such as resveratrol, curcumin, sulforaphane, gingerol,
indole-3 carbinol, withanolide and green tea catechins can induce
apoptosis and are effective against various human cancer cells tested
[7–11]. These also have an added advantage of lesser toxicity
compared to current standard therapeutic drugs [12].
The present work investigates the chemopreventive potential of
alpha-tomatine (a-tomatine) against prostate cancer cells. a-
tomatine is the major saponin in tomato (Lycopersicon esculentum). It
possesses antimicrobial, antifungal, anti-inflammatory and immu-
nopotentiating activities [13–18]. It is protective against diben-
zo[a,l]pyrene (DBP)-induced liver and stomach tumors in rainbow
trout [19] and also promotes anti-proliferative effects against human
colon HT-29, liver HepG2, breast MCF-7 and stomach AGS
cancer cells [20,21]. Thus far, it is only known that a-tomatine acts
on phosphoinositide 3-kinase and protein kinase B (PI3K/Akt) and
extracellular signaling-regulating kinase (ERK) signaling pathways
in lung adenocarcinoma A549 cells [22]. The present study, hence,
seeks to investigate the effect of a-tomatine on the growth of human
prostatic adenocarcinoma PC-3 cells and to identify its potential
growth inhibitory mechanism. Results from the present study would
provide new insights into the beneficial role of a-tomatine for
prevention of prostate cancer development and progression.
Materials and Methods
Phytochemicals, standard drug and reagents
a-tomatine (purity.97%) was purchased from Extrasythese
(Genay, France). Paclitaxel from Ascent Scientific (Weston-
SuperMare, UK), a standard drug used in chemotherapy regimen
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for prostate cancer was used as positive control in this study.
Curcumin (Merck, Germany) was used as positive control in NF-
kB translocation assay. Dimethyl sulfoxide (DMSO) and tumor
necrosis factor-alpha (TNF-a) were purchased from Sigma Aldrich
(St. Louis, MO). Both the tested compound and positive controls
were prepared in 100% DMSO, stored at220uC, and then diluted
as needed in cell culture medium. Penicillin/streptomycin,
Dulbecco Modified Eagle Medium (DMEM), Roswell Park
Memorial Institute (RPMI 1640), keratinocyte growth medium,
fetal bovine serum (FBS) and MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenytetrazolium bromide) were purchased from Invitrogen
(Carlsbad, CA).
Cell lines
Prostate cancer PC-3 (CRL-1435), normal human liver WRL-
68 (CL-48) cells, and normal human prostate RWPE-1 (CRL-
11609) were obtained from the American Type Culture Collection
(Manassas, VA) and cultured in RPMI-1640, DMEM and
keratinocyte growth medium, respectively. Both RPMI-1640 and
DMEM were supplemented with 10% heat-inactivated FBS,
100 U/mL penicillin and 100 mg/mL streptomycin. Cells were
cultured at 37uC in a humidified atmosphere of carbon dioxide–
air (5:95).
In vitro cytotoxicity screening
Briefly, adherent cells were seeded in sterile 96-wells plates at
optimum cell density. After 18–24 hours, cells were treated with
increasing concentrations (0.16–5.0 mM) of a-tomatine for
24 hours. Cells treated with 0.2% DMSO was used as vehicle
control. Following treatment, cells were incubated in the dark with
2 mg/ml MTT at 37uC for 2 hours, then the medium was
carefully removed and 100 ml of DMSO was added to dissolve the
formazan crystals formed. Absorbance was measured at 570 nm in
a plate reader. Cell viability was calculated using the following
formula: (mean absorbance in test wells)/(mean absorbance in
control well)6100%. Dose-response curves were plotted using
GraphPad Prism 4 (GraphPad Software Inc., San Diego, CA).
Half maximal effective concentration (EC50) values were deter-
mined using non-linear regression model with sigmoidal dose
response (variable slope) following the algorithm of GraphPad
Prism 4.
Real time cell proliferation analysis
Real time growth kinetics of PC-3 cells was examined by
impedance-based Real-Time Cell Analysis (RTCA) system
(Roche Diagnostic, Mannheim, Germany). RTCA utilizes E-
plate which contains inter-digitated micro-electrodes on the
bottom of the plate that detect local ionic changes as cells
proliferate and is measured as electrode impedance. Briefly,
50 ml of medium was added in 16-wells E-plate and
background readings were recorded. Cell suspension (50 ml)
at cell density of 1.256104 cells/well was added to each well of
the E-plate. The attachment, spreading and proliferation of the
cells were monitored every 5 minutes intervals. When the cells
entered logarithmic growth phase, they were treated with
100 ml of a-tomatine at various concentrations and continu-
ously monitored every 10 minutes for up to 72 hours. Cells
treated with 0.2% of DMSO was used as vehicle control and
monitored in parallel with the a-tomatine and paclitaxel-
treated cells. Cell sensor impedance was expressed as an
arbitrary unit called the Cell Index (CI). The CI at each time
point was defined as (Rn2Rb)/15, where Rn is the cell-
electrode impedance of the well and the Rb is the background
impedance of the well with the media alone. Growth curves
were normalized to the CI at the last measured time point
before compound addition for each well.
Figure 1. The effect of a-tomatine on cell viability of PC-3, WRL-68 and RWPE-1 cells. Cells were treated with a-tomatine for 24 hours and
cell proliferation was measured using MTT reduction assay. Each value represents the mean 6 SD of three independent experiments, performed in
triplicates. EC50 values of a-tomatine on PC-3 cancer cell, WRL-68 normal cells and RWPE-1 normal prostate cells at 24 hours treatment were
1.6760.3 mM, .5.0 mM and 3.8560.1 mM, respectively.
doi:10.1371/journal.pone.0018915.g001
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Figure 2. Dynamic assessment of cell viability after treatment with a-tomatine. Normalized Cell Index (CI) measured over 72 hours on A)
prostate cancer PC-3, B) human normal liver WRL-68 and C) human normal prostate RWPE-1 cells. Briefly, cells at logarithmic growth phase were
treated with a-tomatine and CI values were recorded every 10 minutes intervals using RTCA MP system. Cells treated with 5.0 mM paclitaxel and 0.2%
DMSO were used as positive and negative controls, respectively. A change in impedance as the cells spread on the E-plate was displayed as CI value.
Plotted CI values were normalized to the last time point before addition of treatment.
doi:10.1371/journal.pone.0018915.g002
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Annexin V/propidium iodide (PI) double staining assay
Apoptosis-mediated cell death of tumor cell was examined by a
double staining method using FITC-labeled Annexin V/PI
apoptosis detection kit (BD Bioscience, San Jose, CA) according
to the manufacturer’s instructions. Briefly, control and a-tomatine-
treated cells were collected, washed in cold phosphate-buffered
saline (PBS) twice, stained with fluoresceinisothiocyanate (FITC)-
conjugated Annexin V and PI dyes. The externalization of
phoshotidylserine and the permeability to PI were evaluated by
FACS Calibur flowcytometer (BD Bioscience, San Jose, CA). Data
from 10,000 gated events per sample were collected. Cells in early
stages of apoptosis were positively stained with Annexin V;
whereas, cells in late apoptosis were positively stained with both
Annexin V and PI.
Multiparametric High Content Screening (HCS) assays
HCS (Cellomics Inc, Pittsburgh, PA, USA) enables concurrent
quantitative measurement of multiple independent cellular
phenotypes using fluorescent probes. Both Cellomics multipara-
metric cytotoxicity and apoptosis HitKitTM (Pittsburgh, PA, USA)
were used to examine cellular changes in the a-tomatine-treated
PC-3 cells. Multiparametric cytotoxicity HitKitTM contains four
fluorescent dyes, i.e. blue fluorescent Hoechst 33342, membrane
permeability, mitochondrial membrane potential, and cytochrome
c dyes. They respectively detect changes in nuclear morphology
(nuclear condensation), membrane permeability, mitochondrial
membrane potential and expression of cytochrome c. The
multiparametric apoptosis kit quantifies three fundamental
parameters related to the process of apoptosis, i.e. (i) nuclear
condensation, detected by the blue fluorescent nuclear dye,
Hoechst 33342; (ii) F-actin content, detected by green fluorescent
Alexa Fluor H 488Phalloidin stain; (iii) mitochondrial membrane
potential, based on the uptake of MitoTracker H Red into
mitochondria of cells. Briefly, PC-3 cells were seeded overnight at
density of 8000 cells/well into flat-bottomed 96-well plates (Perkin-
Elmer Inc., Wellesley, MA, USA). Following treatment with
different concentrations of a-tomatine (0.25 to 2.0 mM), fixation
and staining for imaging analysis of the PC-3 cells were performed
according to the manufacturer’s instructions. Cells treated with
0.2% DMSO and 5.0 mM paclitaxel were used as negative and
positive controls, respectively. Plates were analyzed using Thermo
Scientific ArrayScanHVTI HCS Reader (Cellomics Inc, Pitts-
burgh, PA, USA). This is a computerized automated fluorescence
imaging microscope that automatically identifies stained cells and
measures the intensity and distribution of fluorescence in
individual cells. Images for each fluoroprobe were acquired at
different channels using suitable filters with 206objective at fixed
exposure time. The Cell Health Profiling BioApplication software
Figure 3. Annexin V/PI double staining assay. Cells were exposed to either 0.2% DMSO (vehicle control), 5.0 mM paclitaxel (positive control), or
a-tomatine for the indicated time. The treated cells were stained with Annexin V and PI and then subjected to FACS analysis. The percentages of early
apoptotic cells (Annexin V positive, PI negative) and late apoptotic cells (Annexin V and PI positive) observed at different incubation time with a-
tomatine are shown. Results are presented as the mean6 SD of three independent experiments. * P,0.05, ** P,0.01, *** P,0.001 vs vehicle control.
doi:10.1371/journal.pone.0018915.g003
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was used for image acquisitions and analysis. For each well, at least
25 fields, corresponding to at least 500 cells were automatically
acquired and analyzed. All experiments were performed in
triplicates. Cell average intensity (Mean) under the modified
object mask within selected range in each channel was used as
assay indicator, and reported as average fluorescence intensity.
Cell cycle phase distribution of a-tomatine-treated cells was
determined using Cellomics Cell Cycle BioApplication as
Figure 4. HCS analysis of apoptosis associated cellular morphology on a-tomatine-treated PC-3 cells. PC-3 cells were treated with
different concentrations of a-tomatine (0.5–2.0 mM). Cell morphology changes associated with apoptosis such as A) percentage of dead cells, B)
alterations in nuclear condensation, C) membrane permeability, D) mitochondrial membrane potential, E) expression of cytochrome c and F) F-actin
contents are reflected by the average fluorescence intensity detected. Cells treated with 0.2% DMSO and 5.0 mM paclitaxel were used as negative and
positive controls, respectively. All measured parameters were expressed as average fluorescent intensities and averaged for at least 500 cells per well.
Data is representative of three independent experiments.* P,0.05, ** P,0.01, *** P,0.001 vs vehicle control.
doi:10.1371/journal.pone.0018915.g004
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described previously [23]. It applies similar principles as FACS in
assessing cell cycle distribution where the intensity of Hoechst
stained nucleus is deemed proportional to the cell’s DNA content.
Total fluorescence intensity of the dye from the nucleus of each
cell typically exhibits a bimodal distribution. The first peak
typically contains cells with 2N DNA content (G0/G1 phase), the
second peak with a double intensity of the first, contains cells with
4N DNA content (G2/M phase). Under normal conditions, there
are more cells in the G0/G1 versus the G2/M phase. The region
between these two peaks represents cells with DNA content
between 2N and 4N (S phase) which are cells in the process of
doubling their DNA. Cells found with DNA,2N distribution are
usually apoptotic cells. To identify the range of each of the DNA
content categories, the software first identifies 2N (G0/G1 phase)
and 4N (G2/M phase) DNA content peaks using vehicle control
cells. Then, it automatically classified each cell’s nuclear total
intensity into one of the categories of DNA content: sub G1
(DNA,2N), G0/G1 (DNA,2N), S (2N,DNA.4N) and G2/M
(DNA,4N) phases in a-tomatine-treated cells. The percentage of
each cell cycle phase for vehicle control, paclitaxel-treated cells
and a-tomatine-treated cells were then reported.
Caspase activity
The activities of caspase-3, -8 and -9 were measured using the
fluorometric assay kit (Calbiochem, USA) following the protocol of
the manufacturer. Briefly, cells were treated with a-tomatine
(2.0 mM) with or without inhibitors (caspase-8: z-IETD-FMK;
caspase-9: z-LEHD-FMK; caspase-3-like: DEVD-CHO). After
treatment, the cells were harvested using trypsinization and cell
lysates were prepared as described [24]. The cell lysates were
mixed with reaction buffer and 10 ml of fluorogenic peptide
substrate: Ac-DEVD-AMC (caspase-3), Ac-IETD-AMC (caspase-
8) and Ac-LEHD-AMC (caspase-9), and incubated for 2 hours at
37uC in the dark. Inhibitors were added 30 minutes before
addition of fluorogenic substrate. Wells containing 50 ml of sample
buffer, 50 ml of assay buffer and 10 ml of substrate were used as
blank. Purified caspase was used as positive control while
untreated cell extract was used as negative control. Fluorescence
was then measured at excitation of 390 nm and emission of
500 nm. Fold-increase in the protease activity was determined by
comparing the levels of the treated cells with untreated controls.
NF-kB translocation assay
NF-kB translocation in PC-3 cells was examined using NF-kB
activation HCS kit which contains Hoechst 33342 and Alexa
Fluor 488 conjugated anti-NF-kB dyes. PC-3 cells were seeded
into sterile flat-bottomed 96-well plates (Perkin-Elmer Inc.,
Wellesley, MA, USA) at 8000 cells/well (100 ml/well). After 18–
24 hours, cells were treated with different concentrations of a-
tomatine for 30 minutes, followed by treatment with 10 ng/ml
Figure 5. Cytotoxic and proapoptotic effects of a-tomatine on PC-3 cells. PC-3 cells were treated for 24 hours with A) 0.2% DMSO, B) 5.0 mM
paclitaxel, and C) 2.0 mM a-tomatine. The treated cells were examined for nuclear condensation using blue Hoechst 33342 stain, changes in
membrane permeability using a green fluoroprobe, mitochondrial membrane potential using MitoTracker Red CMXRos dye, and cytochrome c
expression using a blue green fluoroprobe. Scale bar indicates 20 mm.
doi:10.1371/journal.pone.0018915.g005
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TNF-a for another 30 minutes. Cells pre-treated with 0.2%
DMSO and 50 mM curcumin were used as negative and positive
inhibitor controls, respectively. Fixation, permeabilization and
immunofluorescence staining of cells were performed according to
the manufacturer’s instructions. For target translocation analysis,
cells stained with Hoechst dye were identified as objects in channel
1 and an adjustable mask called Circ was created around every
nucleus. In non-activated cells, Alexa Fluor 488-stained NF-kB
was detected in channel 2 in the cytoplasm where an annular
region called Ring was defined beyond the nuclear region. Images
were acquired using suitable filters with 206 objective at fixed
exposure times. For each well, at least 500 cells were automatically
acquired and analyzed. The output feature MEAN_CircRingAv-
gIntenDiffCh2 represents the difference between the intensity of
nuclear and cytoplasmic NF-kB associated fluorescence (Nuc-Cyto
Diff), reported as translocation parameter, as previously described
[25].
NF-kB/p50 and NF-kB/p65 transcription factor assay
PC-3 cells at 70–80% confluence were treated with a-
tomatine for 30 minutes, followed by treatment with TNF-a
(10 ng/ml) for another 30 minutes. The cells were then washed
with PBS and the both nuclear and cytoplasmic fractions of the
treated cells were extracted using nuclear extraction kit
(Cayman Chemical, Ann Arbour, MI). Concentrations of the
active forms of NF-kB/p50 and NF-kB/p65 in the both
Figure 6. Cell cycle distribution of a-tomatine-treated PC-3 cells. The percentage of a-tomatine-treated cells at A) Sub G1, B) G0/G1, C) S, and
D) G2/M phases of PC-3 cells. Each bar represents the mean 6 SD of data from three independent experiments.* P,0.05, ** P,0.01, *** P,0.001 vs
vehicle control.
doi:10.1371/journal.pone.0018915.g006
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fractions were measured using Cayman NF-kB/p50 and NF-
kB/p65 ELISA kits (Ann Arbour, MI) according to the
instructions of the manufacturer. The differences in NF-kB/
p50 and NF-kB/p65 levels between the nuclear and cytoplasmic
fractions were reported.
Statistical analysis
All assays were conducted in at least three separate experiments.
Results are expressed as the mean value 6 standard deviation
(SD). Statistical analysis was performed with one-way analysis of
variance (ANOVA), with Dunnett’s Multiple Comparison Test to
identify between-group differences using GraphPad Prism soft-
ware (version 4.0; GraphPad Software Inc., San Diego, CA).
Statistical significant is expressed as ***, p,0.001; **, p,0.01; *,
p,0.05. Log EC50 calculations were performed using the built-in
algorithms from dose-response curves with variable slope.
Results
a-tomatine dose-dependently inhibited proliferation of
PC-3 cancer cells
To evaluate the effect of a-tomatine on cell viability of PC-3,
WRL-68 and RWPE-1 cells, MTT assay was performed.
Treatment of a-tomatine to PC-3 cells resulted in a significant
dose-dependent (from 0.16 to 5.0 mM) inhibition of cell growth
(Figure 1). The EC50 value at 24 hours post-treatment with a-
tomatine for PC-3 cells was estimated at 1.6760.3 mM. a-
tomatine only caused cytotoxicity towards normal prostate
RWPE-1 cells at highest concentration (5.0 mM) of a-tomatine,
with EC50 value of 3.8560.1 mM. Normal human liver WRL-68
cells treated with the highest concentration of a-tomatine tested
(5.0 mM) resulted in ,35% of nonviable cells and this suggest that
a-tomatine is less cytotoxic against WRL-68 cells when compared
to PC3 cells. The EC50 values of a-tomatine towards WRL-68
cells (.5 mM) and RWPE-1 (3.8560.1 mM) and were higher than
that of PC-3 cells (1.6760.3 mM), suggesting the selective
cytotoxicity of a-tomatine towards prostate cancer PC-3 cells.
Real-time growth kinetics analysis of a-tomatine using
cell impedance-based analyzer
The dynamics of PC-3 cells proliferation on the 16-wells E-
plates were monitored at every 5 minutes interval from the time of
plating until the cells entered the logarithmic growth phase,
following which the cells were treated with different concentrations
of a-tomatine. After treatment, CI values were acquired at every
10 minutes interval for 72 hours. It was observed that a rapid
decrease in CI value occurred as early as an hour after treatment
with 5.0 mM and 2.5 mM of a-tomatine on PC-3 cells (Figure 2A),
suggesting that PC-3 cells were dying from the treatment with
these concentrations. PC-3 cells treated at lower concentrations
(0.16–1.25 mM) of a-tomatine were proliferating in parallel to cells
treated with vehicle control as indicated with increase in CI values.
In contrast, WRL-68 cells treatment with a-tomatine showed no
reduction in CI values even at the highest tested concentration of
5.0 mM compared to control levels and it exhibited a continuous
rise in CI values throughout the 72 hours of treatment (Figure 2B).
This showed that WRL-68 cells growth was not affected by a-
tomatine. Treatment with 2.5 mM a-tomatine initially inhibited
normal prostate RWPE-1 cell proliferation but eventually
recovered to the level of vehicle control cells (Figure 2C).
Treatment with higher concentration (5.0 mM), however, de-
creased the CI values suggesting that a-tomatine inhibited the
proliferation of RWPE-1 cells at high concentration (Figure 2C).
These data suggested that a-tomatine at low concentration
(2.5 mM) can inhibit the growth of PC-3 prostate cancer cells
but not the normal prostate RWPE-1.
a-tomatine induces apoptosis on PC-3 cancer cells
To determine if a-tomatine induces apoptosis in PC-3
prostate cancer cells, Annexin V/propidium iodide (PI) double
staining assay and flow cytometry analysis were performed.
Treatment with 2.0 mM a-tomatine for 1, 3, 6 and 24 hours
resulted in a gradual increase in early apoptotic cells (Annexin
V positive only) from 2.0760.12% to 5.0060.97%,
14.5761.55%, and 21.5062.48%, respectively (Figure 3, black
bars). The late apoptotic cells (Annexin V and PI positive) were
also increased significantly, from 2.6360.56% to 4.0060.93%,
6.9361.3%, and 16.961.92% (Figure 3, white bars). Positive
control cells treated with 5.0 mM paclitaxel for 24 hours also
resulted in 7.1360.75% of early apoptotic cells (Figure 3, black
bars) and 21.5361.74% of late apoptotic cells (Figure 3, white
bars) in the culture compared with only 0.2360.09% of early
apoptotic cells (Figure 3, black bars) and 0.3760.12% of late
apoptotic cells (Figure 3, white bars) in the negative control
cells treated with 0.2% DMSO. Hence, these results showed
that a-tomatine inhibited PC-3 cells growth by inducing
apoptosis in these cells.
Multiparametric HCS assays
To further confirm the induction of apoptosis by a-tomatine, the
treated cells were examined for cellular changes associated with
apoptosis using HCS analysis. Treatment with 2.0, 1.0 and 0.5 mM
a-tomatine resulted in approximately 95%, 83% and 20% cell loss,
respectively (Figure 4A). In comparison, positive control cells treated
with 5.0 mM paclitaxel resulted in only 45% cell loss and none from
the vehicle control cells (Figure 4A). The a-tomatine treated cells
also exhibited a concentration-dependent increase in nuclear
chromatin staining with Hoechst 33342 (Figures 4B and 5C),
suggesting an increase in nuclear condensation. Increased in nuclear
chromatin staining with Hoechst 33342 was also observed in the
paclitaxel positive control cells (Figure 4B and 5B) whereas the
fluorescent intensity was significantly lower and healthy nuclear
morphology was observed in the vehicle control cells (Figures 4B
and 5A). Membrane permeability of the treated cells also increased
significantly as evidenced by high fluorescent intensity in the
cytoplasm of a-tomatine (Figure 4C and 5C) and paclitaxel- treated
cells (Figure 4C, and 5B) compared to the vehicle control
(Figures 4C and 5A). A reduction in mitochondrial membrane
potential is observed in both paclitaxel (Figure 4D and 5B) and a-
tomatine (Figure 4D and 5C) treated cells compared to intact
mitochondrial membrane potential of the vehicle control cells
(Figure 4D and 5A). More specific apoptosis indicators such as
release of cytochrome c and F-actin polarization or cleavage were
found increased in a concentration-dependent manner in the
Figure 7. Effect of a-tomatine on caspases activation. Fold increase of the levels of A) caspase-3, B) caspase-8, and C) caspase-9 in PC-3 cells
treated with 2.0 mM a-tomatine, compared to vehicle control. The caspase activities were determined in the presence or absence of specific inhibitors
in time course manner. The fluorescence intensity was measured at excitation wavelength of 390 nm and emission wavelength of 500 nm. The
increase of protease activities was determined by comparing the levels in a-tomatine-treated PC-3 cells with the vehicle control. Each bar represents
the mean 6 SD of data from three independent experiments.* P,0.05, ** P,0.01, *** P,0.001 vs vehicle control.
doi:10.1371/journal.pone.0018915.g007
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cytoplasm of PC-3 treated cells, with the highest increase observed
at 2.0 mM a-tomatine (Figure 4E, 4F and 5C). These results further
confirmed that a-tomatine inhibited PC-3 cell growth by inducing
apoptosis.
a-tomatine-induced apoptosis in PC-3 cells is not
associated with cell cycle arrest
To determine whether induction of apoptosis in PC-3 cells by a-
tomatine could be related to the cell cycle arrest, cell cycle
distribution of the treated cells was assessed by labelling the cell’s
DNA with blue fluorescent Hoechst 33342 stain, whose intensity is
proportional to the cell’s DNA content. The sub G1 population
representing apoptotic cells in the 2.0 mM a-tomatine treated cells
was markedly increased (95%) compared to positive control cells
treated with paclitaxel (40%, Figure 6A). This increase was
reflected by significant reduction in cells at G0/G1 (Figure 6B), S
(Figure 6C), and G2/M phases (Figure 6D). No significant changes
in the percentage of population of cells in other phases were
observed in 0.5 and 1.0 mM treated cells, suggesting that induction
of apoptosis was not mediated by cell cycle arrest.
a-tomatine induced caspases activation
Caspases are present in the proforms (inactive) and become
active after site-specific cleavage to participate in the process of
apoptosis. To determine whether caspases are involved in
apoptosis induction by a-tomatine, the protein levels of active
caspases in a-tomatine-treated cells were evaluated. Activation of
the executioner procaspase-3 by a-tomatine was found to be
time-dependent (Figure 7A). Caspase-3 activity was significantly
elevated at the first hour of treatment and progressed to a
maximal level (6-fold over vesicle control) after 24 hours of
incubation (Figure 7A). High levels of pro-caspase-8 and pro-
caspase 9 were detected as early as 1 hour after the addition of
a-tomatine, and reached a maximal level at 6 hours of
incubation where the high levels of caspase 8 and 9 persisted
over 24 hours of incubation (Figure 7B and 7C). These findings
suggest that a-tomatine activated caspase-3, caspase-8 and
caspase-9 as early as 1 hour after treatment. Cell permeable-
specific inhibitors of caspase-3-like (DEVD-CHO, Figure 7A),
caspase-8 (z-IETD-FMK, Figure 7B) and caspase-9 (z-LEHD-
FMK, Figure 7C) were added into a-tomatine treatment to
determine whether the activation of caspase-3, -8 and -9 by a-
tomatine can be blocked by these inhibitors. In the presence of
inhibitors, fold increase of caspase-3 (Figure 7A), caspase-8
(Figure 7B) and caspase-9 (Figure 7C) were reduced. These
results further confirmed the activation of caspase-3, -8 and -9 by
a-tomatine in PC-3 cells.
a-tomatine inhibits TNF-a-induced NF-kB nuclear
translocation
It has been shown that activation of NF-kB blocks apoptosis and
promotes cell proliferation [26]. We assessed whether a-tomatine
inhibits activation of NF-kB induced by the inflammatory cytokine,
TNF-a using Alexa Fluor 488-conjugated anti-NF-kB antibody. In
cells treated with medium only (Figure 8A and 8Bii), high fluorescent
intensity of NF-kB was found in cytoplasm but dimly in nuclei,
indicating that NF-kB was not activated under resting condition.
Following stimulation with TNF-a alone, NF-kB fluorescent intensity
significantly increased in nuclei, suggesting that TNF-a stimulation
resulted in NF-kB activation and translocation from cytoplasm into
nuclei occurred in the stimulated cells (Figure 8A and 8Bi). However,
in PC-3 cells treated with curcumin, a known inhibitor of NF-kB
activation, it was observed that significant inhibition of TNF-a-
induced NF-kB nuclear translocation as evidenced by low nuclear
NF-kB-related fluorescence intensity (Figure 8A). Similarly, a-
tomatine also inhibited TNF-a-induced NF-kB activation in a
dose-dependent manner with strong inhibition observed at 2.0 mM
treatment (Figure 8A, and 8Biii). These results showed that a-
tomatine inhibit NF-kB activation.
a-tomatine treatment inhibited NF-kB/p50 and NF-kB/
p65 nuclear translocation
To further confirm TNF-a-induced NF-kB activation was
inhibited in a-tomatine treated PC-3 cells through the inhibition of
NF-kB nuclear translocation, NF-kB/p50 (Figure 9A) and NF-
kB/p65 (Figure 9B) in nuclear and cytoplasmic fractions of the
treated cells were measured by ELISA. Pretreatment with 2.0 mM
of a-tomatine resulted in significant decreased in both NF-kB/p50
(Figure 9A) and NF-kB/p65 (Figure 9B) level in nuclear fractions,
compared to cells treated with TNF-a control (Figure 9A and 9B).
These results showed that a-tomatine inhibits TNF-a-induced NF-
kB activation by inhibiting nuclear translocation of NF-kB/p50
and NF-kB/p65 in the treated PC-3 cells.
Discussion
a-tomatine was reported to inhibit growth of human colon HT-
29, liver HepG2, breast MCF-7 and stomach AGS cancer cells
[20,21] but its anti-proliferative mechanisms require further
definition. The present study reports that a-tomatine inhibits
NF-kB activation and induces apoptosis on androgen-independent
human prostatic adenocarcinoma PC-3 cells. The EC50 of a-
tomatine towards PC-3 cells was estimated at 1.6760.3 mM and
this value is comparable to earlier studies on different cancer cell
lines [20,21]. Dynamic assessment by xCelligence system showed
that a-tomatine is a fast-acting compound, inhibiting the cancer
cells proliferation as early as an hour after treatment with 2.5 and
5.0 mM a-tomatine and its growth suppressive effect was not fully
reversible as the cancer cell proliferation failed to recover
throughout 72 hours of treatment. It is also less cytotoxic against
human liver normal cells and human prostate normal cells.
Although our data showed that a-tomatine inhibited the growth of
normal prostate RWPE-1 cells at high concentration (5.0 mM),
where utilization of high dose of a-tomatine can be a key
consideration for cancer treatment, earlier in vivo studies showed
no apparent toxic effects in rainbow trout [19] and does not affect
body and liver weights of mice [14,27].
Figure 8. The inhibitory effect of a-tomatine on TNF-a-induced NF-kB nuclear translocation. PC-3 cells were pretreated with a-tomatine
for 30 minutes and followed by 10 ng/ml of TNF-a stimulation for 30 minutes. A) Cells treated with 50 mM curcumin and medium only were used as
positive NF-kB inhibitor and negative control, respectively. Cells were fixed, immunostained with anti-NF-kB antibody, and counterstained with
Hoechst 33342. NF-kB nuclear translocation index was measured using Thermo Scientific ArrayScanHVTI HCS Reader and expressed as the difference
between nuclear and cytoplasmic NF-kB related fluorescence intensity. Each bar represents the mean 6 SD of data in triplicate.* P,0.05, ** P,0.01,
*** P,0.001 vs cells treated withTNF-a alone. B) Images of PC-3 cells treated with 10 ng/mL TNF-a alone (i), medium only (ii), and 2.0 mM of a-
tomatine pretreatment before 10 ng/ml TNF-a stimulation (iii). Control and treated PC-3 cells were stained with Hoechst (blue) and the Alexa Fluor
488-conjugated anti-NF-kB antibody (green). Images were acquired for each fluorescence channel, using suitable filters with 206objective. Scale bar
indicates 20 mm.
doi:10.1371/journal.pone.0018915.g008
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Flow cytometry analysis of Annexin V/PI staining showed that
a-tomatine conspicuously induced apoptosis. This observation was
confirmed by multiparametric cell-based high content screening
(HCS) analysis that showed morphological features characteristic
of apoptotic cell death such as nuclear condensation, loss of
membrane symmetry, polarization of F-actin, release of cyto-
chrome c and reduction in mitochondrial membrane potential.
Disruption of the mitochondrial membrane potential is an early
event in apoptosis and triggers release of cytochrome c and other
apoptogenic molecules from the mitochondria to the cytosol [28].
Figure 9. Comparison of NF-kB/p50 and NF-kB/p65 protein levels between nuclear and cytoplasmic fraction. PC-3 cells were treated
with 0.5, 1.0, 2.0 mM a-tomatine for 30 minutes, followed by treatment with 10 ng/ml TNF-a for another 30 minutes. Nuclear and cytoplasmic
fractions of the PC-3 treated cells were extracted, the concentration of the active form of A) NF-kB/p50 and B) NF-kB/p65 in both fractions were
measured with ELISA kits. Differences of NF-kB/p50, NF-kB/p65 in the nuclear and cytoplasmic fractions are reported. Each bar represents the mean
6 SD of data in triplicate.* P,0.05, ** P,0.01, *** P,0.001 vs cells treated with TNF-a control.
doi:10.1371/journal.pone.0018915.g009
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These apoptogenic molecules contribute to the activation of
caspases and subsequent cell death. More intensive molecular
studies indicate that apoptotic cell death can be triggered either
through receptor (extrinsic)-mediated pathway where the ligand-
receptor binding activates caspase-8 or the mitochondrial
(intrinsic)-mediated pathway where cytochrome c is released from
the mitochondrial and activates caspase-9 [29,30]. Both of these
mechanisms will eventually merge and lead to the hierarchical
activation of the downstream caspase-3, 6 and 7, which are
responsible for the characteristic apoptosis-associated morpholog-
ical changes such as chromatin condensation, membrane bleb-
bing, and loss of overall cell shape [31,32]. The present study
demonstrated that treatment with a-tomatine increased activities
of caspase-3 and -9 and caused depolarization of mitochondrial
membrane potential and release of cytochrome c. These results
suggest that induction of apoptosis is mediated through the
intrinsic pathway. Pro-caspase-8 is an intracellular component that
directly communicates with the death domain of cell membrane
receptors and its activation in the a-tomatine-treated cells suggests
that apoptosis is also mediated through the extrinsic pathway
which perhaps merged with the intrinsic pathway and activated
the executioner caspase 3. Consistent with these data, addition of
cell permeable-specific inhibitors of caspase-8 (z-IETD-FMK),
caspase-9 (z-LEHD-FMK), or caspase-3-like (DEVD-CHO)
enzymes revealed that addition of caspase inhibitors completely
decreased a-tomatine-induced activation of caspase-3, -8 and -9,
confirmed the role of caspase-3, -8 and -9 in a-tomatine-induced
apoptosis. Curcumin is an example of dietary agent that mediates
apoptosis via both intrinsic and extrinsic pathways [33].
a-tomatine could also significantly alter polymerization of actin
filaments in the treated PC-3 cells. This observation is in line with
reports that showed polymerization or cleavage of actin cytoskel-
eton during the early and late phases of apoptosis [34–37].
Cisplatin, a well-known anticancer drug is an example of drug that
induces F-actin damage prior to changes in nuclear morphology
[38].
While the present study found no evidence of cell cycle arrest by
a-tomatine, there are evidence that suggest induction of apoptosis
could be mediated through the inhibition of nuclear factor-kappa
B (NF-kB) signaling pathway. Constitutive NF-kB activation has
been observed in many types of cancer, including androgen-
independent prostate cancer [26]. Overexpression of NF-kB/p65
protein was found in the nuclear fraction of prostate cancer clinical
specimens [39,40], suggesting the pathophysiological role for NF-
kB in prostate cancer progression. Constitutive activation of NF-
kB in tumor cells could promote cancer cells survival by blocking
apoptosis and promote cancer cells growth through angiogenesis,
metastasis and invasion [41]. Accumulating evidence indicate that
constitutive activation of NF-kB in tumor cells always contribute
to chemoresistance and radioresistance, and represents an
independent risk factor for recurrence after radical prostatectomy
[40,42,43]. Hence, targeting the NF-kB signaling pathway
remains an attractive therapeutic option for prostate cancer.
Treatment of PC-3 cells with a-tomatine resulted in a strong
inhibition of NF-kB activation, which was consistent with a
decrease in nuclear levels of NF-kB/p65 and NF-kB/p50. The
ability of a-tomatine in inhibiting NF-kB activation by blocking
the nuclear translocation of NF-kB/p65 and NF-kB/p50
transcription factors suggests its promising role in prostate cancer
prevention. Inhibition of NF-kB activation could indirectly
contribute to the pro-apoptotic action of a-tomatine on PC-3
cells as NF-kB controls the transcription of anti-apoptotic and cell
proliferation genes, essential for the survival of cancer cells [44].
In summary, these results show that a-tomatine has good
potentials as dietary phytochemical with pro-apoptosis activity. a-
tomatine can be further explored for its therapeutic potential in
the treatment of cancers where constitutive activation of NF-kB
and apoptosis resistance remain a major concern in cancer
chemotherapy. To establish the relevance of in vitro findings,
further study is underway to investigate in vivo anti-tumor and NF-
kB activities of a-tomatine using prostate xenograft cancer model.
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Abstract
Background: Nuclear factor-kappa B (NF-kB) plays a role in prostate cancer and agents that suppress its activation may
inhibit development or progression of this malignancy. Alpha (a)-tomatine is the major saponin present in tomato
(Lycopersicon esculentum) and we have previously reported that it suppresses tumor necrosis factor-alpha (TNF-a)-induced
nuclear translocation of nuclear factor-kappa B (NF-kB) in androgen-independent prostate cancer PC-3 cells and also
potently induces apoptosis of these cells. However, the precise mechanism by which a-tomatine suppresses NF-kB nuclear
translocation is yet to be elucidated and the anti-tumor activity of this agent in vivo has not been examined.
Methodology/ Principal Findings: In the present study we show that suppression of NF-kB activation by a-tomatine occurs
through inhibition of I kappa B alpha (IkBa) kinase activity, leading to sequential suppression of IkBa phosphorylation, IkBa
degradation, NF-kB/p65 phosphorylation, and NF-kB p50/p65 nuclear translocation. Consistent with its ability to induce
apoptosis, a-tomatine reduced TNF-a induced activation of the pro-survival mediator Akt and its inhibition of NF-kB
activation was accompanied by significant reduction in the expression of NF-kB-dependent anti-apoptotic (c-IAP1, c-IAP2,
Bcl-2, Bcl-xL, XIAP and survivin) proteins. We also evaluated the antitumor activity of a-tomatine against PC-3 cell tumors
grown subcutaneously and orthotopically in mice. Our data indicate that intraperitoneal administration of a-tomatine
significantly attenuates the growth of PC-3 cell tumors grown at both sites. Analysis of tumor material indicates that the
tumor suppressing effects of a-tomatine were accompanied by increased apoptosis and lower proliferation of tumor cells as
well as reduced nuclear translocation of the p50 and p65 components of NF-kB.
Conclusion/ Significance: Our study provides first evidence for in vivo antitumor efficacy of a-tomatine against the human
androgen-independent prostate cancer. The potential usefulness of a-tomatine in prostate cancer prevention and therapy
requires further investigation.
Citation: Lee S-T, Wong P-F, He H, Hooper JD, Mustafa MR (2013) Alpha-Tomatine Attenuation of In Vivo Growth of Subcutaneous and Orthotopic Xenograft
Tumors of Human Prostate Carcinoma PC-3 Cells Is Accompanied by Inactivation of Nuclear Factor-Kappa B Signaling. PLoS ONE 8(2): e57708. doi:10.1371/
journal.pone.0057708
Editor: Andrei L. Gartel, University of Illinois at Chicago, United States Of America
Received August 16, 2012; Accepted January 25, 2013; Published February 21, 2013
Copyright:  2013 Lee et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by Malaysian Ministry of Higher Education (MOHE) High Impact Research Grant (HIRG) E000002-20001 and University Malaya
Research Grant (UMRG) RG161/09HTM. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: rais@um.edu.my
Introduction
Prostate cancer is the second most frequently diagnosed cancer
and the sixth leading cause of cancer death in men worldwide [1].
As progression of this malignancy is dependent on the androgen
receptor, therapies that target activating ligands (the hormones
testosterone and dihydrotestosterone) produce response rates in
patients of up to 95% [2]. Unfortunately, nearly all prostate cancer
patients develop hormone-refractory prostate cancer (HRPC) [2].
For these patients curative treatments are not available and
docetaxel-based chemotherapy provides palliation with response
rates of approximately 50% and median survival of 18 to 20
months with survival benefit of about 2 months [3]. For patients
with HRPC, low toxicity molecular targeting strategies are
needed.
Accumulating evidence suggests that the transcription factor
nuclear factor-kappa B (NF-kB) plays a pivotal role in prostate
cancer growth, survival, angiogenesis and metastatic progression
[4,5,6,7,8]. NF-kB consists of a p50/p65 heterodimer, that is
masked by the inhibitor of NF-kB, I kappa B alpha (IkBa) that
causes its retention in the cytoplasm under resting condition.
Various stimuli, including tumor necrosis-alpha (TNF-a), phorbol
ester and lipopolysaccharides (LPS), result in IkBa kinase
activation, which mediates IkBa phosphorylation at Ser32 and
Ser36 followed by its ubiquitination and proteasome-mediated
degradation. This releases the NF-kB p50/p65 heterodimer,
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which then translocates to the nucleus, where it binds to consensus
sequence motifs to induce gene transcription. It has been
demonstrated that NF-kB is constitutively activated in androgen-
insensitive prostate carcinoma cells, and overexpression of NF-kB
p65 protein was found in the nuclear fraction of prostate cancer
clinical specimens [5,9], suggesting a role for NF-kB in prostate
cancer progression. Consistently, it has been report that aberrant
IKK activation leads to the constitutive activation of the NF-kB
survival pathway in androgen-independent prostate cancer cells
[10]. In addition, activation and localization of NF-kB represent
independent risk factors for disease recurrence after radical
prostatectomy [9,11]. Hence, effective inhibition of NF-kB could
be a promising strategy for treatment of prostate cancer and
prevention of relapse.
Alpha (a)-tomatine is the major saponin in tomato (Lycopersicon
esculentum). Previous studies have reported its immunopotentiating
[12] and in vitro anti-cancer activities [13,14,15,16]. It also has
protective effects against dibenzo[a,l]pyrene (DBP)-induced liver
and stomach tumors in rainbow trout without causing significant
changes in total weight, liver weight, tissue morphology and
mortality [17]. Thus far, the mechanism by which a-tomatine
mediates its anti-prostate cancer effect is not well understood. Our
previous study reported the pro-apoptotic effect of a-tomatine
against androgen-independent human prostatic adenocarcinoma
PC-3 cells through the inhibition of TNF-a-induced NF-kB
nuclear translocation [18]. In the present study, the mechanism of
the inhibition of a-tomatine on NF-kB signaling pathway is further
characterized. For the first time, this study demonstrates the potent
anti-tumor activity of a-tomatine against human androgen-
independent prostate cancer in vivo.
Materials and Methods
Ethics statement
Experiments with mice were performed in accordance with the
protocol approved by the University of Queensland Animal Ethics
Committee (AEC Approval Number: MMRI/210/10).
Materials
a-tomatine was purchased from Tokyo Chemical Industry
(Tokyo, Japan). Dimethyl sulfoxide (DMSO), TNF-a, fetal bovine
serum (FBS), 3,3,5,5 tetramethylbenzidine (TMB), Calpain Inhib-
itor I, ALLN (N-acetyl-leucyl-leucyl-norleucinal) and anti-human
beta (b)-actin antibody were purchased from Sigma Aldrich (St.
Louis, MO). Penicillin/streptomycin, Roswell Park Memorial
Institute (RPMI-1640) media and 0.4% trypan blue solution were
purchased from Invitrogen (Carlsbad, CA). Protein A/G plus
agarose beads, Akt inhibitor VIII, and antibodies against p65, p50,
IkBa, Akt, IKKa, and IKKb were obtained from Santa Cruz
Biotechnology, CA. The glutathione S-transferase-IkBa (GST-
IkBa) fusion protein and polyvinylidene fluoride (PVDF) mem-
brane were purchased from Millipore (Bedford, MA). Kinase
buffer, antibodies against phospho-specific IkBa (Ser32/36),
phosphor-specific p65 (Ser536), phosphor-specific Akt (Ser473),
B cell leukaemia-2 (Bcl-2), B cell leukaemia-x long (Bcl-xL),
cellular inhibitor of apoptosis 1 (c-IAP1), cellular inhibitor of
apoptosis 2 (c-IAP2), survivin, X-linked inhibitor of apoptosis
(XIAP), histone H3 and cleaved-Poly (ADP-ribose) polymerase
(PARP) antibodies were purchased from Cell Signaling (Beverly,
MA). Antibodies against Ki-67 and proliferating cell nuclear
antigen (PCNA) were purchased from BD Biosciences (San Diego,
CA).
Cell line
The prostate cancer PC-3 cell line was purchased from the
American Type Culture Collection (Manassas, VA). Luciferase-
expressing prostate cancer PC-3 cell line was a kind gift of Dr.
Patrick Ming Tat Ling, Queensland University of Technology,
Australia [19,20]. Both PC-3 and luciferase-expressing PC-3 cells
were cultured in RPMI-1640 supplemented with 10% FBS,
100 U/mL penicillin and 100 mg/mL streptomycin. Cells were
cultured at 37uC in a 5% CO2 humidified incubator.
Cell treatment and fractionation
For the in vitro assays, PC-3 cells at 70-80% confluency were
treated with a-tomatine (2 mM) for 30 minutes, and then exposed
to10 ng/ml TNF-a for various time periods. Akt inhibitor VIII
(10 mM) which inhibits activation of Akt as evidenced by reduced
phosphorylation of this kinase at Thr308 and Ser473 [21] was
used as inhibitor control for studying the effect of a-tomatine on
Akt activation as described previously [22]. Both nuclear and
cytoplasmic fractions of treated and vehicle control cells were
isolated using a nuclear extraction kit (Cayman Chemical, Ann
Arbour, MI) according to the manufacturer’s instructions. Briefly,
cells were harvested using a cell scrapper then pelleted by
centrifugation at 4uC before two washes with ice-cold PBS
supplemented with phosphatase inhibitor solution at 4uC. Pelleted
cells were swollen for 15 minutes in ice-cold hypotonic buffer
supplemented with complete protease and phosphatase inhibitors.
10 % Nonidet P-40 assay reagent was then added and cytosolic
fractions were collected by brief centrifugation. Pellets were
resuspended in ice-cold complete nuclear extraction buffer then
vortexed on ice for 30 seconds at highest setting. These cell
pelleting and vortexing steps were repeated for a total of 6 cycles.
The final pellet was resuspended then centrifuged at 14,000 x g for
10 minutes at 4uC. The supernatants containing nuclear fractions
were collected.
Cell viability analysis
Cell viability was examined using a trypan blue exclusion assay
as described previously [23]. Briefly, cells in control and treated
groups were harvested, stained with 0.4% trypan blue solution and
total viable cells were counted using hemacytometer. The
proportion of viable cells was calculated by dividing the number
of viable test cells by the number of viable control cells at the end
of each experimental treatment.
IkBa kinase assay
The effect of a-tomatine on TNF-a-induced IKK activation was
analyzed as described previously [24]. Briefly, PC-3 cells were
preincubated with either 2 mM a-tomatine or 0.1% DMSO
(vehicle) for 30 minutes, and then treated with 10 ng/ml TNF-a
for the indicated times. IKK complex was immunoprecipitated
from whole cell extracts using antibodies against IKKa and IKKb.
Protein A/G plus agarose beads were added and incubated at 4uC
for overnight. The beads were washed with lysis buffer and
resuspended in a kinase buffer before GST-IkBa as IKK substrate
was added. After incubation at 30uC for 30 minutes, the reaction
was terminated by addition of Laemmli’s loading buffer and
heated at 100uC for 5 minutes. Western blot analysis was
performed to detect phosphorylated-IkBa (p-IkBa) and to
determine the total amounts of IKKa and IKKb in each sample.
To determine whether a-tomatine directly targets IKK, IKKa and
IKKb immunoprecipitated from 10 ng/ml TNF-a and 0.1%
DMSO (vehicle) treated cells. In vitro kinase assay was performed in
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the absence or presence of indicated concentrations of a-tomatine
at 30uC for 30 minutes.
Subcutaneous and orthotopic implantation of PC-3 cells
Male BALB/c nude mice (6 weeks old) were purchased from the
Animal Resources Centre (Canning Vale, Western Australia). For
subcutaneous tumor growth study, luciferase-expressing PC-3
prostate cancer cells (16106 in 0.1 ml Dulbecco’s PBS) were
inoculated subcutaneously into the lower flanks of each mouse. On
day 7 after cancer cell inoculation, each mouse had one palpable
tumor and were randomly assigned to four groups (n = 8/group).
These groups of mice were then given intraperitoneal injections of
vehicle solution, 10 mg/kg docetaxel, 5 mg/kg a-tomatine or
10 mg/kg a-tomatine thrice a week for an additional 3 weeks. All
the mice were monitored weekly for tumor growth and body
weight. Tumor dimensions were measured with calipers and
volume calculated using a standard formula: (length6width2)60.5
[25]. The experiment was terminated 28 days after cancer cell
inoculation at which time bioluminescent signals of tumors in live
mice were captured on a Xenogen IVIS Spectrum imaging system
(Alameda, CA, USA) using Live Imaging Acquisition and Analysis
software. Briefly, mice were injected intraperitoneally with
luciferin potassium salt, anesthetized and luminescence images
acquired. Luminescence signal intensity was quantified as region
of interest analysis of total photons per second for each tumor.
Tumors were excised, washed with ice-cold phosphate buffered
saline (PBS) and stored at -80uC until examined by Western blot
analysis.
Orthotopic growth of PC-3 cells was performed as described
previously [19]. Briefly, under a dissecting microscope (Olympus,
Tokyo, Japan), the prostate of 6 weeks old anesthetized SCID mice
were exposed through a surgical incision and 26105 cells in 10 ml
Dulbecco’s PBS injected into the dorsal prostate. Organs were
then replaced, and the abdomen was closed in two layers with silk
sutures. Five days after implantation, mice were randomly
assigned to two groups that received vehicle solution or 10 mg/
kg a-tomatine intraperitoneally thrice a week for 14 days (n = 6
per group). Body weight was measured weekly. Bioluminescent
signal of the PC-3 cell tumor in each mouse was measured at the
end of the study using a Xenogen IVIS Spectrum imaging system
as described above. All mice were then sacrificed by cervical
dislocation.
Tissue processing and protein extraction
For protein analysis of mouse tumors, tissues were minced,
suspended in tissue protein extraction reagent (Thermo-Fisher
Scientific, Waltham, MA) supplemented with complete protease
and phosphatase inhibitors, and homogenized using a gentle-
MACS Dissociator (Miltenyi Biotec, Germany). The homogenized
tissue was transferred to a pre-chilled microcentrifuge tube,
incubated on ice for 30 minutes and then centrifuged at 15,000
x g for 20 minutes at 4uC. The supernatant containing total
cellular proteins was collected for Western blot analysis. Nuclear
proteins were extracted using a nuclear extraction kit according to
the manufacturer’s instructions. Briefly, hypotonic buffer supple-
mented with 1 mM DTT and 0.01% Nonidet P-40 per gram of
tissues was added to minced tissues, which were then homogenized
with a gentleMACS Dissociator followed by incubation on ice for
15 minutes. Cytoplasmic proteins were separated by centrifuga-
tion. The pellets were resuspended in ice-cold complete nuclear
extraction buffer then vortexed on ice for 30 seconds at highest
setting. These cell pelleting and vortexing steps were repeated for a
total of 6 cycles. The suspensions were then centrifuged at 14,000
x g for 10 minutes at 4uC and supernatants containing nuclear
fractions were collected for Western blot analysis.
Western blot analysis
Protein samples were separated by SDS-PAGE and then
transferred onto PVDF membranes which were probed with
primary antibodies, followed after washes by horseradish perox-
idase-conjugated secondary antibodies and visualized colorimetri-
cally after further washes using TMB solution. Protein bands were
visualized and quantified using a gel documentation system
(BioRad, Richmond, Calif).
Statistical analysis
All assays were performed on at least three separate occasions.
Results are expressed as the mean value 6 standard error of the
mean (SEM). Statistical analysis was performed with one-way
analysis of variance, with Dunnett’s Multiple Comparison Test to
identify between-group differences using GraphPad Prism soft-
ware (version 5.0; GraphPad Software Inc., San Diego, CA). For in
vivo tumor growth experiments, statistical significance of differ-
ences in tumor volume, body weight and total bioluminescence
intensity between control and treatment groups was assessed by
two-way ANOVA (GraphPad Software Inc., version 5.0, San
Diego, CA), with p values , 0.05 considered significant. Statistical
significance is expressed as ***, p,0.001; **, p,0.01; *, p,0.05.
Results
a-tomatine inhibits TNF-a-induced nuclear translocation
of NF-kB p50 and p65 and phosphorylation of NF-kB p65
We previously showed that a-tomatine inhibited the growth of
androgen-independent human prostatic adenocarcinoma PC-3 in
vitro with the half maximal effective concentration (EC50) value of
1.676 0.3 mM [18]. At this chosen dose, a-tomatine was shown to
be less cytotoxic to human normal prostate RWPE-1 (EC50 3.856
0.1 mM) and normal liver WRL-68 cells (EC50 . 5 mM) [18].
Treatment with 2 mM a-tomatine induces apoptosis and inhibits
the TNF-a-induced NF-kB nuclear translocation on PC-3 cells
[18]. In the present study, the mechanism of a-tomatine in
inhibition of TNF-a-induced NF-kB nuclear translocation was
investigated by analyzing its effect on phosphorylation and
translocation of NF-kB sub-units in prostate cancer PC-3 cells.
As shown in Figure 1A, the time-dependent phosphorylation of
NF-kB p65 induced by TNF-a over a 60 minutes period was
completely suppressed by pretreatment of cells with 2 mM a-
tomatine. Examination of treated and control cell populations
using a trypan blue exclusion assay indicated that the concentra-
tion of a-tomatine and TNF-a used and the time of exposure had
minimal effect on cell viability (Figure 1B). In addition to the
observed loss of p65 phosphorylation, a-tomatine prevented TNF-
a induced translocation from the cytoplasm to the nucleus of both
p50 and p65 NF-kB sub-units (Figure 1C). These findings indicate
that a-tomatine inhibits the phosphorylation of NF-kB p65 and
prevents the nuclear translocation of NF-kB p50 and p65.
a-tomatine inhibits TNF-a-dependent IkBa
phosphorylation and degradation
The translocation of NF-kB to the nucleus is preceded by the
phosphorylation, ubiquitination and proteolytic degradation of
IkBa [26]. To determine whether the observed inhibition of TNF-
a-induced NF-kB nuclear translocation caused by a-tomatine was
due to inhibition of IkBa degradation, we pretreated cells with a-
tomatine and then exposed them to TNF-a stimulation for time
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periods up to 60 minutes. TNF-a induced IkBa degradation in
control cells as early as 5 minutes after stimulation (Figure 2A). In
contrast, in a-tomatine-pretreated cells, TNF-a stimulation did not
result in the degradation of IkBa, instead its expression was
sustained up to 60 minutes of treatment (Figure 2B). The effect of
a-tomatine on TNF-a-induced IkBa phosphorylation was exam-
ined using an antibody that detects IkBa phosphorylated at Ser32
and Ser36. Calpain inhibitor ALLN was used to prevent
degradation of phosphorylated IkBa. Western blot analysis
indicated that TNF-a induced IkBa phosphorylation as early as
5 minutes post-stimulation, but a-tomatine completely suppressed
this event (Figure 2B). These results indicate that a-tomatine
Figure 1. Effect of a-tomatine on TNF-a-induced phosphorylation of p65 and nuclear translocation of NF-kB p50/p65. (A) PC-3 cells at
70–80% confluency were treated with either 0.1% DMSO (vehicle) or 2 mM a-tomatine in DMSO for 30 minutes, followed by treatment with 10 ng/ml
TNF-a for the indicated times. Cytoplasmic extracts were analyzed by Western blot analysis using an antibody against the phosphorylated form of
p65. (B) Cell viability was assessed by counting cells that excluded trypan blue using a hemocytometer. (C) Effect of a-tomatine on nuclear and
cytoplasmic levels of NF-kB p50 and p65 in human prostate cancer PC-3 cells. Nuclear and cytoplasmic fractions extracted from PC-3 cells treated
either 0.1% DMSO or 2 mM a-tomatine in DMSO for 30 minutes, followed by treatment with 10 ng/ml TNF-a for the 30 minutes were analyzed by
Western blot analysis with antibodies against NF-kB p50 and p65 proteins. b-actin and histone H3 proteins were loading control for cytoplasmic and
nuclear extracts, respectively. Graphical representation of densitometry analysis of NF-kB p50 and p65 Western blot analyses from three independent
experiments are shown below each panel. The ratio of the signal intensity of each protein to loading control was normalized to the vehicle control. *
P,0.05, ** P,0.01, *** P,0.001 vs vehicle control.
doi:10.1371/journal.pone.0057708.g001
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Figure 2. Effect of a-tomatine on IkBa Kinase activity. (A) Cells were grown to 70–80 % confluence, treated with either 0.1% DMSO (vehicle) or
2 mM a-tomatine in DMSO for 30 minutes, followed by treatment with 10 ng/ml of TNF-a for the indicated times. The presence of IkBa was detected
by Western blot analysis. (B) To determine whether a-tomatine inhibits IkBa degradation by blocking IkBa phosphorylation, cells were treated with
either 0.1% DMSO (vehicle) or 2 mM a-tomatine in DMSO for 30 minutes, followed by 50 mg/ml calpain inhibitor ALLN for 30 minutes, and then
treated with 10 ng/ml of TNF-a for the times indicated. Anti-phospho-IkBa Western blot analysis was performed on cytoplasmic extracts. b-actin
served as a loading control. (C) PC-3 cells were preincubated with either 2 mM a-tomatine or 0.1% DMSO (vehicle) for 30 minutes, and then treated
with 10 ng/ml TNF-a for the indicated times. IKKa and IKKb were immunoprecipitated from lysates from cells and in vitro kinase assays were
performed using GST-IkBa as substrate as described in ‘‘Materials and Methods’’. Western blot analysis was performed to detect phosphorylated IkBa.
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inhibited TNF-a-induced phosphorylation and degradation of
IkBa and subsequent nuclear translocation of NF-kB.
a-tomatine inhibits TNF-a-induced IKK activation
TNF-a induces IkBa phosphorylation and degradation via
activation of the IKK complex [26]. To determine if pretreatment
with a-tomatine affects IKK activation, in vitro kinase assays were
performed using immunoprecipitated components of the IKK
complex, and GST-IkBa as the IKK phosphorylation substrate.
As shown in Figure 2C, TNF-a treatment stimulated IKK activity
as phosphorylated-IkBa was detected as early as 5 minutes after
treatment and remained detectable 10 minutes later. In contrast,
phosphorylated-IkBa was not detected in cells treated with 2 mM
a-tomatine during the 15 minutes period of TNF-a stimulation
(Figure 2C). Western blot analysis demonstrated that TNF-a and
a-tomatine had no effect on the expression of the components of
the IKK complex, IKKa or IKKb (Figure 2C), indicating that a-
tomatine blocked TNF-a-induced phosphorylation of IkBa by
attenuating the action of IKK rather than by causing degradation
of this kinase. In a second set of experiments, we assessed whether
a-tomatine suppressed IKK activity by directly binding to IKK
protein by using IKKa and IKKb immunoprecipitated from cells
treated with TNF-a. The kinase reaction mixture was incubated
with increasing concentrations of a-tomatine (1, 2 and 5 mM). As
shown in Figure 2D, whereas TNF-a caused an increase in
phosphorylation of IkBa, this was not reduced by inclusion of
increasing concentrations of a-tomatine. This suggests that while
a-tomatine efficiently inhibits IKK-mediated phosphorylation of
IkBa, it did not do this by directly inhibiting IKK.
a-tomatine inhibits TNF-a-induced Akt activation
It has been reported that the serine-threonine kinase Akt can
activate IKK [27]. To gain insight into whether this pathway may
be relevant in TNF-a–induced activation of NF-kB signaling, we
pretreated PC-3 cells with 2 mM a-tomatine for 30 minutes then
exposed these cells to TNF-a for time periods up to 15 minutes. In
control experiments cells were treated with an Akt inhibitor, Akt
inhibitor VIII, at 10 mM for 3 hours as described previously [22].
As shown in Figure 2E, TNF-a induced Akt activation in a time-
dependent manner and a-tomatine suppressed this activation as
effectively as Akt inhibitor VIII with no significant effect on the
expression of total Akt protein.
a-tomatine represses TNF-a-induced NF-kB dependent
expression of pro-survival proteins
Several studies have indicated that the transcription factor NF-
kB regulates the expression of proteins implicated in facilitating
tumor cell survival including Bcl-2, Bcl-xL, c-IAP, survivin and
XIAP [28,29]. Accordingly, we next examined whether a-
tomatine inhibition of TNF-a-induced NF-kB nuclear transloca-
tion is accompanied by alterations in the expression of these pro-
survival proteins. In these experiments cells were pretreated with
a-tomatine (2 mM) for 30 minutes before induction of TNF-a-
induced effects for 6 hours. This time period was selected to
permit accumulation of levels of pro-survival proteins sufficient for
Western blot analysis. As during this time period a-tomatine
treatment resulted in varying levels of cell rounding and
detachment in treated and control cells, both adherent and non-
adherent cells were collected for protein extraction. As shown in
Figure 3 Western blot analysis revealed that TNF-a induced
marked upregulation of c-IAP1 and c-IAP2 while increases in
expression of Bcl-xL, survivin and XIAP were also apparent but at
lower levels and Bcl-2 expression was marginally increased in
response to this cytokine. It was striking that a-tomatine caused
sharp down-regulation of each of these mediators of cell survival
under basal conditions as well as completely blocking TNF-a-
induced upregulation of each protein (Figure 3). These data
indicate that, consistent with its ability to inhibit TNF-a-induced
NF-kB nuclear translocation, a-tomatine blocks the expression of
the pro-survival mediators typically upreguated by this cytokine.
(D) IKK complex immunoprecipitated from vehicle and TNF-a-treated PC-3 cell extracts with an anti-IKKa and IKKb antibodies was assayed for IKK
activity. The kinase reaction mixture was incubated with a-tomatine as indicated. The expressions of phosphorylated IkBa and IKK were examined by
Western blot analysis using anti-phospho-IkBa, anti-IKKa and anti-IKKb antibodies. To examine the basal level of expression of IKK proteins, whole-cell
extracts analyzed by Western blotting using anti-IKKa and anti-IKKb antibodies. (E) PC-3 cells were pretreated with 2 mM a-tomatine for 30 minutes,
and then treated with 10 ng/ml TNF-a for the indicated times. Lysates extracted from cells treated with 10 mM Akt inhibitor VIII for 3 hours serve as
inhibition control. Cytoplasmic extracts were used for Western blotting using anti-phosphospecific Akt (Ser473) antibody. The same blot was
reprobed with nonphosphorylated Akt antibody. Graphical representation of densitometry analysis of phosphor-Akt Western blot analysis from three
independent experiments is shown below the panel. The ratio of the signal intensity of each protein to loading control was normalized to the vehicle
control. * P,0.05, ** P,0.01, *** P,0.001 vs vehicle control.
doi:10.1371/journal.pone.0057708.g002
Figure 3. a-tomatine represses TNF-a-induced NF-kB depen-
dent expression of pro-survival proteins. PC-3 cells grown to 70–
80 % confluence were treated with either 0.1% DMSO or 2 mM a-
tomatine for 30 minutes, 10 ng/ml TNF-a was then added and the cells
were incubated for a further 6 hours. Whole-cell extracts were
prepared, and were analyzed by Western blot analysis using antibodies
against Bcl-2, Bcl-xL, c-IAP1, c-IAP2, XIAP and survivin. The results shown
here are representative of three independent experiments.
doi:10.1371/journal.pone.0057708.g003
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a-tomatine attenuates growth of PC-3 cell xenograft
tumors in mice
To examine the effect of a-tomatine on tumor growth in vivo, we
challenged PC-3 cell tumors grown subcutaneously in mice. In
these experiments tumors were allowed to establish for 1 week
before challenge 3 times per week for 3 weeks with a-tomatine (5
or 10 mg/kg/mouse), the prostate cancer therapeutic docetaxel
(10 mg/kg/mouse) [30] and vehicle solution. Figure 4A shows that
10 mg/kg a- tomatine was as efficient as 10 mg/kg docetaxel at
retarding growth of PC-3 cell subcutaneous mouse tumors. In
addition, there was also a marked decrease in tumor volume in
response to lower dose of a-tomatine (5 mg/kg). Specifically, 3
weeks after the commencement of drug challenge the average
tumor volume in vehicle control mice (1000 6 180 mm3), was
approximately 1.4 fold higher as compared to mice treated with
5 mg/kg a-tomatine (720 6 60 mm3), and approximately 4.7 fold
higher compared with mice treated with 10 mg/kg of a-tomatine
(210 6 35 mm3) or docetaxel (183 6 32 mm3) (Figure 4A). Of
note, a-tomatine treatment at both 5 mg/kg (Figure 4B, blue) and
10 mg/kg (Figure 4B, green) did not provoke body weight loss in
contrast with docetaxel (Figure 4B, red) which caused a reduction
in body weight of ,10% more than those seen in untreated tumor
bearing mice (Figure 4B, black). In fact, both control and
docetaxel treatment groups showed a trend of decreasing body
weight after 14 days of cancer cells inoculation, potentially due to
high tumor burden and toxicity of docetaxel, respectively (Figure
4B). Consistent with the tumor volumes determined from caliper
measurements, the intensity of bioluminescence measured on day
28 was significantly lower in both docetaxel and 10 mg/kg a-
tomatine treatment groups (Figure 4C and D). These results
suggest that a-tomatine retards the growth of PC-3 cell
subcutaneous xenograft tumors at an effective dose of 10 mg/kg.
We also used an orthotopic mouse model to examine the effect
of a-tomatine on prostate tumor growth. In this experiment, PC-3
cell tumors were allowed to grow in mice for 5 days before thrice
weekly treatment for 2 weeks with 10 mg/kg a-tomatine. As
Figure 4. Anti-tumor activity of a-tomatine against subcutaneous PC-3 cell tumors. Luciferase expressing PC-3 cell xenograft tumors
established in male nude mice (n = 8 per treatment group) for 1 week were treated thrice weekly for 3 weeks with vehicle, docetaxel (10 mg/kg) or
a-tomatine (5 or 10 mg/kg). (A) Graph of tumor volume in each treatment group versus the number of days after initial injection of PC-3 cells. (B)
Graph of mean body weight for each treatment group versus the number of days after initial injection of PC-3 cells. (C) Bioluminescence intensities
emitted from PC-3 cell xenograft tumors at the end of the experiment for each treatment group. (D) Bioluminescence images of PC-3 subcutaneous
xenografts. The first row shows the vehicle control group; middle row shows the docetaxel treatment group; bottom row shows the 10 mg/kg a-
tomatine treatment group. Each bar or point represents the mean 6 SEM of data (n = 8).* P,0.05, ** P,0.01, *** P,0.001 vs vehicle control.
doi:10.1371/journal.pone.0057708.g004
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shown in Figure 5A, and consistent with the data obtained from
the xenograft mouse model, a-tomatine significantly suppressed
the tumorigenicity of PC-3 cell orthotopic tumors. In addition, the
total body weight of mice was not adversely affected by a-tomatine
treatment (Figure 5B). The images in Figure 5C shows strong
bioluminescent signal from the prostate of control mice, demon-
strating that the tumor cells were successfully implanted. In
addition, 4 out of 6 a-tomatine treated mice showed only weak
bioluminescent signals and another 2 mice had no signal. These
findings demonstrate that a-tomatine has potent anti-tumor effects
against mouse xenograft and orthotopic PC-3 cell tumors.
a-tomatine reduces expression of proliferation markers,
increases expression of apoptosis markers and inhibits
nuclear translocation of NF- kB in xenograft tumors
To examine the mechanism by which a-tomatine suppressed
the growth of PC-3 cell tumors in mice, we next examined tumor
tissue recovered from mice carrying subcutaneous tumors for
expression of markers of proliferation (PCNA and Ki-67) and
apoptosis (cleaved-PARP and cleaved-caspase-3). This analysis
was not possible for orthotopic tumors as insufficient material was
available for the a-tomatine treated mice. As shown in Figure 6,
Western blot analysis of lysates from six independent tumor
samples indicated that while both markers of proliferation (PCNA
and Ki-67) decreased in response to a-tomatine treatment (Figure
6A and B), levels of both markers of apoptosis (cleaved-PARP and
caspase-3) increased (Figure 6C and D). These data suggest that
both anti-proliferative and pro-apoptotic effects of a-tomatine
contribute to the reduced growth of PC-3 cell tumors in mice. As
NF-kB translocation to the nucleus is important for promoting
increased cell proliferation and survival and we have shown that
this translocation event is reduced in vitro by a-tomatine, we were
interested to examine recovered subcutaneous mouse tumors for
localization of NF-kB. As shown in Figure 6E, Western blot
analysis from six independent tumor samples indicated that there
was a distinct decrease in the levels of NF-kB components in the
nucleus of tumor cells in response to a-tomatine treatment. These
data suggest that the anti-tumor effects of a-tomatine in vivo may
be due to its ability to block the proliferative and anti-apoptotic
Figure 5. Anti-tumor activity of a-tomatine against orthotopic PC-3 cell tumors. Luciferase expressing PC-3 cell orthotopic tumors
established in male SCID mice (n = 6 per treatment group) for 5 days were treated thrice weekly for 2 weeks with vehicle or a-tomatine (10 mg/kg).
(A) Bioluminescence intensities emitted from PC-3 cell orthotopic tumors for each treatment group after 14 days of treatment. (B) Bioluminescent
images at the end of the experiment of SCID mice carrying orthotopic tumors of luciferase expressing PC-3-luc cells. The upper row shows the vehicle
control group, whereas the bottom row shows the a-tomatine (10 mg/kg) treatment group. (C) Graph of mean body weight for each treatment
group versus the number of days after initial injection of PC-3 cells. Each bar or point represents the mean6 SEM of data (n = 6).* P,0.05, ** P,0.01,
*** P,0.001 vs vehicle control.
doi:10.1371/journal.pone.0057708.g005
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effects of NF-kB signaling by reducing its translocation to the
nucleus.
Discussion
We provide the first evidence that the saponin a-tomatine can
efficiently inhibit the growth of prostate cancer tumors in vivo
without inducing overt toxicity. Our analysis of recovered mouse
tumors suggest that mechanistically a-tomatine mediates its anti-
prostate cancer effects in vivo by blocking, at least in part, the
proliferative and anti-apoptotic effects of NF-kB signaling by
reducing translocation of this protein complex to the nucleus. Our
detailed in vitro analyses indicate that a-tomatine suppression of
NF-kB activation occurs through indirect inhibition of IKK kinase
activity, leading to suppression of IkBa phosphorylation and
degradation, NF-kB/p65 phosphorylation and NF-kB p50/p65
nuclear translocation. Consistent with its ability to induce
apoptosis, a-tomatine inhibition of NF-kB activation in vitro was
accompanied by significant reduction in expression of TNF-a
induced pro-survival mediators c-IAP, Bcl-2, Bcl-xL, survivin and
XIAP.
The NF-kB signaling pathway is an important target for disease
treatment because its dysregulation is required for inappropriate
inflammatory responses as well as cancer and other ailments [31].
In response to most activating stimuli, NF-kB signaling occurs
through sequential activation of IKK, phosphorylation of IkBa at
serine 32 and 36, leading to its degradation, and the nuclear
translocation of NF-kB where it regulates transcription of a range
of genes including those that promote cell proliferation and
survival [32]. Consistent with our data from a-tomatine,
suppression of NF-kB activation has been shown to be a critical
mechanism of action of several plant-derived anticancer agents,
such as curcumin, lycopene, silibinin, genistein, resveratrol and
green tea polyphenols [33]. In the present study, we showed that
a-tomatine is an indirect inhibitor of IKK. Presumably, a-
tomatine inhibits upstream signaling components that lead to
activation of the IKK complex, such as Akt serine-threonine
kinase , NF-kB inducing kinase, mitogen-activated protein kinase
kinase kinase (MEKK)1, MEKK3, TGF activated kinase 1
(TAK1) and glycogen synthase kinase-3 beta [34,35,36,37,38].
Indeed, we found that a-tomatine inhibits TNF-a-induced Akt
activation, although further experiments are needed to address if
this effect is responsible for the changes we observed in
phosphorylation and translocation of NF-kB components or the
anti-tumor actions of a-tomatine against subcutaneous and
orthotopic tumors grown in mice. These results are in agreement
with those of previous studies that suggest that a-tomatine
suppresses invasion and migration of human lung cancer cells in
vitro through the inhibition of the Akt [15,16]. As conventional
chemotherapeutic agents, including docetaxel target normal as
well as tumor cells and lead to deleterious effects for prostate
cancer patients there is a pressing need to identify less toxic agents
to control this disease. In recent years, a number of naturally
occurring dietary agents of reduced toxicity have been reported to
induce apoptosis and inhibit tumor growth, highlighting the
promise of using naturally derived agents for chemotherapy and
chemoprevention of prostate and other cancers [39,40,41].
Furthermore, it is also possible that an inhibitor of NF-kB
activation could be an adjuvant for overcoming tumor resistance
to radiation and chemotherapies, such as paclitaxel, doxorubicin,
5-fluorouracil, and vinca alkaloids (vinblastine and vincristine),
that occur via NF-kB activation [42,43,44]. It is thought that this
induced resistance in a wide variety of tumor cells occurs via
induction of NF-kB effector genes, including Bcl-2 [45], Bcl-xL
[46], survivin [47], XIAP [48], c-IAP1 [49] and c-IAP2 [49] that
are known to mediate protective responses to chemotherapeutic
agents and radiation. Therefore, targeting NF-kB through the
actions of a-tomatine, which we have shown to block NF-kB
activation and transcription of NF-kB effector genes, may result in
improvements in treatment of prostate cancer. In support of this,
other dietary agents, including resveratrol, curcumin, genistein,
(2) epigallocatechin gallate and soya isoflavone that can block
various steps leading to NF-kB activation and sensitize tumor cells
to the beneficial effects of chemotherapeutic drugs and radiation in
treatment of cancer [50,51,52,53,54,55,56].
We previously reported that a-tomatine induces caspase-
dependent death of PC-3 cells in vitro accompanied by increased
caspase-3 activity and the release of cytochrome c [18]. Caspases
have been shown to be involved in apoptosis through activation of
PARP downstream molecule [57]. Importantly, here we have
demonstrated the pro-apoptotic effect of a-tomatine in vivo by
showing a significant increase in the cleavage of PARP and
caspase-3 in a-tomatine-treated tumors. In addition, our data
show that a-tomatine elicits anti-proliferative effects in vivo as we
observed reduced levels of the markers of proliferation Ki-67 and
PCNA. Our data from PC-3 tumors also suggest that these pro-
apoptotic and anti-proliferative effects of a-tomatine are mediated,
at least in part, by reduced nuclear translocation of NF-kB p50
and p65. Indeed our in vitro studies clearly demonstrate that a-
tomatine is very effective at blocking activation and translocation
of the components of the NF-kB complex providing support for
the possibility that this mechanism is also important for its effects in
vivo against prostate cancer PC-3 cell tumors.
In summary, we present the first evidence that a-tomatine is an
effective anti-tumor compound against prostate cancer xenograft
and orthotopic tumors. This agent may prove to be useful in the
prevention and treatment of androgen-independent prostate
cancer and this warrants further investigation.
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Figure 6. Western blot analysis of PCNA, Ki-67, cleaved-PARP, cleaved-caspase-3 and NF-kB in PC-3 tumor tissues samples. (A–D) PC-
3 tumors excised from mice treated with vehicle, 5 mg/kg or 10 mg/kg of a-tomatine were lysed and examined by Western blot analysis.
Representative images are shown. Markers of proliferation (PCNA and Ki-67). Markers of apoptosis (cleaved PARP and cleaved caspase-3). b-actin was
used as loading control. (E) Western blot analysis on nuclear extracts probing for NF-kB p50 and p65 levels. Equal loading of protein was confirmed
by stripping and reprobing the blots with histone H3 antibody. Graphical representation of densitometry analysis of each Western blot data from six
independent tumor samples is shown below each panel. The ratio of the signal intensity of each protein to loading control was normalized to the
vehicle control. * P,0.05, ** P,0.01, *** P,0.001 vs vehicle control.
doi:10.1371/journal.pone.0057708.g006
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a  b  s  t  r  a  c  t
Alpha  ()-tomatine,  a major  saponin  found  in  tomato  has  been  shown  to inhibit  the  growth  of
androgen-independent  prostate  cancer  PC-3  cells.  The  effects  of  -tomatine  in combination  with  the
chemotherapeutic  agent  paclitaxel  against  PC-3  cells were  investigated  in the  present  study. Combined
treatment  with  a sub-toxic  dose  of  -tomatine  and  paclitaxel  signiﬁcantly  decreased  cell  viability  with
concomitant  increase  in the  percentage  of apoptotic  PC-3  cells.  The  combined  treatment,  however,  had
no cytotoxic  effect  on  the  non-neoplastic  prostate  RWPE-1  cells.  Apoptosis  of PC-3  cells was  accompanied
by  the inhibition  of PI3K/Akt  pro-survival  signaling,  an  increase  in the  expression  of the  pro-apoptotic
protein  BAD  but a decrease  in the  expressions  of anti-apoptotic  proteins,  Bcl-2  and  Bcl-xL.  Results  from
a  mouse  xenograft  model  showed  the  combined  treatment  completely  suppressed  subcutaneous  tumor
growth without  signiﬁcant  side  effects.  Consistent  with  its in  vitro  anti-cancer  effects,  tumor  materi-
als  from  mice  showed  increased  apoptosis  of  tumor  cells  with  reduced  protein  expression  of  activated
PI3K/Akt.  These  results  suggest  that  the  synergistic  anti-cancer  effects  of  paclitaxel  and  -tomatine  may
be beneﬁcial  for refractory  prostate  cancer  treatment.
© 2013 Elsevier GmbH. All rights reserved.
Introduction
Prostate cancer is the second most frequently diagnosed can-
cer and the sixth leading cause of cancer death in men  worldwide
(Jemal et al. 2011). The majority of patients with advanced prostate
cancer respond well to initial treatment with anti-hormonal ther-
apies, but almost all of these patients will eventually develop
hormone-refractory prostate cancer and bone metastatic disease
(Bracarda et al. 2005). Taxane-based drugs such as paclitaxel and
docetaxel are potent chemotherapeutic agents used for the treat-
ment of hormone-refractory prostate cancer (Mancuso et al. 2007).
These drugs are microtubule inhibitors which bind to -tubulin
resulting in microtubule stabilization, disruption of mitosis and
Abbreviations: CI, combination index; EC50, half maximal concentration;
FBS, fetal bovine serum; FITC, ﬂuoresceinisothiocyanate; GSK, glycogen synthase
kinase; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenytetrazolium bromide; NF-
B,  nuclear factor-kappa B; PARP, poly (ADP-ribose) polymerase; PCNA, proliferating
cell nuclear antigen; PI, propidium iodide; PI3K, phosphoinositide 3-kinase; PTEN,
phosphatase and tensin homolog; PTX, paclitaxel; PVDF, polyvinylidene ﬂuoride;
RIPA, radioimmunoprecipitation assay; TMB, 3,3,5,5 tetramethylbenzidine.
∗ Corresponding author. Tel.: +60 3 79677808/79677578; fax: +60 3 79677813.
E-mail address: rais@um.edu.my (M.R. Mustafa).
ultimately apoptosis (Schiff et al. 1979). The main limitations of
taxane-based drugs include inherent toxicity associated with their
use and short-lived survival beneﬁt of approximately 2–3 months
largely due to chemoresistance (Chang 2007; Dagher et al. 2004).
Accordingly, there remains an unmet need for the identiﬁcation
and development of novel agents that can be used to improve the
treatment outcomes of chemotherapy.
We are interested in the utility of naturally occurring plant
compounds as agents to safely augment the anti-cancer activity
of standard chemotherapies. Alpha ()-tomatine (Fig. 1), a major
saponin present in tomato has been shown to have potent in vitro
and in vivo anti-tumor activity against human prostate cancer PC-3
cells (Lee et al. 2011, 2013). These reports indicate that -tomatine-
induced apoptosis of PC-3 cells is mediated, at least in part, through
the inhibition of nuclear factor-kappa B (NF-B) nuclear translo-
cation (Lee et al. 2011, 2013). In the present study, we examined
the ability of -tomatine to augment the anti-cancer actions of
a taxane-based drug, paclitaxel (PTX). Accordingly, we  sought to
examine the effect of the combined -tomatine and PTX treat-
ment on constitutively active phosphoinositide 3-kinase (PI3K)/Akt
signaling, which is an upstream mediator of NF-B and confers
chemoresistance in advanced prostate cancer (Lee et al. 2004;
Madrid et al. 2000).
0944-7113/$ – see front matter ©  2013 Elsevier GmbH. All rights reserved.
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Fig. 1. Chemical structure of -tomatine.
Materials and methods
Materials
-Tomatine was purchased from Tokyo Chemical Industry
(Tokyo, Japan). Dimethyl sulfoxide (DMSO), fetal bovine serum
(FBS), 3,3,5,5 tetramethylbenzidine (TMB), PTX and anti-human
beta ()-actin antibody were purchased from Sigma–Aldrich
(USA). Penicillin/streptomycin, Roswell Park Memorial Institute
(RPMI-1640), keratinocyte growth medium, fetal bovine serum
(FBS) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenytetrazolium
bromide (MTT) were purchased from Invitrogen (USA). An anti-
body against Akt was obtained from Santa Cruz Biotechnology,
USA. An Akt kinase assay kit, phosphospeciﬁc anti-Akt (Ser473),
phosphospeciﬁc anti-PI3K p85 (Tyr458)/p55 (Tyr199), anti-PI3K,
anti-Bcl-2, anti-Bcl-xL, anti-BAD, anti-cleaved (ADP-ribose) poly-
merase (PARP), anti-cleaved caspase-3 antibodies were purchased
from Cell Signaling Technologies (USA). Antibody against pro-
liferating cell nuclear antigen (PCNA) were purchased from
BD Biosciences (USA).
Cell lines
Androgen-independent prostate cancer PC-3, androgen-
dependent prostate cancer LNCaP and non-neoplastic human
prostate RWPE-1 cell lines were obtained from the American Type
Culture Collection (ATCC) (USA). The luciferase-expressing PC-3
cell line was a kind gift from Dr. Patrick Ming Tat Ling, Queensland
University of Technology, Australia. PC-3, LNCaP and luciferase-
expressing PC-3 cells were cultured in RPMI-1640 supplemented
with 10% FBS, 100 U/ml penicillin and 100 g/ml streptomycin.
RWPE-1 cells were cultured in keratinocyte growth medium. All
cells were maintained at 37 ◦C in a 5% CO2 humidiﬁed incubator.
6
In vitro cytotoxicity assay
Brieﬂy, 18–24 h after seeding, adherent cells in sterile 96-wells
plates were treated for 24 h with -tomatine and PTX alone or in
combination at concentrations shown in the relevant ﬁgure legend.
Cell viability was determined following 24 h treatment using the
MTT  assay as described previously (Lee et al. 2011).
Assessment of the effect of combined drug treatments in PC-3 cells
The effect of combined treatment of -tomatine and PTX was
quantiﬁed by determining the combination index (CI) according
to the algorithm of Chou and Talalay (Chou 2010) using CalcuSyn
software (Biosoft, Inc., Cambridge, United Kingdom). A CI value of
1 indicates an additive effect whereas <1 represents synergism and
>1 antagonism (Chou 2010).
Cell cycle analysis
Cell cycle distribution was examined by propidium iodide (PI)
staining of nuclei acids using a BD Cycletest Plus DNA Reagent Kit
as described previously (Dasmahapatra et al. 2004).
Assessment of apoptosis by Annexin V/PI double staining assay
Apoptosis-mediated death of tumor cells was examined by a
double staining method using a ﬂuoresceinisothiocyanate (FITC)-
labeled Annexin V/PI apoptosis detection kit (BD Bioscience, San
Jose, CA) as described previously (Lee et al. 2011).
Cell lysis
PC-3 cells at 70–80% conﬂuence were treated with vehicle
solution, 1 M -tomatine, 5 nM PTX or -tomatine and PTX in
combination. Protein extraction was  performed as described pre-
viously (Lee et al. 2013).
Western blot analysis
Separation of proteins by SDS-PAGE, immunoblotting, and
densitometric scanning of the membranes were performed as
described previously (Lee et al. 2013). Signal intensity of the respec-
tive protein was  normalized to loading control and expressed as a
percentage of vehicle treated control.
Assessment of Akt kinase activity
Akt kinase activity was  quantiﬁed using an Akt kinase assay
kit (Cell Signaling Technology, Inc.), following the instructions
of the manufacturer. Protein lysates from treated PC-3 cells
were incubated overnight with an immobilized anti-phospho-Akt
monoclonal antibody (bead conjugate). The enzymatic activity of
immunoprecipitated phosphorylated Akt was then assessed in vitro
using the supplied glycogen synthase kinase (GSK)-3/ fusion
protein as substrate, in the presence of ATP. Phosphorylation of
GSK-3/ was  detected using an anti-phospho-GSK-3/  anti-
body. The signal intensity of phospho-GSK-3/ was normalized to
total GSK and presented as a percentage of vehicle treated control.
Author's personal copy
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Fig. 2. Dose-dependent cytotoxicity of (A) -tomatine and (B) PTX in PC-3 and LNCaP cancer cells. (C) Cytotoxic effect of combined 1 M -tomatine and 5 nM PTX treatment
in  PC-3, LNCaP and RWPE-1 cells. Data are shown as mean ± SEM of three independent experiments. Statistical signiﬁcance is expressed as ***p < 0.001; **p < 0.01; *p < 0.05
versus  vehicle control. (D) Top, isobologram analysis of the cytotoxicity of -tomatine and PTX treatments alone or in combination. Bottom, CI values determined from the
formula described in Materials and methods.
Growth of subcutaneous PC-3 cell tumors in mice
Experiments with mice were performed in accordance with a
protocol approved by the University of Queensland Animal Ethics
Committee. Male BALB/c nude mice (6 weeks old) were pur-
chased from the Animal Resources Centre (Canning Vale, Western
Australia). Luciferases-expressing PC-3 cells were inoculated sub-
cutaneously into the lower ﬂanks of each mouse as described
previously (Lee et al. 2013). On day 7 after cancer cell inoculation,
each mouse had one palpable tumor and were randomly assigned
to four groups (n = 6/group). These groups of mice were then given
intraperitoneal injections of vehicle solution, 5 mg/kg PTX, 5 mg/kg
-tomatine or 5 mg/kg -tomatine + 5 mg/kg PTX thrice weekly for
an additional 3 weeks. The mice were monitored weekly for tumor
growth and body weight. Tumor dimensions were measured with
calipers and the tumor volumes were calculated using a standard
formula: (length × width2) × 0.5 (Plymate et al. 2003). The exper-
iment was terminated 28 days after cancer cell inoculation, from
which the time bioluminescent signals of tumors in live mice were
ﬁrst captured using a Xenogen IVIS Spectrum imaging system (USA)
as described previously (Lee et al. 2013).
Tissue processing and protein extraction
Tissue processing and protein extraction were performed as
described previously (Lee et al. 2013).
Statistical analysis
In vitro assays were performed in at least three separate experi-
ments. Results are expressed as the mean value ± standard error of
the mean (SEM). Statistical analysis was performed with one-way
analysis of variance (ANOVA), with Dunnett’s Multiple Compar-
ison Test to identify between-group differences using GraphPad
Prism software (San Diego, CA). For in vivo tumor growth experi-
ments, statistical signiﬁcance of the differences in tumor volume,
body weight and total bioluminescence intensity between con-
trol and treatment groups was assessed by two-way ANOVA using
GraphPad Prism software (San Diego, CA), with p values <0.05 con-
sidered signiﬁcant. Statistical signiﬁcance is expressed as *p < 0.05;
**p < 0.01; ***p < 0.001.
Results
˛-Tomatine acts synergistically with paclitaxel to inhibit the
in vitro growth of PC-3 cells
The in vitro growth inhibitory effects of -tomatine and PTX on
prostate cancer cells was ﬁrstly evaluated as single agent at con-
centrations of 0.5, 1, 2 and 4 M for -tomatine and 2.5, 5, 10, 25
and 50 nM for PTX on PC-3 and LNCaP cancer cells. The -tomatine
concentrations were chosen based on our previous report of half
maximal concentration (EC50) in PC-3 cancer cells at 1.67 ± 0.3 M
(Lee et al. 2011). As shown in Fig. 2A, the growth of PC-3 and
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Fig. 3. (A) The percentages of PC-3 cells at sub-G0, G0/G1, S and G2/M phases 24 h after drug treatments. (B) Flow cytometric analysis of apoptotic PC-3 cells using annexin
V/PI  double staining following 24 h with the indicated treatments. Data are shown as means ± SEM of three independent experiments. Statistical signiﬁcance is expressed as
***p  < 0.001; *p < 0.05 versus vehicle control.
LNCaP cells were signiﬁcantly inhibited by -tomatine in a dose-
dependent manner. Treatment with -tomatine for 24 h inhibited
the proliferation of LNCaP cells with an EC50 value of 2.65 ± 0.1 M.
PC-3 cells, hence, were more sensitive to growth inhibition by -
tomatine compared to LNCaP cells.
PTX inhibited the proliferation of PC-3 and LNCaP cells in a dose-
dependent manner, with an EC50 at 32.11 ± 4.39 nM for PC-3 cells
and 44.80 ± 2.49 nM for LNCaP cells at 24 h exposure (Fig. 2B). We
next tested the effect of combined drug treatment at sub-maximal
levels of toxicity (1 M -tomatine and 5 nM PTX) on PC-3, LNCaP
and non-neoplastic prostate RWPE-1 cells. MTT  assay revealed that
this combination of treatment doses resulted in greater growth
inhibition with PC-3 cell viability reduced to ∼50% (Fig. 2C). In
contrast, the combined treatment reduced LNCaP cell viability to
only ∼30% (Fig. 2C). Viability of non-neoplastic prostate cells was
largely unaffected by single agent or combined drug treatments
(Fig. 2C). These results showed that a greater anti-proliferative
effect of -tomatine was observed in PTX-treated PC-3 cells com-
pared to treatments using -tomatine or PTX alone and in the
treated LNCaP cells. Hence, subsequent mechanistic and animal
studies were performed only on PC-3 cells.
Chou–Talalay method was used to determine whether the com-
bined drug action is antagonistic, additive or synergistic (Chou
2010). CI values obtained using this method were plotted and tabu-
lated in Fig. 2D. These compounds were found to act synergistically
against PC-3 cells at the dose of 1 M -tomatine and 5 nM PTX
with a CI value of 0.691 (Fig. 2D).
Induction of apoptosis by ˛-tomatine and PTX in PC-3 cells
PTX is known to induce G2/M cell cycle arrest (Horwitz 1992).
To examine whether the synergistic effect of PTX and -tomatine
is due to enhancement of PTX-induced G2/M arrest by -tomatine,
we performed ﬂow cytometric analysis of PI-stained PC-3 cells to
evaluate the effect of single agent and combination treatments
on cell cycle distribution. Combined treatment of -tomatine and
PTX abrogated the G2/M arresting effects of individual PTX treat-
ment. The combined treatment, however, resulted in an increased
distribution of cell in sub-G0 phase (50.23 ± 9.86%), compared
to 5.39 ± 2.51% and 13.38 ± 3.22% in cells treated with 1 M -
tomatine and 5 nM PTX alone, respectively (Fig. 3A), suggesting that
there is an increase in apoptotic population.
We next performed Annexin V/PI double staining of the treated
PC-3 cells to assess the proportion of cells progressing through
the phases of apoptotic cell death. In these analyses, cells in the
early stages of apoptosis were stained positively with Annexin
V, whereas cells in late stages of apoptosis were stained posi-
tively with both Annexin V and PI. As shown in Fig. 3B, PC-3
cells treated with -tomatine in combination with PTX showed
a marked increase in cells in both the early (17.83 ± 3.07%) and
late (24.12 ± 2.96%) stages of apoptosis compared to cells treated
with only -tomatine (early 4.73 ± 2.25%; late 2.18 ± 1.13%) or PTX
(early 6.75 ± 3.26%; late 5.92 ± 1.97%). Taken together, these results
showed that combined -tomatine and PTX treatment induces
more cell death than the individual agents.
Synergism of ˛-tomatine and PTX growth inhibition is
accompanied by the inhibition of PI3K/Akt signaling and altered
expression of downstream regulators of apoptosis
We  have previously shown that -tomatine inhibited nuclear
translocation of NF-B in PC-3 cells (Lee et al. 2011). To extend this
analysis, we  investigated the effect of this combined -tomatine
and PTX treatment on PI3K/Akt, an important determinant of
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Fig. 4. Protein expressions of (A) phospho-GSK-3/ (B) phospho-Akt and (C) phospho-PI3K in PC-3 cells treated with the indicated treatments. Bar graphs show densitometry
analysis of each Western blot data of three independent experiments. Data are shown as means ± SEM. Statistical signiﬁcance is expressed as ***p < 0.001; **p  < 0.01; *p < 0.05
versus  vehicle control.
chemoresistance and upstream mediator of NF-B (Lee et al. 2004;
Madrid et al. 2000). The enzymatic activity of Akt was ﬁrstly
examined by an in vitro kinase assay using a GSK-3/ fusion pro-
tein as substrate. PC-3 cells were treated with 1 M -tomatine,
5 nM PTX or in combination for 3 h before the onset of apoptosis.
Treated and control cell populations were examined using trypan
blue exclusion assay which indicated that this exposure had mini-
mal  effect on cell viability (data not shown). Western blot analysis
showed that combined -tomatine and PTX treatment caused a
marked reduction in phospho-GSK-3/ levels (Fig. 4A, left) where
Akt activity was reduced by ∼60% (Fig. 4A, right). In contrast, single
agent treatment with -tomatine and PTX caused ∼28% reduction
and ∼30% increase in Akt activity, respectively (Fig. 4A). We  also
directly assessed the effect of -tomatine and PTX on Akt activa-
tion by detection of phospho-Akt and total Akt on PC-3 cell lysates.
As shown in Fig. 4B, combined -tomatine and PTX treatment
reduced the phosphorylated Akt levels by ∼50%, which is close to
the 60% reduction in cells treated with PI3K inhibitor wortman-
nin (1 M).  The effects in this assay of the individual agents on Akt
activation (Fig. 4B), paralleled closely the effects observed from our
in vitro kinase assay using a GSK-3/ fusion protein as substrate
(Fig. 4A).
We also examined the direct effect of these agents on PI3K,
an upstream regulator of Akt by Western blot analysis. As shown
in Fig. 4C, the effects of single agent treatment with -tomatine
and combined treatment were similar to those observed for Akt
activity (Fig. 4A and B), whereas single agent treatment with 5 nM
PTX produced no signiﬁcant change in the protein expression
of phospho-PI3K (Fig. 4C). In addition, neither single agent nor
combination treatments had any effect on the levels of total Akt
and PI3K (Fig. 4B and C).
As we  observed that the combined treatment inhibited the
constitutive PI3K/Akt activation in PC-3 cells, we were interested
in the effect of this combination on downstream regulators of
apoptosis including BAD, Bcl-xL and Bcl-2. In cells treated with
combined treatment of -tomatine and PTX for 8 h, the expres-
sions of anti-apoptosis proteins Bcl-2 and Bcl-xL were signiﬁcantly
downregulated (Fig. 5A, Bi, and Bii). However, there was no signif-
icant change in the expressions of Bcl-2 and Bcl-xL in response to
either single agent treatment (Fig. 5A, Bi, and Bii). Conversely, the
expression of the pro-apoptotic protein BAD increased in PC-3 cells
treated with combined treatment of -tomatine and PTX (Fig. 5A
and Biii).
These data suggest that combined treatment with -tomatine
and PTX promotes apoptosis of PC-3 cells by reducing the consti-
tutive PI3K/Akt activity, thereby reducing the expression of Bcl-xL
and Bcl-2 pro-survival proteins, and increasing the expression of
BAD pro-apoptosis mediator.
˛-Tomatine enhances the anti-tumorigenic effects of the PTX
against PC-3 tumor xenografts in nude mice
By the end of the experiment, combined treatment of -
tomatine (5 mg/kg) and PTX (5 mg/kg) caused a marked reduction
of PC-3 cell tumor volume and bioluminescent signal, whereas
individual treatments with -tomatine and PTX had much
less pronounced effects (Fig. 6A–C). More importantly, none
of the treatments caused a reduction in mouse body weight
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Fig. 5. (A) Protein expressions of Bcl-2, Bcl-xL and BAD in PC-3 cells treated with the indicated treatments. (B) (i–iii) Densitometry analysis of each Western blot data of three
independent experiments. Data are shown as means ± SEM. Statistical signiﬁcance is expressed as ***p < 0.001 versus vehicle control.
(Fig. 6D). Taken together, these results suggest that -tomatine
improves the efﬁcacy of PTX in inhibiting PC-3 cell tumor growth
in vivo.
Combined ˛-tomatine and PTX treatment inhibits PI3K/Akt
signaling and increases apoptosis in PC-3 xenograft tumors
We  examined tumor tissues recovered from mice for the
expression of a marker of proliferation (PCNA) and apoptosis
(cleaved PARP and cleaved caspase-3). Lysates from six inde-
pendent tumor samples indicated that while PCNA expression
decreased in response to the combination treatment (Fig. 7A), the
levels of cleaved PARP and cleaved caspase-3 had increased (Fig. 7B
and C), compared to those treated with single agents. These data
showed that anti-proliferative and pro-apoptotic effects of the
combination treatment contribute to the reduced growth of PC-3
cell tumors in mice.
As we  have shown that constitutive activation of PI3K/Akt
signaling is reduced in vitro by the combined treatment, we also
examined the tumors recovered from mice for the expression of
phospho-PI3K, phospho-Akt and its downstream molecule BAD. As
shown in Fig. 7D and E, there was  a distinct decrease in the lev-
els of phospho-PI3K and phospho-Akt in tumor cells in response to
the combined treatment, whereas the expression of BAD increased
in response to the combined treatment (Fig. 7F). These ﬁndings
support the proposal that the in vivo anti-tumor effect of com-
bined -tomatine and PTX is accompanied with the inhibition of
pro-survival PI3K/Akt signaling.
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Fig. 6. (A) Tumor volumes in each treatment group are presented as growth curves. (B) Endpoint bioluminescence intensities of tumors in each treatment group. (C)
Representative bioluminescence images of PC-3 subcutaneous xenografts. (D) Graph of mean body weight for each treatment group versus the number of days after initial
injection of PC-3 cells. Each point or bar represents the mean ± SEM of data (n = 6 per group). Statistical signiﬁcance is expressed as ***p < 0.001; **p < 0.01 versus vehicle
control.
Discussion
Preclinical in vitro and in vivo studies have indicated that phy-
tochemicals, such as genistein and lycopene can enhance the
anti-tumor activity of chemotherapeutic agents (Hwang et al. 2005;
Tang et al. 2005). The use of phytochemicals and chemotherapeutic
agents in combination has the advantage of low toxicity and poten-
tiation of the actions of toxic chemotherapies thereby providing the
opportunity to use chemotherapeutic agents at lower concentra-
tions with fewer unwanted side-effects. We  have shown that the
tomato saponin, -tomatine signiﬁcantly enhanced the in vitro and
in vivo anti-tumor activity of PTX. In particular, -tomatine acted
synergistically in vitro with PTX to signiﬁcantly reduce the viabil-
ity of PC-3 prostate cancer cells without impacting the viability
of non-neoplastic prostate RWPE-1cells. In addition, -tomatine
potentiated the action of PTX in vivo causing regression of PC-3
xenograft tumors in mice without negatively impacting the weight
of these animals. These data are suggestive that -tomatine may
be beneﬁcial in clinical settings when combined with conventional
chemotherapeutic agents such as PTX.
Drug resistance promoted by activation of pro-survival
pathways and inactivation of pro-apoptotic mechanisms is a
major problem for treatment of advanced prostate tumors
(Seruga et al. 2011). Paradoxically, it is known that several
conventional chemotherapeutic drugs, including PTX promotes
survival signaling implicated in the development of resistance to
chemotherapy (Li and Sethi 2010). This scenario limits the effec-
tiveness of the chemotherapies and necessitates increases in the
dosage or a change in the drug treatment. Accumulating evidences
has indicated that activation of the PI3K/Akt pathway in advanced
prostate cancer is implicated in the acquisition of resistance to
chemotherapeutic drugs (Lee et al. 2004; McCubrey et al. 2006).
Previous studies also suggested that activated Akt mediates PTX-
induced resistance and thus inhibition of Akt may synergistically
increase PTX sensitivity (Kim et al. 2007; Weng et al. 2009). Con-
sistent with the previous reports, we  observed that PTX increased
pro-survival Akt activity and promoted the cell survival without
affecting the abundant expressions of anti-apoptotic Bcl-2 and Bcl-
xL proteins in PC-3 cells. More importantly, the constitutively active
PI3K/Akt signaling in PC-3 cells due to the loss of phosphatase and
tensin homolog (PTEN), a critical negative regulator of PI3K/Akt
(Huang et al. 2001), was  most efﬁciently suppressed by combina-
tion treatment with PTX and -tomatine. Taken together, our data
denote that -tomatine-mediated sensitization of PC-3 cells to PTX
involves down-regulation of both constitutive and PTX-induced Akt
activity by -tomatine. Consistent with our ﬁndings, -tomatine
has previously been shown to have anti-metastatic effect on lung
cancer cells via inactivation of PI3K/Akt signaling (Shieh et al. 2011;
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Fig. 7. Western blot analysis of (A) PCNA, (B) cleaved-caspase-3, (C) cleaved-PARP, (D) phospho-Akt, (E) phospho-PI3K and (F) BAD in PC-3 tumor tissues samples. Graphical
representation of densitometry analysis of each Western blot data from six independent tumor samples is shown below each panel. Data are shown as means ± SEM. Statistical
signiﬁcance is expressed as ***p < 0.001 versus vehicle control.
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Shih et al. 2009). Therefore, therapeutic targeting of PI3K/Akt by
-tomatine presents a promising approach to cancer therapy.
Deregulated anti-apoptotic proteins Bcl-2 and Bcl-xL have
been shown to function as oncoproteins in the development of
androgen-independent prostate cancer and chemoresistance in
prostate cancer (Catz and Johnson 2003; Lebedeva et al. 2000). Our
data indicate that the increased susceptibility of PC-3 cells caused
by combined PTX and -tomatine treatment was  accompanied
with down-regulation of the Akt-regulated anti-apoptotic proteins
Bcl-2 and Bcl-xL and increased expression of the pro-apoptotic
protein BAD. These data are consistent with report showing
that Akt upregulates expression of Bcl-2 through cAMP-response
element-binding protein (Pugazhenthi et al. 2000). Previous study
demonstrated that PTEN suppresses the Bcl-2 through inhibiting
Akt activity and thereby induces the chemosensitivity (Huang et al.
2001). As constitutively active PI3K/Akt and abundant Bcl-2 pro-
tein expression were observed in untreated PTEN null PC-3 cells,
reduction of PI3K/Akt activity by -tomatine may  therefore induce
chemosensitization of the PC-3 cells to PTX-induced apoptosis
accompanied with downregulation of Bcl-2 protein expression.
In addition, activated Akt is known to prevent cell death by
phosphorylating several apoptosis regulating proteins including
pro-apoptotic Bcl-2 family member BAD, leading to its disassoci-
ation from the anti-apoptotic Bcl-2 family member Bcl-xL, and in
turn, promotes survival (Datta et al. 1997). Conversely, disruption
of this pro-survival pathway will induce the dephosphorylation of
BAD leading to the formation of a heterodimer with Bcl-xL and
inhibit the anti-apoptosis function of Bcl-xL and thus trigger cell
death (Yang et al. 1995). We  therefore propose that the enhanced
apoptotic effect by the combination of -tomatine and PTX is
attributed to the down-regulation of Akt-regulated pro-survival
proteins and upregulation of Akt-regulated pro-apoptotic proteins.
In conclusion, this study demonstrated that -tomatine, a phy-
tochemical from tomatoes, improves the ability of PTX to induce
in vitro and in vivo death of androgen-independent prostate can-
cer PC-3 cells. Our data suggest that this compound has the ability
to potentiate sub-lethal doses of PTX to toxic levels, indicating the
potential of -tomatine as an adjunct to taxane-based chemother-
apy for the treatment of prostate cancer.
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